UICIDE A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2003 by ICON Group International, Inc. Copyright 2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Suicide: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83641-8 1. Suicide-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on suicide. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON SUICIDE ..................................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Suicide........................................................................................... 7 E-Journals: PubMed Central ..................................................................................................... 141 The National Library of Medicine: PubMed .............................................................................. 146 CHAPTER 2. NUTRITION AND SUICIDE ......................................................................................... 273 Overview.................................................................................................................................... 273 Finding Nutrition Studies on Suicide ....................................................................................... 273 Federal Resources on Nutrition ................................................................................................. 276 Additional Web Resources ......................................................................................................... 277 CHAPTER 3. ALTERNATIVE MEDICINE AND SUICIDE ................................................................... 279 Overview.................................................................................................................................... 279 National Center for Complementary and Alternative Medicine................................................ 279 Additional Web Resources ......................................................................................................... 296 General References ..................................................................................................................... 298 CHAPTER 4. DISSERTATIONS ON SUICIDE ..................................................................................... 299 Overview.................................................................................................................................... 299 Dissertations on Suicide ............................................................................................................ 299 Keeping Current ........................................................................................................................ 329 CHAPTER 5. CLINICAL TRIALS AND SUICIDE ................................................................................ 331 Overview.................................................................................................................................... 331 Recent Trials on Suicide ............................................................................................................ 331 Keeping Current on Clinical Trials ........................................................................................... 332 CHAPTER 6. PATENTS ON SUICIDE ................................................................................................ 335 Overview.................................................................................................................................... 335 Patents on Suicide...................................................................................................................... 335 Patent Applications on Suicide.................................................................................................. 343 Keeping Current ........................................................................................................................ 347 CHAPTER 7. BOOKS ON SUICIDE ................................................................................................... 349 Overview.................................................................................................................................... 349 Book Summaries: Federal Agencies............................................................................................ 349 Book Summaries: Online Booksellers......................................................................................... 352 The National Library of Medicine Book Index ........................................................................... 374 Chapters on Suicide ................................................................................................................... 375 Directories.................................................................................................................................. 377 CHAPTER 8. MULTIMEDIA ON SUICIDE ......................................................................................... 381 Overview.................................................................................................................................... 381 Video Recordings ....................................................................................................................... 381 Audio Recordings....................................................................................................................... 382 Bibliography: Multimedia on Suicide ........................................................................................ 383 CHAPTER 9. PERIODICALS AND NEWS ON SUICIDE ...................................................................... 387 Overview.................................................................................................................................... 387 News Services and Press Releases.............................................................................................. 387 Newsletter Articles .................................................................................................................... 393 Academic Periodicals covering Suicide ...................................................................................... 394 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 397 Overview.................................................................................................................................... 397 NIH Guidelines.......................................................................................................................... 397 NIH Databases........................................................................................................................... 399
viii Contents
Other Commercial Databases..................................................................................................... 405 APPENDIX B. PATIENT RESOURCES ............................................................................................... 407 Overview.................................................................................................................................... 407 Patient Guideline Sources.......................................................................................................... 407 Finding Associations.................................................................................................................. 416 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 419 Overview.................................................................................................................................... 419 Preparation................................................................................................................................. 419 Finding a Local Medical Library................................................................................................ 419 Medical Libraries in the U.S. and Canada ................................................................................. 419 ONLINE GLOSSARIES................................................................................................................ 425 Online Dictionary Directories ................................................................................................... 426 SUICIDE DICTIONARY .............................................................................................................. 429 INDEX .............................................................................................................................................. 521
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with suicide is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about suicide, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to suicide, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on suicide. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to suicide, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on suicide. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON SUICIDE Overview In this chapter, we will show you how to locate peer-reviewed references and studies on suicide.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and suicide, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “suicide” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Suicide in Two Patients With a Diagnosis of Probable Alzheimer Disease Source: Alzheimer Disease and Associated Disorders. 13(2): 88-90. 1999. Summary: This article presents case studies of two patients with Alzheimer's disease (AD) who committed suicide during a clinical trial for eptastigmine, a cholinesterase inhibitor. A 57-year-old man who had developed symptoms approximately 2 years before his death died from a self-inflicted gunshot wound; and a 73-year-old man who developed symptoms approximately 3 years before his death jumped from a 19th story window. These patients shared several clinical features found in the literature, including being in the early stage of the disease; having a high level of education with preserved insight; having access to firearms; and being aware of not responding to pharmacological treatment. Case studies from the literature are examined in an attempt to identify additional factors that may contribute to the decision of AD patients to
4
Suicide
commit suicide. The authors conclude that the presence of certain risk factors increases the risk of a person with AD committing suicide, even in the absence of classic suicide risk factors. 11 references. •
Case Studies of Suicide in Older Persons With Alzheimer's Disease and Related Dementias Source: Journal of Mental Health and Aging. 4(4): 397-402. Winter 1998. Summary: This commentary addresses the issue of suicide in aged persons with Alzheimer's disease and other dementia and provides patient summaries and brief descriptions of circumstances surrounding eight successful suicides. Suicidal ideation, attempts, depression, and serious physical illness were prominent in this case series. The medical examiner found no ambivalence about accidental death, nor was alcohol or other drug use indicated that would have lowered inhibitions. The case reports suggest that while impaired memory and reasoning may have existed, executive functions and attention were more intact. Also, while some memory loss in patients with Alzheimer's disease and other dementia exists, memories from early periods in a patient's life possibly including violent events often remain, particularly if those events had involved previous attempted suicide, or if another family member had committed suicide. The case studies illustrate that a patient's expressions of wishing to die should not be ignored, and that close monitoring of these patients' mental health is essential. 13 references.
•
Physician-Assisted Suicide in Alzheimer's Disease Source: Journal of the American Geriatrics Society. 45(5): 647-651. May 1997. Summary: This journal article explores the issue of physician-assisted suicide (PAS) in Alzheimer's disease (AD). It reviews arguments for and against PAS in AD, considers the question of equal access for the AD population in relation to the possible legalization of PAS in the United States, and compares practices in the United States and the Netherlands. It examines the potential implications of legalized PAS for a healthcare system with inadequate long-term and hospice care, and explores the possibility of PAS leading to euthanasia of AD patients. The article considers alternatives to PAS that avoid the overtreatment of end-stage patients with severe AD or other dementias. It is noted that a hospice approach is increasingly considered to be highly appropriate for the care of people with advanced dementia. The author suggests that treatment limitations be routinized in the moderate stages of AD according to advance directive or family entrustment. The author recommends caution in moving toward PAS and calls for greater public debate of this issue. 26 references.
•
Attitudes of Elderly Patients and Their Families Toward Physician-Assisted Suicide Source: Archives of Internal Medicine. 156: 2240-2248. October 28, 1996. Summary: This journal article describes a study of the attitudes of 168 older patients and 146 of their relatives toward physician-assisted suicide (PAS). The study also explored how accurately family members could predict patients' attitudes toward PAS and the extent to which they agreed on their predictions. Older patients receiving outpatient care for medical and psychiatric problems were asked about their attitudes toward PAS in cases of terminal illness, chronic illness, and mental incompetence. Relatives were asked the same questions and also were asked to predict how the patient had responded. The results suggest that relatives were more likely than patients to favor PAS for terminally ill people (59 percent versus 40 percent) and to favor legalization of
Studies
5
PAS (56 percent versus 34 percent), but similar proportions were in favor of PAS for chronically ill patients (25 percent versus 18 percent) and for mentally incompetent patients (15 percent versus 14 percent). The family members showed a marginal ability to predict patients' attitudes toward PAS, and they had difficulty agreeing with each other on these predictions. According to the authors, the patients who opposed PAS were those who may be most vulnerable to the misuse of PAS: women, African Americans, people with less education, people with lower incomes, and people with dementia. 5 tables, 28 references. •
Suicide in Two Patients With Alzheimer's Disease Source: Journal of the American Geriatrics Society. 43(2): 187-189. February 1995. Summary: This article presents case reports of two patients who were diagnosed with probable Alzheimer's disease and who had committed suicide: a 54-year-old woman whose intentional death was physician-assisted, and an 80-year-old man who died from a self-inflicted gunshot wound. Both patients were highly educated professionals in the early stages of dementia with unusually intact insight as to the nature of their disease and their future severe disability. Both patients had enrolled in experimental drug treatment trials and eventually became disappointed with the results. Neither patient had classic risk factors for suicide, nor suffered from depressive disorders, psychiatric illness, a history of previous suicide attempts, or substance abuse. The cases suggest that patients with probable AD may commit suicide and that patients with preserved insight who perceive that they are not responding to treatment must be considered as potential suicide candidates even in the absence of other risk factors. 21 references.
•
Alzheimer Disease and Physician-Assisted Suicide Source: Alzheimer Disease and Associated Disorders. 7(2): 65-68. Summer 1993. Summary: This journal article examines ethical issues related to Alzheimer's disease and physician assisted suicide. The author cites the 1990 case in which the Michigan pathologist Jack Kevorkian assisted a 54 year old woman in suicide. The woman was in the early stages of Alzheimer's disease and did not want to face further decline. The author suggests that legalization of assisted suicide for such reasons may impede both the development of Alzheimer care programs that make dementia more tolerable and the elimination of restrictive laws in the area of treatment refusal and withdrawal. In addition, he presents evidence indicating that elderly people with terminal illnesses have a relatively low orientation toward self destruction and, with adequate palliative and long term care, would prefer to continue living. He concludes that the acceptance of assisted suicide is incompatible with the goal of creating a health care system that provides good care for the terminally ill or those with long term progressive illness such as Alzheimer's disease. 9 references.
•
Geriatricians' Attitudes Toward Assisting Suicide of Dementia Patients Source: Journal of the American Geriatrics Society. 40(9): 878-885. September 1992. Summary: This study explored the attitudes of Board-certified internist geriatricians in four regions of the United States toward physician-assisted suicide of dementia patients, with specific reference to the case of Janet Adkins and Dr. Kevorkian. In May 1990, Dr. Kevorkian helped Mrs. Adkins, a woman in her 50's with a diagnosis of Alzheimer's disease, to end her life. A total of 727 geriatricians responded to a questionnaire that asked six questions about physician-assisted suicide of dementia patients, two of which were specifically about the Adkins case. The respondents judged Dr. Kevorkian harshly:
6
Suicide
66 percent felt his action was not morally justifiable, while 14 percent felt it was. Respondents, however, were more sympathetic towards Mrs. Adkins. Only 29 percent believed that her decision to commit suicide was morally wrong, versus 49 percent who felt it was not; 41 percent felt that if they themselves were in Adkin's place they would consider suicide, and 39 percent said that they would not. A total of 57 percent of respondents opposed easing restrictions on physician-assisted suicide of competent dementia patients, and only 26 percent were in favor of easing restrictions. Geriatricians in the Midwest tended to be more conservative in their responses than those in the Far West or Northeast. The authors conclude that the range of responses to the survey are a measure of the helplessness experienced by physicians, patients, and the general public alike at the prospect of a chronic, debilitating illness like Alzheimer's disease. 15 references. •
Morals and Moralism in the Debate Over Euthanasia and Assisted Suicide Source: New England Journal of Medicine. 323(11): 750-752. September 13, 1990. Summary: The newspaper headlines in early June about Dr. Jack Kevorkian and the 'suicide machine' with which Mrs. Janet Adkins took her life captured the attention of the nation and stimulated anew the long-running public debate over assisted suicide and euthanasia. A remarkably consistent series of interviews with the press, physicians, lawyers, and ethicists expressed their abhorrence of Dr. Kevorkian's act. However, the unusual circumstances of this highly publicized case should not be permitted to obscure the profound and genuine suffering and legitimate wish for release that motivates some patients to consider suicide. The debate over assisted suicide and euthanasia should shift to an examination of the needs and values of patients in a context that recognizes the limits of modern medicine and the inevitability of death. A strict proscription against aiding in death may betray a limited conceptual framework that seeks the safety of ironclad rules and principles to protect the physician from the true complexity of individual cases. 10 references.
•
Suicide in Tinnitus Sufferers Source: Journal of Audiological Medicine. Volume 1: 30-37. 1992. Summary: In this article, the authors report six case histories of patients who died in violent circumstances (five suicides and one killed by his son). The authors discuss the role of tinnitus as a factor leading to their deaths, and also consider the potential risk factors for suicide, in terms of demographic features, associated mental illness, and tinnitus parameters. The patients in this group were mainly working class, male, lived alone, and had a history of psychiatric illness and previous suicide threats or attempts. Their tinnitus was generally of recent onset, pulsatile, and in their left ear. The number of cases quoted is small, so it is difficult to make firm conclusions, but the authors believe this represents the first published series on the subject. 1 table. 10 references. (AA-M).
•
Suicidal Thinking in Community Residents Over Eighty Source: International Journal of Geriatric Psychiatry. 12: 337-343. 1997. Summary: This journal article describes a study of the relationship between suicidal thinking and both cognitive impairment and depression in community residents aged 81 years and older in Cambridge, United Kingdom. A random sample of 125 patients and 118 informants was drawn from an preexisting epidemiological study of dementia. Participants were interviewed using the Cambridge Examination for Mental Disorders
Studies
7
of the Elderly (CAMDEX). Patient and informant versions of the 15-item Geriatric Depression Scale (GDS) and the Scale for Suicidal Ideation were incorporated into the CAMDEX. The most common psychiatric diagnosis was Alzheimer's disease (AD), either alone or coexisting with vascular dementia. Nine participants, all women, had experienced suicidal thoughts within the previous 2 years. All of these women had other medical diagnoses, the most common of which was cardiovascular disease. Patients with suicidal thinking had higher CAMDEX depression scores, a weaker wish to go on living, a stronger wish to die, and higher rates of depressive illness and mixed AD/vascular dementia as primary psychiatric diagnoses. Suicidal thinking was not associated with GDS score, AD alone, awareness of memory difficulties, or severity of dementia. 1 figure, 3 tables, 35 references.
Federally Funded Research on Suicide The U.S. Government supports a variety of research studies relating to suicide. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to suicide. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore suicide. The following is typical of the type of information found when searching the CRISP database for suicide: •
Project Title: 5-HT2C-RECEPTOR EXPRESSION AND FUNCTION IN DEPRESSION Principal Investigator & Institution: Schmauss, Claudia; Psychiatry; Columbia University Health Sciences New York, NY 10032 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2004 Summary: (Applicant's abstract) The expression and function of one subtype of serotonin (5-HT) receptors, the 5-HT2C receptor, is regulated by RNA editing and alternative splicing of its encoded pre-mRNA. In postmortem prefrontal cortical tissue from depressed suicide victims, the editing pattern of 5-HT2C pre-mRNA differs significantly from the editing pattern of control brains that could potentially result in a decreased efficiency of 5-HT2C receptor-G protein interactions. The overall objectives of the proposed research plan are to varify further a possible relationship between depression and an altered editing pattern of prefrontal cortical 5-HT2C pre-mRNA, and to define the possible functional consequences of this altered editing pattern and to test possible underlying mechanisms. Three specific aims are proposed to attain these objectives. In specific aim 1, the investigator proposes an extended replication of the differential 5-HT2C editing finding piloting this work. The 5-HT2C receptor editing
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
8
Suicide
pattern would be compared in brains of groups of male depressed suicide victims and depressed non-suicide subjects to assess the relative contribution of depression versus suicide. Editing patterns of 5-HT2C receptor mRNAs would be identified by nucleotide sequencing of cDNAs generated by RT-PCR. Proposed specific aim 2 would assess the functional significance of altered 5 HT2C receptor mRNA editing using stably transfected lines of NIH3T3 cells that express the three major altered 5-HT2C receptor isoforms associated with depression, as well as the more rare nonedited and fully edited isoforms. Functional assays would determine the comparative ability of the edited and nonedited isoforms to couple to G protein and activate the phospholipase C second messenger system. The effects of RNA editing on the guanyl nucleotide sensitivity of 5HT2C receptor-G protein interactions, and the interaction of different receptor isoforms would also be preliminarily assessed. Related functional experiments would compare GTP(S binding to membranes of prefrontal cortical tissues of depressed suicide victims and depressed non-suicide subjects to determine the effect of 5-HT2C editing alterations associated with depression on basal and agonist-promoted activation of G proteins by 5HT2C receptors. Specific aim 3 would compare the effects of mechanistically distinct antidepressants, and the 5-HT2A/2C receptor antagonist ketanserin, on the neocortical 5-HT2C receptor RNA editing pattern, in wild-type mice. These studies would attempt to assess whether the observed alteration of 5-HT2C RNA editing in depression reflects medication effects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: A PROSPECTIVE STUDY OF SUICIDE PREVENTION IN THE USAF Principal Investigator & Institution: Knox, Kerry L. Assistant Professor; Community and Prev Medicine; University of Rochester Orpa - Rc Box 270140 Rochester, NY 14627 Timing: Fiscal Year 2002; Project Start 22-JUL-2002; Project End 30-JUN-2007 Summary: (provided by applicant): The overall goal of this proposal is to allow me to develop the skills necessary to become an independent investigator and a leading scholar in the design and evaluation of the effectiveness of community-based preventive mental health intervention research. My primary focus will be on prevention of suicide. I have a unique opportunity to assess, both retrospectively and prospectively, the effects of a program developed in the United States Air Force that may have implemented effective strategies for reducing the suicide rate among its members. The program in the USAF is an unusual example of a community level prevention to address suicide prevention specifically, and mental health illness in general, integrating universal and targeted approaches to prevention. In the United States, research and programs on prevention of suicide and related morbidities has languished while other public health challenges have not. In part this has been due to the lack of political and social will to address mental health problems, especially suicide. Recently, our nation's top leading public health official, the U.S. Surgeon General recognized prevention of suicide and suicidal behaviors as a national priority. Taken together, my current capacity to access a "naturalistic laboratory", in a climate of political imperative to advance the status of the field of suicide prevention, renders a prospect of tremendous potential for participating in advancing the field of mental preventive mental health. As the field of preventive trials for mental health moves forward, the availability of investigators who are broadly trained not only to conduct program evaluations but also can direct and carry out field trials for the evaluation of the effectiveness of interventions will become vital. I propose to transition to this level of competency, through engaging in a rigorous training program with a interdisciplinary team of mentors, expert consultants and collaborators. This career development award will build upon my already strong skills in
Studies
9
epidemiology and public health, social sciences, and basic science research. It is designed to enhance my knowledge and skills in preventive mental health, focusing on suicide, and to develop new skills in investigative methodologies applicable to field trials. The major research question of this proposal is to investigate whether the USAF Suicide Prevention Program results in a reduction in events of suicide, attempted suicide, and related morbidities, such as domestic violence, alcoholism and depression and maintains the reduction over time. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACUTE PHARMACOTHERAPY OF UNIPOLAR PSYCHOTIC DEPRESSION Principal Investigator & Institution: Flint, Alastair J.; Uhn Toronto General Hospital 200 Elizabeth St, Ccrw1-800 Toronto, Timing: Fiscal Year 2002; Project Start 06-SEP-2002; Project End 31-MAY-2007 Summary: (provided by applicant): Psychotic depression (PD) is a severe disorder that is present in 20% of mixed-age inpatients and in more than 40% of elderly inpatients hospitalized for the treatment of major depression. Acutely, PD is associated with a greater level of depression severity, functional impairment, and resistance to antidepressant treatment than nonpsychotic depression. Longitudinally, PD is associated with a greater likelihood of recurrence, a shorter symptom-free interval, greater disability, and an increased long-term risk of suicide. Among elderly patients, PD has also been associated with a high one year mortality rate. Although electroconvulsive therapy (ECT) is a highly effective treatment for PD, pharmacotherapy is more easily administered and generally preferred by many patients and psychiatrists. Furthermore, ECT is less available to, and less frequently used by minority ethnic groups, patients with low incomes, and those residing in rural areas. In the early 1980's a landmark NIMH randomized controlled trial demonstrated that a combination of high doses of both a tertiary amine tricyclic and a conventional antipsychotic was more efficacious than monotherapy with either medication. However, this combination has been associated with a high incidence of significant side effects, particularly in elderly patients. This collaborative U01 project builds on findings from the four sites principal investigators and others. Based on preliminary studies suggesting that sertraline, a serotonin-reuptake-inhibitor (SSRI) and olanzapine, an atypical antipsychotic, may be effective in the acute treatment of PD, this study uses a two-armed randomized doubleblind parallel-group design to compare the efficacay and tolerability of combining these two medications to olanzapine alone. By blocking recruitment of subjects age greater than or equal to 60 on a 1:1 basis the study will determine the relationship between older age and remission, time to remission and tolerability. A 12-week acute phase efficacy study is followed by a 20-week continuation trial during which subjects who achieved partial remission enter a placebo-controlled augmentation trial that is based on their initial assignment. Remitted subjects are also followed during stabilization to determine the stability of remission and predictors of clinical and functional deterioration. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ADOLESCENT DEVELOPMENT:VULNERABILITIES/OPPORTUNITIES
BRAIN
Principal Investigator & Institution: Dahl, Ronald E. Professor; New York Academy of Sciences 2 E 63Rd St New York, NY 10021 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2004
10 Suicide
Summary: (provided by applicant): The New York Academy of Sciences is sponsoring a 2.5 day conference titled "Adolescent Brain Development: Vulnerabilities and Opportunities," scheduled for September 18-20, 2003, in New York City. Adolescent development involves complex changes in neurobehavioral systems underpinning the control of emotion and behavior; this period is often difficult and accompanied with steep rise in mortality and morbidity related to the control of behavior and emotions, some of which have significant long-term consequences. A multitude of biological, psychological, and social changes occur rapidly during this interval and a developmental framework is essential to examine questions about specific maturational processes-including pubertal brain and body changes-and the unique opportunities and vulnerabilities created by these developmental processes. Establishing a better understanding of these processes can help inform the timing and focus of interventions (and eventually preventive efforts) to shift the trajectories away from negative outcomes, and toward healthy positive pathways. A critical problem in this area is the dearth of basic knowledge about human brain development during puberty and adolescence-particularly the maturation of neurobehavioral systems involved in affect regulation and behavioral choices that have enormous clinical and social policy relevance. However, significant progress has recently been made in a number of areas relevant to these issues. There is a critical need at this time for better integration across the variety of areas where rapid progress is being made with a specific focus on the neurobehavioral changes during normal adolescent development that contribute to increased risk-taking and/or reward seeking. The purpose of this conference is to bring together basic and clinical investigators from a number of different areas to begin a better-integrated dialogue to move the field forward. Discussion during the conference will include studies in animal models that can inform key aspects of human brain development and the usefulness of new tools (such as functional neuroimaging and genetic studies). The long-term goal is to stimulate further interdisciplinary research and advance understanding with clinical and policy relevance to a wide range of adolescentonset health problems-particularly the development of nicotine dependence, alcohol and other substance use, risk-taking behaviors, depression and suicide. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ADOLESCENT PATHWAYS TO MOOD DISORDER AND RISK OF SUICIDE Principal Investigator & Institution: Greenhill, Laurence L. Professor; New York State Psychiatric Institute 1051 Riverside Dr New York, NY 10032 Timing: Fiscal Year 2001 Summary: This application is for a five-year project that uses a high-risk design to study the familial transmission of early-onset suicidal behavior. The probands consist of 200 adolescents depressed suicide attempters and non-attempters who will be well characterized in studies at NYS Psychiatric Institute. We will recruit some of this group from a cohort of 100 individuals previously studied for serotonergic function by us under R01 MH47113 at which time they were adolescents with major depression and half were suicide attempters. For each proband, the biological parents and full siblings (age 10 and older) of adolescent/young adult attempters and non-attempters will also be studied. Probands and their biological first-degree relatives will be characterized as to Axis I and II disorder, suicide attempt history, tendency to impulsive aggression and family environment. Parents and siblings will be genotyped with polymorphic markers for tryptophan hydroxylase and other candidate genes per Projects 2 and 4. After initial assessment, the probands and their siblings 24 years old or less will be followed at one
Studies 11
and years after intake to observe the development of aggression, psychopathology, and suicidal behavior. The project will test the following hypotheses: (1) first- degree relatives of adolescent attempters will have higher rates of suicide attempts than the offspring of non-attempters; (2) impulsive aggression will be greater in relative of attempters, and will predict development of suicide attempts in siblings, especially in those siblings who also develop Axis I disorders; (3) the familial transmission of suicide attempts will not be explained by the familial transmission of mood disorders alone; (4) familial transmission of suicide attempts will persist after controlling for the expected greater exposure to familial adversity in the offspring of attempters; and (5) polymorphism of the of the tryptophan hydroxylase gene and other genes related to central serotonergic function will be associated with impulsive aggression and suicide attempts among proband and their first-degree relatives. We will also acquire pilot data on the relationship of baseline serotonergic and clinical indices to long-term outcome in the 100 previously studied cases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ADOLESCENT PSYCHOPATHOLOGY AND ALCOHOL USE DISORDERS Principal Investigator & Institution: Clark, Duncan B. Associate Professor; Psychiatry; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2001; Project Start 01-SEP-1999; Project End 31-AUG-2004 Summary: This Independent Scientist Award (K02) is proposed for the applicant to acquire necessary skills to apply the developmental psychopathology conceptual framework and innovative statistical techniques for categorical longitudinal data to creating a model for the relationships among alcohol use disorders (AUD) and other mental disorders in adolescence. Based on empirical findings to date, the specific hypotheses focus on antisocial disorders (i.e., conduct disorder, oppositional defiant disorder) and negative affect disorders (i.e., mood and anxiety disorders) as possible predictors, consequences, or moderators of the structure, course and consequences of adolescent AUD. The applicant, trained as a child clinical psychologist and adult psychiatrist, is the Scientific Director of the NIAAA-funded Pittsburgh Adolescent Alcohol Research Center (PAARC). The career development plan focuses on the acquisition of a thorough foundation in statistical modeling techniques and related methodological issues, including the implications of sampling strategies, missing data imputation, model selection, and controversies concerning causal inference from observational data. The applicant will learn statistical methods based on regression for modeling time-dependent relationships among continuous and categorical variables. The focus on methods for categorical variables is relevant to longitudinal research involving symptom and diagnostic categories. Relevant statistical techniques include methods for observed variables, including proportional hazards and random regression modeling and methods for latent variables, including latent class analysis, latent transition analysis, and growth mixture modeling with latent trajectory classes. Bayesian approaches to model selection and causal inference will also be considered. These methods will be specifically applied to examining the relationships among AUD, antisocial disorders, and negative affect disorders using longitudinal data from PAARC (n=1000 adolescents). Methods for evaluating the extent and the influence of sampling bias will assessed through comparison of the model generated using PAARC data with models generated with other data sets, including studies using high-risk and community sampling approaches. The integration of the concepts of developmental psychopathology with innovative longitudinal statistical modeling methods will
12 Suicide
contribute to the applicant's long-term career goal to advance research on adolescent AUD by clarifying the importance of psychopathology in determining the structure, course and consequences of adolescent alcohol abuse and dependence. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ADOLESCENT ORIENTATION
SUBSTANCE
USE,
SUICIDE
AND
SEXUAL
Principal Investigator & Institution: Feldman, Michael J.; New York State Psychiatric Institute 1051 Riverside Dr New York, NY 10032 Timing: Fiscal Year 2001; Project Start 20-SEP-2001; Project End 31-AUG-2003 Summary: (provided by the applicant) Substance use disorders in adolescents are a serious public health problem. They can be chronic, cause significant impairment in school and social functioning and show marked continuity with adult substance use disorders. Prior research demonstrates that drug use is especially prominent among gay, lesbian and bisexual (GLB) youth. It may be related to the increased rates of suicide attempts seen in this population. The overall goal of this study is to compare levels of alcohol and illicit substance use, in GLB youth, to those in heterosexual peers. It will also assess substance use as a potential mechanism to explain the relationship between GLB status and suicide. We propose a secondary analysis of two different samples that will include younger as well as older GLB youth. One sample is the first wave of a longitudinal epidemiological study of Puerto Rican youth, age 11- 13 years. That study compares levels of antisocial behavior in Puerto Rican youth living in one borough of New York City (N=375) to those for youth living in metropolitan San Juan, Puerto Rico (N=375). Each youth and a parent are assessed for psychiatric symptoms, drug use, impairment and risk and protective factors. Each youth also completes a sexual development interview. The other sample, (N=1,500, compares rates of suicidality in youth exposed to a recent suicide at their school to rates for youth from matched control schools. This two-stage study screens youth for psychiatric disorders, drug use, and suicidality in addition to psychosocial risk factors and sexual development. Specific aims of the proposed study are: (1) To describe and compare rates of alcohol, marijuana and other illicit drug use in different sexual orientation groups, (2) To extend the findings regarding drug use from older to younger GLB youth less than 14 years of age, (3) To examine rates of attempts, psychiatric disorders and comorbidity related to sexual orientation, (4) To examine whether concurrent psychiatric illness is a mediator in the relationship between GLB status and drug use, and (5) To examine whether drug use is a mediator in the association between GLB status and attempts. Although the proposed study uses only cross-sectional data, it offers a unique opportunity to examine sexual orientation in large samples that include significant proportions of younger and ethnically diverse youth. The findings will contribute to the description of psychiatric problems associated with a GLB orientation and generate further hypotheses to explore what mechanisms link a GLB sexual orientation with drug use and suicidality. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALCOHOL AND INTENTIONAL INJURY IN THE U.S ARMY Principal Investigator & Institution: Bell, Nicole S.; Social Sectors Develop Strategies Strategies, Inc. (Ssds) Natick, MA 01760 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2005 Summary: Alcohol use has been linked to family violence, assaults, and suicides. Some studies suggest that all these forms of intentional injury may result from a similar
Studies 13
constellation of risk factors, such as alcohol abuse, depression, impulsivity, and aggression. The factors that may mediate the role of alcohol and those that may determine whether the endpoint is violence against others versus violence against self are less clear. Long-term health and occupational experiences of perpetrators and victims of violence are not clear, nor have potential modifying factors for these outcomes been elucidated. Specific Aims: This study uses a large linked database to identify fixed and time-varying factors that modify the relationship between alcohol use and perpetrating or experiencing violence or suicide. Factors can be measured prior to the event as well as during the event. In addition, we will follow perpetrators and victims of violence subsequent to the violent episode to document long-term health and occupational experiences of these individuals. Methods: This study uses data from the Total Army Injury and Health Outcomes Database (TAIHOD). Data are available on almost 3 million unique soldiers who were on active duty 1980-1998, including personnel records (occupation, hazardous duty pay, gender, age, rank, education, marital status, dependents, overseas assignments-all updated every 6 months), hospitalization (including ICD-9-CM codes, cause of injury codes indicating mechanism and intentionality), disability evaluations, health habit surveys (including typical alcohol use, the CAGE, drinking and driving, and, other health behaviors, and satisfaction with one's life and family), occupational surveys (job satisfaction, harassment on the job) and outpatient data. In addition, Spouse Abuse Registry Data have recently been added to the TAIHOD, which include information on victims and perpetrators as well as severity of the assault. Most questions will be addressed using a retrospective cohort design. Standard time-to-event statistical techniques will be employed (e.g., Cox Proportional Hazards Models). MIMIC models (i.e., confirmatory factor analyses with background variables) will be used to investigate more complex relationships where there may be multiple possible outcomes (e.g., different levels of severity of assault; or violence against self versus others). Conclusions: This study offers a number of advantages over prior research. This population is fully employed and has full access to healthcare and housing, controlling many potential socioeconomic confounders. Data are very complete with little lost information. Data for both victims and perpetrators regarding the incident of violence, precursors to the event, and longrange health and occupational outcomes are available. This study will allow us to costeffectively assess the role of alcohol in intentional injuries, for a large diverse population encompassing a wide range of occupational, racial, and gender groups. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALCOHOL CONSUMPTION & SPECIFIC CAUSES OF FATAL INJURIES Principal Investigator & Institution: Chen, Li-Hui; Health Policy and Management; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 31-JUL-2003 Summary: (provided by applicant): The broad objectives of this proposal are to better understand the relationship between usual drinking behavior and the incidence of various types of fatal injuries among different age, gender, and race/ethnic groups, and to use this to prevent further fatalities. The specific aims of this proposal are: 1) To compare specific types of fatal injuries with regard to their association with usual drinking behavior and to determine the effect of usual drinking.behavior on various types of fatal injuries. 2) To examine the association of usual drinking behavior with the risk of various types of fatal injuries by age, gender, and race/ethnic groups. 3) To disseminate the results to both scientific and public communities and to make relevant
14 Suicide
policy recommendations. Injuries are the third leading cause of death, claiming more than 145,000 lives each year in the United States. Although acute alcohol consumption is an established risk factor for fatal injuries, little is known of the relationship between usual drinking behavior and risk of fatal injury among various types of causes and different age, gender, and race/ethnic groups. Previous research on alcohol and injury either is limited to select population groups, or lacks sufficient sample size. Moreover, no published paper simultaneously explores major specific injury categories in relation to alcohol consumption, based on the general population. The proposed population based case-control project will be based on two nationwide surveys, the 1993 National Mortality Followback Survey (NMFS) and the 1992 National Longitudinal Alcohol Epidemiologic Survey (NLAES). Cases will be deaths in the United States due to various types of injuries; each will be analyzed separately -- they include motor vehicle injuries, unintentional poisoning, unintentional falls, unintentional fire deaths, unintentional drowning, firearm related unintentional injuries, firearm related suicide, other suicide, firearm related homicide, and other homicide Controls will be all respondents in the NLAES and from the same population as NMFS. Stratified analyses will be performed on each individual injury having sufficient number of cases. Age, gender, race/ethnicity, education, employment, occupation, income, marriage status, geographic region, and illicit drug use will be considered in analyses. Weighted analyses will be performed using SUDAAN. The results will provide needed information for evaluating injury related alcohol policies and for developing new intervention programs to effectively improve safety and for designing further studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALCOHOL DEPENDENCE AND SUICIDE Principal Investigator & Institution: Conner, Kenneth R. Assistant Professor; Psychiatry; University of Rochester Orpa - Rc Box 270140 Rochester, NY 14627 Timing: Fiscal Year 2001; Project Start 14-SEP-2000; Project End 31-AUG-2005 Summary: This award will allow the Principal Investigator, Dr. Conner, to develop expertise in the study of suicide risk-identification in alcoholics. He will develop expertise through collaborative research and research training at the University of Rochester Center for the Study and Prevention of Suicide (CSPS) and education and training in alcoholism research at the Research Institute on Addictions (RIA) in Buffalo, NY. He will also earn a Master's in Public Health degree. Following the award, his goal is to continue programmatic research on the identification of risk factors for suicide in alcoholics, to apply this knowledge in developing community and clinic-based riskassessment and prevention strategies, and in the long-term to reduce suicide morbidity and mortality in alcoholics. He has chosen to focus on alcoholism, suicide and their association because of their profound public health significance. Alcohol use disorders are the most common psychiatric diagnosis among suicide victims under age 50 but very little is known about the risk factors for suicide in alcoholics. The proposed research is a case-control study of 60 alcohol-dependent suicide victims age 18-49 compared with 60 community controls and 60 clinic controls with alcohol dependence matched for gender, race and age. Cases will be from the population of all suicides in this age group identified over a 3 year period in Monroe County, NY (Rochester) and six surrounding rural counties identified by the Monroe County Medical Examiner. Information about cases and controls will be gathered using comparable methods of informant interviews, structured questionnaires, and record review. The study will test a model for suicide in alcoholism with four foci: aggression, depression, attachment disruption, and alcohol and drug misuse severity. Multiple logistic regression is the
Studies 15
principal analytic strategy, with separate analyses for comparisons of suicide victims and clinic controls and community controls respectively. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALCOHOLISM IN WOMEN WITH ANOREXIA AND BULIMIA NERVOSA Principal Investigator & Institution: Herzog, David B. Professor; Massachusetts General Hospital 55 Fruit St Boston, MA 02114 Timing: Fiscal Year 2003; Project Start 15-MAY-2003; Project End 30-APR-2005 Summary: (provided by applicant): This is a revised submission of a proposal to conduct secondary analyses of alcoholism (ALC) in women with eating disorders (EDs). The co-occurrence of ALC and EDs has been well documented. To date, there have been no prospective studies reporting on the course and sequence of comorbid EDs and ALC. The aims of this study are to 1) describe the association between ALC and EDs 2) examine the longitudinal sequence of comorbidity in terms of onset, remission, relapse, and mortality and 3) test a conceptual model that describes the nature of the association between ALC and EDs. The data will also allow for the analysis of longitudinal patterns of alcohol consumption in women with ALC and EDs. A longitudinal, prospective, naturalistic study of 246 treatment-seeking women with AN and BN has been conducted for a median of 9 years with a low attrition rate of 7%. Extensive data on weekly assessments of ED symptomatology, ALC, comorbid psychopathology, and treatment participation, as well as monthly ratings of psychosocial functioning have been gathered. At entry into the longitudinal study, 42 (17%) participants reported a history of ALC. During the course of 9-year follow-up, 24 (12%) of the women with no history of ALC were diagnosed with ALC prospectively, resulting in a total of 66 (27%) women reporting a lifetime history of ALC in the sample. During the course of followup, 6 women from this subset have died, resulting in 60 remaining subjects with a lifetime history of ALC2 Preliminary analyses show fatal outcome was associated with severity of ALC over the course of follow-up, even after controlling for age and duration of ED episode at intake (LRT = 11.0, df= 1, p =.0009). [Lifetime history of ALC was marked in three of the four deaths by suicide, and severity of ALC over the course of the study was associated with increased rates of suicide attempts in women with AN (LRT = 7.02, df = 1, p =.008).] Findings from this study will inform clinicians and patients about the nature of the association between ALC land EDs, underscore interactions between course and outcome variables, and assist in the design of future ALC and ED treatment studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANGIOTENSIN AND CELLULAR MEDIATORS OF VASCULAR APOPTOSIS Principal Investigator & Institution: Gibbons, Gary H. Associate Professor; Medicine; Morehouse School of Medicine Atlanta, GA 30310 Timing: Fiscal Year 2001; Project Start 15-APR-1998; Project End 31-MAR-2002 Summary: (Adapted from Investigator's Abstract): An emerging body of evidence suggests that vascular cell programmed cell death or apoptosis may be an important determinant of vascular remodeling and lesion formation during the pathogenesis of diseases such as hypertension and atherosclerosis. Although the phenomenon is well described, the factors that regulate vascular smooth muscle cell (VSMC) death in vascular disease are poorly characterized. The applicant is intrigued by his observation
16 Suicide
that angiotensin II (Ang 11) inhibits VSMC apoptosis via the AT-1 receptor, yet induces VSMC apoptosis via the AT-2 receptor. However, little is known about the mechanisms by which G-protein-coupled receptors modulate programmed cell death. The goal of the proposed project is to systematically dissect the signal transduction pathways that couple extracellular factors such as Ang II with intracellular mediators of the genetic program governing VSMC suicide. The observation that a single ligand (Ang II) can induce diametric effects on the regulation of VSMC apoptosis provides the applicant with a unique opportunity to define the molecular mechanisms by which cell membrane receptor activation specifies whether VSMC survive or die. The proposed project will test the hypothesis that the opposing effects of AT-1 vs AT-2 receptor stimulation on VSMC fate involves a differential activation of G-proteins that transduce countervailing influences on the activation of protein kinase-mediated signals coupled to the regulation of VSMC apoptosis. Specifically, the studies will focus on defining the role of a sequential signaling cascade involving PI-3-kinase, ERK and Akt as essential mediators of the anti-apoptotic effect of Ang II. The proposed project will utilize both pharmacologic and genetic approaches to systematically define the components of the signal transduction that are necessary and sufficient for preventing VSMC death in response to Ang II. Genetic engineering technologies will be employed to create novel in vitro and in vivo model systems for characterizing the molecular determinants of VSMC fate. It is anticipated that the comparative analysis of AT-1 vs AT-2 receptors will elucidate how differences in structural motifs encoded in Ang 11 receptors selectively specify whether VSMC live or die by differential activation of G-proteins, PI-3-kinase, ERK and Akt. These studies will provide important new insights into the molecular mechanisms governing the cell suicide program in VSMC and the potential role of apoptosis in the pathogenesis of vascular diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTIPROGESTINS AND ACTIVE CELL DEATH IN BREAST CANCER Principal Investigator & Institution: El Etreby, M F. Surgery; Medical College of Georgia 1120 15Th St Augusta, GA 30912 Timing: Fiscal Year 2000; Project Start 01-JUL-1998; Project End 30-JUN-2004 Summary: (adapted from the applicants abstract) Antiprogestins are a promising new class of mammary tumor inhibitors with a unique mechanism of action which does not seem to involve a classical progesterone antagonism. The objective of this application is to confirm an additive antitumor activity and to clarify the intracellular mechanism of action of the antiprogestin mifepristone, and the antiestrogen tamoxifen, in inhibition of growth of established tumors (chemotherapy) and in prevention or delay of tumor development (chemoprevention/adjuvant setting) in clinically relevant breast cancer models. The focus of the mechanistic studies is to explore the role of (and the specific pathways for) induction of apoptosis in breast cancer cells as a treatment response. The importance of (and the effect of treatments on) estrogen (ER) and progesterone (PR) receptors as well as the potential additive or synergistic interaction between mifepristone and tamoxifen will also be explored. The research design includes the use of the ER(+) and PR(+) MCF-7 and the ER(-) and PR(-) MDA-231 human breast cancer cell lines grown in culture (in vitro studies) or inoculated into female nude mice supplemented with 17BETA-estradiol (in vivo studies). Companion experiments utilizing the MXT [hormone-dependent ER(+) and PR(+)] and MXT-OVEX [hormoneindependent ER(-) and PR(-)] homograft mammary carcinoma models of the mouse are also included to compare the antitumor effects in a normal (nonimmunologically
Studies 17
suppressed) animal with those induced in nude mice. The following cellular parameters and their time-dependent sequence will be assessed: morphological features (e.g., mitotic and apoptotic indices), in vitro cell viability (cytotoxicity), Cdk1 protein concentration, DNA fragmentation, PKA and PKC isoform activity and subcellular distribution, as well as the changes in the expression of bax, bcl2 and TGFBETA isoforms. The expression of other known "cell death genes" or "cell cycle determinants" will also be included whenever they seem appropriate. These various outcome measures will be evaluated using immunocytochemistry, pulsed field gel electrophoresis, Western blots, Northern analysis, specific ELISA, enzyme kinetics and saturation lignad binding assays. The results generated from the described studies will confirm an additive antitumor activity of mifepristone and tamoxifen. This activity is mainly the result of a steroid receptor-mediated interaction with the cell suicide mechanism which involves distinct changes in gene expression (an increase in the bax/bcl2 ratio) in distinct subpopulations (different receptor status) of breast cancer cells. These changes initiate a direct and/or an indirect cell death command via distinct PKC or PKA second messenger signaling pathways and/or via expression or specific TGF-b isoforms. Induction of apoptosis in two distinct subpopulations of breast cancer cells and/or through multiple reinforcing molecular biochemical mechanisms would provide an excellent rationale for a combination therapy. The expected additive effect may delay malignant progression, reduce metastatic spread and increase survival of breast cancer patients. The studies could also impact the future clinical development of "antiprogestins" for this indication. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOLOGY OF HEADPIN (A NOVEL SERPIN) IN ORAL CANCER Principal Investigator & Institution: Clayman, Gary L. Associate Professor; Head and Neck Surgery; University of Texas Md Anderson Can Ctr Cancer Center Houston, TX 77030 Timing: Fiscal Year 2002; Project Start 15-JAN-2002; Project End 31-DEC-2006 Summary: Squamous cell carcinoma (SCC) of the oral cavity is a debilitating and often fatal disease afflicting approximately 30,000 individuals annually in the United States and is a major health problem worldwide. To better understand the molecular biology governing the invasive and aggressive behavior of these tumors, differences in gene expression have been studied between non-malignant oral mucosa and SCC derived from the oral cavity. Using differential display reverse transcription-based PCR, a novel serine proteinase inhibitor (serpin) was cloned, called headpin, that is down regulated in SCC biopsies and in 50 percent of established head and neck squamous cell carcinoma (HNSCC) tumor lines. Headpin was mapped to a serpin cluster on chromosome 18q21, which is a region that often exhibits loss of heterozygosity in head and neck cancers. Purified and functional recombinant human headpin (rHeadpin) has been generated and kinetic analysis indicates it is a bona fide suicide-inhibitor of both cathepsin L (catL) and cathepsin K (catK). Immunohistochemistry using a highly specific mAb raised against headpin has confirmed that the protein is abundant in non-malignant oral epithelium and lost or down-regulated in primary and metastatic SCC from the oral cavity. Based on the current body of literature linking expression of catL to progression of tumors, the implicit role of catK in degrading bone extracellular matrix, and the ability of headpin to inhibit both of these enzymes, suggest that loss of headpin protein expression from oral SCCs contributes to their aggressive clinical behavior. To test this hypothesis, the full target spectrum of proteinases inhibited by headpin will be assessed, while investigating the in vitro and in vivo consequences of headpin re-expression in
18 Suicide
tumors, define the mechanism(s) of headpin loss in tumor specimens, and analyze the predictive clinical SIGNIFICANCE of headpin expression in archival specimens from patients with oral SCC. Progress in this area could lead to development of new molecular based targets for the management of oral cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOMATERIAL ACTIVATION/APOPTOSIS
SURFACE
CONTROL
OF
FBGC
Principal Investigator & Institution: Brodbeck, William G. Pathology; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2001; Project Start 01-FEB-2000 Summary: A continuing effort exists to identify methods and mechanisms that can be exploited to enhance the biocompatibility of implanted prosthetic devices. My approach is based on the concept that the foreign body response, which ultimately leads to structural, mechanical, or functional implant failure, can be controlled by modifications in implant materials surface design and properties. Critical cellular components of the foreign body reaction are adherent macrophages and foreign body giant cells (FBGCs), and several functional capacities of these cells, including inflammatory and wound healing cytokine secretions, are influenced by material surface properties. In addition, it has been demonstrated float apoptosis, or intentional cell suicide, can be induced by imposing geometric constraints on other adherent cell types. Therefore, it is hypothesized that the presentation of different surface chemistries and geometric constraints to macrophages and FBGCs can be utilized to influence cytokine production and the induction of apoptosis by these cells. Both in vitro and in vivo model systems will be employed to address two specific aims arising from the hypothesis: First, I will evaluate the effects of different micropatterned surface chemistries and geometric constraints on the activation of macrophages and FBGCs for the production of inflammatory and wound healing cytokines. And, secondly, I will investigate the effects of micropatterned surface chemistries and geometric constraints on the induction of apoptosis of adherent macrophages and FBGCs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIPOLAR DISORDER ACROSS THE LIFE SPAN Principal Investigator & Institution: Calabrese, Joseph R. Professor and Director; Psychiatry; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2003; Project Start 03-SEP-2003; Project End 31-MAY-2008 Summary: (provided by applicant): Bipolar disorder (BPD) affects a minimum of 2.3 million American adults aged 18 and older (1.2% of US population) and in the 5-9% of children with serious emotional disturbances, the prevalence of BPD is unknown, in 1990, BPD in established market economies resulted in 1.7 million years of lost healthy life due to premature death or disability, third only to major depression and schizophrenia. About 15% of patients with BPD commit suicide. The proportion of the NIMH dollar that goes to support research in BPD is less than expected by NIMH leadership, and there are no NIMH-funded BPD research centers. These data suggest there exists an urgent need for an NIMH research center dedicated to BPD research across the life cycle. The proposed Center addresses many of the recommendations in the 1999 "Bridging Science and Services" report by focusing on the utilization of novel longitudinal study designs in complex comorbid groups of patients with BPD from ages 5 through the end of life, as well as by focusing on function and disability, not just
Studies 19
symptom improvement. The scientific theme of this Center will be conduct of studies designed to "improve clinical outcomes in underserved population of BPD, including those receiving care within community mental health centers (CMHC), children and adolescents, and adults currently abusing alcohol and/or drugs. The pilot projects include: 1) a single-center psychosocial intervention study designed to develop an efficient and practical way of improving treatment adherence in 166 adults with BPD in a CMHC, 2) a single-center child services project intended to improve the early and accurate recognition of BPD in 615 children and adolescents evaluated at a CMHC, and 3) a six-month, two-center, double-blind, parallel-group comparison of two regimens of combination therapy (lithium/divalproex/lamotrigine versus lithium/divalproex/placebo) for the acute and continuation outpatient management of 90 adult patients with rapid cycling BPD comorbid with alcohol, cannabis, and/or cocaine abuse/dependence at Case Western Reserve University/University Hospitals of Cleveland and a CMHC. This application will be used to build and maintain a network of sites to conduct clinical trials research that concurrently addresses issues of efficacy and effectiveness in BPD across the life cycle. This Developing Center application will be used to develop research partnerships with community settings and grow ongoing relationships, and is intended to lead to an Advanced Center submission in five years. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CASE CONTROL STUDY OF ALCOHOL OUTLETS & FIREARM VIOLENCE Principal Investigator & Institution: Branas, Charles C. Biostatistics and Epidemiology; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 30-APR-2006 Summary: (provided by applicant): Both interpersonal violence (including homicide) and self-directed violence (including suicide) are the end result of a "causative web" of contributing factors that includes alcohol, firearms, and risky neighborhoods. Nevertheless, injury reduction measures that focus on firearms can sometimes be protracted strategies that must contend with ambivalent political support and uncertain consequences. Because individuals may place themselves at risk simply by entering a neighborhood where alcohol is present, regardless of their consumption, alcohol may function as a strong, although sometimes indirect, contributor to violence committed with firearms. Moreover, the management of certain alcohol-related factors that contribute to violence are often politically easier to accomplish than the management of many firearms-related factors. One reasonable approach to the control of violent deaths due to firearms may be to focus on alcohol outlets. However, the ecological evidence that alcohol outlets produce violence remains conflicted. Localities interested in rezoning alcohol outlets for health reasons are similarly conflicted when deciding how best to proceed. Using Philadelphia County as a study site, a population-based casecontrol study will be conducted to better delineate the causal relationship between alcohol outlets and firearm violence. Cases of firearm injury will be compared with age, race, and gender-matched controls identified with random-digit dialing. This study will specifically aim to answer the following questions: (1) Does geographic proximity to alcohol outlets increase the risk of being injured with a firearm when compared to the genographic proximity of alcohol outlets?; and (3) Does geographic proximity to other non-residential land-uses, such as firearms dealers, fast food restaurants, or minimarkets, pose a differential risk of being injured with a firearm when compared to alcohol outlets? The proposed study will fill several gaps in knowledge that continue to limit the understanding of alcohol outlets and violence: (1) A comparison of individual
20 Suicide
and environmental risk factors for alcohol-related violence; (2) Determination of the influence of alcohol outlets on firearm violence; (3) Analysis of the influence of alcohol outlets on self-directed violence; (4) Analysis of the influence of alcohol outlets on violence using other non-residential land-uses for comparison; and (5) Analysis of the influence of alcohol outlets on violence using a case-control (and not ecological) study design. In this way, health policies to change the numbers and locations of alcohol outlets can become more certain, more effective, and more politically admissible. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CASPASE ACTIVATION IN NEURONAL DEATH Principal Investigator & Institution: Ghatan, Saadi; Neurological Surgery; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2001; Project Start 01-JAN-2001 Summary: (Applicant's abstract): Apoptosis refers to a cellular suicide program employed as part of normal development or in response to cellular injury, as seen in neurodegenerative and ischemic diseases. Caspases are a family of cysteine proteases represented by interleukin 1^D-converting enzyme (ICE), and are distal elements in the apoptotic pathway. They mediate irreversible cellular damage through proteolytic cleavage of specific substrates, but little is known regarding the specific settings in which they are activated or how they are regulated. We propose to test the central hypothesis that within the CNS, caspase activation is dependent upon the developmental stage of the neuron, the specific cytotoxic stimulus it receives, and the upstream signal provided by the proapoptotic gene Bax. We will determine if caspases are regulated in a developmental and injury-dependent manner by measuring caspase activity in embryonic and postnatal neuronal cultures, in response to diverse cellular insults. We will determine if Bax is an upstream regulator of caspases, by measuring caspase activity in wild-type and Bax deficient neuronal cultures, in response to diverse death stimuli. Elucidation of cell death regulatory pathways will delineate targets for selective therapeutic intervention in the treatment of diseases where apoptosis plays a role. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CD19-SPECIFIC T-CELL THERAPY FOR FOLLICULAR LYMPHOMA Principal Investigator & Institution: Cooper, Laurence J.; Beckman Research Inst of City of Hope Helford Building Duarte, CA 910103000 Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): Currently, patients with treatment-refractory follicular lymphoma, the most common sub-type of non-Hodgkin's lymphoma, have a poor chance of disease-free survival and this group needs to be treated with innovative approaches. Adoptive transfer of ex vivo-expanded autologous T cells rendered specific for CD19 is a method proposed to augment tumor-specific immune responses in these patients in order to improve disease control. The specificity for CD19 is derived from a chimeric immunoreceptor expressed on the cell surface of genetically modified T cells that combines antibody recognition of CD19 with the effector-function of activated T cells. A phase I clinical trial is proposed for relapsed/recurrent follicular lymphoma based on the introduction of a CD19-specific chimeric immunoreceptor to render CD8+ and CD4+ T cells capable of targeting CD19+ lymphoma cells in an MHC-independent manner and be deleted by ganciclovir as a result of the co-expression of a bifunctional hygromycinlthymidine kinase (HyTK) selection/suicide gene. Following fludarabine-
Studies 21
based lympho-depleting therapy, research participants will receive low-dose recombinant human interleukin-2 (rhlL-2) and an intra-patient dose escalation of autologous CD19R+HyTK+ T cells, expanded in vitro in compliance with current good manufacturing practice. This study will answer questions regarding the safety and feasibility of infusing CD19-specific HyTK+ T cells (specific aim #1), as well as determining the in vivo persistence (specific aim #2) and immunogenicity of the genetically modified T cells (specific aim #3) and will investigate the antitumor efficacy and lymph node-homing properties of the CD19-specific T cells (specific aim #4). The data collected from this clinical trial will facilitate the design of second-generation adoptive immunotherapy protocols, not just for follicular lymphoma, but other Blineage malignancies. The specific aims of this application are: (1) To determine the feasibility and safety of adoptively transferred autologous CD19R+HyTK+ T cells in research participants with recurrent/refractory follicular lymphoma (2) To determine the persistence of adoptively transferred autologous CD19R+HyTK+ T cells in research participants after lympho-depleting therapy. (3) To determine the immune response against adoptively transferred autologous CD19R+HyTK+ T cells in research participants after lympho-depleting therapy (4) To determine the efficacy of adoptively transferred autologous CD19R+HyTK+ T cells and low-dose rhlL-2 in research participants after lympho-depleting therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELLULAR IMMUNOTHERAPY FOR NEUROBLASTOMA WITH CTL CLONES Principal Investigator & Institution: Jensen, Michael C. Dr. City of Hope National Medical Center Duarte, CA 91010 Timing: Fiscal Year 2001; Project Start 17-SEP-2001; Project End 31-AUG-2003 Summary: (Provided by applicant): Disease relapse is the leading cause of mortality for children diagnosed with disseminated neuroblastoma despite the use of highly intensive front-line therapy. Studies conducted in our laboratory have focused on developing strategies to target neuroblastoma with adoptively transferred T lymphocytes genetically modified to express a chimeric immunoreceptor, designated CE7R, for redirected recognition of a neuroblastoma-specific epitope on the L1-CAM adhesion molecule. The engineering of CE7R was accomplished by assembling a cDNA construct encoding a single-chain antibody extracellular domain derived from the murine CE7 hybridoma fused to the cytoplasmic tail of the T cell receptor CD3 complex zeta chain (scFvFc:zeta). In vitro culture systems have been developed for genetically modifying human T cells with naked plasmid DNA by electroporation and expanding modified clones to numbers in excess of 10e10. Ex vivo expanded CE7R scFvFc:zeta-expressing cytotoxic T lymphocyte (CTL) clones specifically recognize human neuroblastoma tumor cells and are activated for tumor cell cytolysis and cytokine secretion. These preclinical studies have provided the rationale to explore the therapeutic utility of cellular immunotherapy with autologous CTL clones engineered to express the CE7R chimeric immunoreceptor and the selection/suicide fusion protein HyTK in children with recurrent/refractory disseminated neuroblastoma. The in vivo persistence, anti-tumor activity, and immunogenicity of infused clones will be assessed following adoptive transfer in order to delineate how the in vivo biology of ex vivo expanded CE7R+ CTL might be further optimized. The specific aims of this project are: 1.) To evaluate the safety and toxicity of adoptively transferred CE7R+/HyTK+ CD8+ CTL clones in children with recurrent/refractory neuroblastoma. 2.) To quantitate the anti-tumor activity of infused clones in patients with measurable disease. 3.) To study the
22 Suicide
persistence of transferred clones in research participants by Q-PCR and the impact of administering exogenous IL-2 on the duration and magnitude of in vivo persistence. 4.) To assess in this patient population the development of antibody and cellular immune responses against the scFvFc:zeta and HyTK chimeric proteins. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHARACTERIZATION OF HUMAN LEUKEMIC STEM CELLS Principal Investigator & Institution: Bonnet, Dominique A. Assistant Professor/Chief; Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2001; Project Start 01-JUN-2000; Project End 31-MAY-2004 Summary: Understanding the processes that regulate the developmental program of normal stem cells and how aberrations in this program initiate leukemic proliferation remain a major challenge in biology. Progress to address these major questions in the human hematopoietic system has been hampered, until recently, by the lack of in vivo assays for normal and leukemic stem cells. The only way to conclusively assay stem cells is to follow their repopulating capacity. The recent development of methods to transplant human hematopoietic cells into immune-deficient mice provides an important approach to characterize stem cells and to develop animal models for hematopoietic diseases including leukemia. The development of an in vivo model that replicates many aspects of human AML and allows the identification of a novel leukemic stem cell (termed the SCID-Leukemia Initiating Cell, SL-IC) based on the ability of that cell to initiate AML in NOD/SCID mice provides the foundation of an assay to define the biological and molecular properties of such new leukemic stem cells. The major long-term objectives of my research program are to further characterize human leukemic stem cells. The research project proposed here will focus on three objectives: 1) determine the existence of an heterogeneity at the leukemic stem cell level (both Lin-CD34+ and Lin-CD341o/- subfractions have leukemic stem cell properties); 2) evaluate the biological properties of the leukemic stem cell pool (i.e., self-renewal, proliferation and differentiation capacities, response to cytokines and/or stromal cell environment); 3) to study the gene expression pattern of six regulatory molecules (AML1, PU.1, GATA- 1, Hox A5, Hox B4 and SCL/tal-1), known to be involved in the early stage of hematopoietic development and/or in the physiopathology of leukemia, before and after induction of differentiation of the leukemic stem cell fraction. The information obtained from these studies will gave us a more complete understanding of the nature of the leukemic stem cells, their biological properties, and the early molecular factors involved in the maintenance and/or differentiation of such leukemic stem cells. Furthermore, the knowledge gained about leukemic stem cells will allow us to devise new therapeutic strategies such as cell purging strategy, gene suicide therapy, antisense therapy and others, targeted specifically to the leukemic stem cell pool. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: APOPTOSIS
CHARACTERIZATION
OF
OST-BASED
ACTIVATION
OF
Principal Investigator & Institution: Brewster, Jay L. Natural Sciences; Pepperdine University 24255 Pacific Coast Hwy Malibu, CA 90265 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant) The proper synthesis and processing of proteins is critical to normal cellular function. The endoplasmic reticulum (ER) is an organelle found in all higher organisms, whose central role in cell function is to mediate protein
Studies 23
synthesis. Humans afflicted with abnormal protein processing in the ER and a related organelle, the Golgi body, suffer from devastating developmental abnormalities and comprise a broad category of disease known as Congenital Disorders of Glycosylation (CDGs). The key aspect of protein processing in the ER and Golgi is the addition of sugars to newly synthesized proteins, called glycosylation. This proposal seeks to characterize fundamental aspects of protein glycosylation, specifically how abnormal glycosylation influences the generation of signals within a cell. These signals are generated as a result of abnormal protein synthesis, which results in ER stress. The activation of ER stress can result in cell suicide (apoptosis), adaptation to the stress, growth arrest, or stimulation of localized inflammation. Our long-term goals focus upon how cells activate apoptosis following ER stress. This proposed project will allow characterization of the molecules that carry this stress signal, and examine how this cell suicide is executed. The improper processing of proteins in the ER and Golgi causes mutations in a variety of genes, and the type of disease that results from such mutations depends upon the identity of the mutated protein. Cystic fibrosis patients suffer lung degeneration that is the result of ER stress-activated signals as a membrane protein is improperly glycosylated, and one type of inherited hypercholesterolemia (high cholesterol) is the result of ER-associated processing deficiencies of a signal receptor. The characterization of ER stress and its signaling mechanisms will offer vital insight into the cell biology of stressed cells, and will be valuable to our understanding of diseases that result from abnormal ER function/processing. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHOLESTEROL AND FATTY ACIDS IN COCAINE ADDICTION RELAPSE Principal Investigator & Institution: Buydens-Branchey, Laure B. Acting Associate Chief of Staff; Narrows Institute for Biomedical Res Inc Biomedical Research, Inc. New York, NY 11209 Timing: Fiscal Year 2002; Project Start 27-SEP-2002; Project End 31-JUL-2005 Summary: (provided by applicant): The goal of this project is to determine whether our preliminary findings of significant associations between low circulating levels of cholesterol and of some polyunsaturated fatty acids (PUFAs) and the relapse rate of detoxified cocaine addicts can be replicated in a larger population sample. Attempts will be also made to determine whether some factors such as poor nutritional habits contribute to the presence of altered cholesterol values or fatty acid profiles in some patients. The role of cholesterol and PUFAs has not been investigated in addictive disorders but our data can be understood in light of recent literature suggesting the existence of associations between low cholesterol levels and a number of psychiatric disorders including depression, suicide and violence. Cholesterol does not cross the blood-brain barrier but it has been suggested that it could be a marker for changes in PUFAs. There is mounting evidence that low levels of some PUFAs are also associated with a variety of psychiatric disorders. Some PUFAs are main components of neuronal synaptic membranes and influence neuronal function. Preclinical studies have demonstrated that PUFAs influence the function of dopamine and 5-HT that play a role in reward mechanisms. One hundred and twenty cocaine addicts admitted to a Substance Abuse Inpatient Unit will be studied. While on the ward, they will undergo assessments of cholesterol and its subfractions and of the entire fatty acids series. After discharge, they will be transferred to a Substance Abuse clinic where follow-up assessments will be conducted for 12 months. The primary outcome measures will be time to relapse as determined monthly by qualitative urine and selfreported use.
24 Suicide
Psychosocial functioning, cocaine craving and dietary intake will also be monitored monthly. Cholesterol and fatty acids will be determined every 3 months. If our preliminary findings are confirmed, the use of fatty acids supplements or changes in dietary habits could have a significant potential in the prevention of relapse in a subgroup of cocaine addicts. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLOZAPINE, CANNABIS AND FIRST EPISODE SCHIZOPHRENIA Principal Investigator & Institution: Green, Alan I. Psychiatry; Harvard University (Medical School) Medical School Campus Boston, MA 02115 Timing: Fiscal Year 2001; Project Start 11-MAY-2001; Project End 30-APR-2004 Summary: (provided by applicant): Accumulating evidence suggests that early intervention (particularly with novel antipsychotics) may improve the long-term course of schizophrenia. While clinicians are routinely using novel antipsychotic drugs for patients within the first episode of schizophrenia, and large-scale investigations of novel antipsychotics in first episode patients are underway, the novel drug clozapine (CLOZ) is not used clinically or in most research studies in patients because of Its side effects and the practical difficulties with its use. The notion behind our proposed research, however, is that CLOZ may be relatively safe and particularly helpful for first episode patients who are comorbid for cannabis use disorder (CUD). These comorbid patients, comprising approximately 50% of first episode patients, have a poor outcome, especially when cannabis use continues over time. A number of lines of evidence provide support for a study of CLOZ in this population: (a) preliminary data suggest that CLOZ (but not risperidone [RISP] -or olanzapine) decreases substance use in patients with schizophrenia; (b) preliminary data suggest that CLOZ (but not RISP or olanzapine) is more efficacious for first episode patients than typical antipsychotics; (c) preliminary data suggest that CLOZ decreases suicide rates in chronic schizophrenia; and (d) established data indicate CLOZ's unique efficacy in poor-outcome patients. The PI's recently published neurobiologic formulation to help explain the beneficial effects of CLOZ on comorbid substance use provides further support for this application. In this revised application (under 'Pilot Effectiveness Trials for Mental Health'), the PI and colleagues begin a line of investigation to study the comparative effects of CLOZ and RISP in patients within their first episode of schizophrenia who are comorbid for CUD. The overarching hypothesis is that CLOZ (compared to RISP) will decrease cannabis and other substance use and will also improve the outcome of these patients. The clinical implication of this hypothesis is that CLOZ may have a clear therapeutic advantage for such patients (and may even be lifesaving) and may well be the drug of choice for them. In this pilot application, we will gather short- and long term preliminary efficacy data (and effect sizes), and further assess the risks and benefits of CLOZ in this population, to provide the basis for a large-scale effectiveness trial to compare the effects of treatment with CLOZ or RISP on cannabis and other substance use, global functioning, clinical symptoms, quality of life, and neurocognitive functioning, as well as on cost effectiveness of treatment in first episode patients with schizophrenia who are comorbid for CUD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CNS PAIN/OPIOIDS
REWARD/AVERSION
CIRCUITRY
ACTIVATED
BY
Principal Investigator & Institution: Borsook, David; Associate Professor; Massachusetts General Hospital 55 Fruit St Boston, MA 02114
Studies 25
Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-AUG-2002 Summary: (provided by applicant) Pain is a critical problem in health care: it affects millions of individuals, costs billions of dollars, and is a major cause of morbidity, suffering, drug abuse and suicide. The aversive nature of pain is presumably a major cause of suffering and of maladaptive pain-associated behaviors. In addition, it has been suggested that chronic pain has a rewarding component, which may reinforce these behaviors. The CNS circuitry underlying the motivational and aversive aspects of pain has not been identified. However, recent animal research suggests that the CNS circuitry mediating reward is also involved in processing aversive experiences such as pain. The long-term objectives are: I) to identify in humans the regions of CNS reward circuitry involved in the response to acute pain and 2) to assess the effect of exogenous and endogenous opioids on activity in these regions. Functional magnetic resonance imaging (fMRI) experiments will examine activation of reward circuitry (nucleus accumbens, amygdala, sublenticular extended amygdala, ventral tegmentum/periaqueductal gray) by noxious thermal stimuli, morphine and the opioid antagonist naloxone alone and in combination. In addition fMRI will be used to evaluate reward circuitry function during acute oploid withdrawal, and to evaluate how opioid withdrawal alters activity in reward circuitry during painful stimulation. The results of these studies should provide a framework for future experiments to address whether activation of reward circuitry in fact mediates the aversive and rewarding aspects of pain and to investigate how this circuitry is activated in chronic pain patients and opioid addicts. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COGNITIVE ADOLESCENTS
AND
PHARMACOTHERAPY
FOR
SUICIDAL
Principal Investigator & Institution: Daniel, Stephanie S. Psychiatry and Behavioral Med; Wake Forest University Health Sciences Winston-Salem, NC 27157 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (provided by applicant): This application for a career development award describes a plan for training and research in the area of clinical trials among children and adolescents, and will allow the candidate to pursue a program of research examining the efficacy of two different combinations of treatments for depressed, suicidal adolescents. The primary objective of this development award is for the candidate to gain expertise as an independent investigator in psychiatric clinical trials, particularly with children and adolescents. On-site mentoring for this development award will be provided by Dr. David Goldston (primary mentor) and by Dr. Curt Furberg (mentor in clinical trials methodology). External mentors for this development award include Drs. John March and John Curry (Duke University Medical Center). External consultants for this development award include Drs. David Brent, Maria Kovacs, Graham Emslie and Thomas Ellis. The research study described in this application is designed to examine the feasibility and efficacy of two different combinations of treatment (combined cognitive-behavioral therapy and pharmacotherapy vs. combined supportive therapy and education and pharmacotherapy) for depressed, suicidal adolescents. A small randomized contolled trial will be used to test the hypothesis that combined cognitive-behavioral therapy and pharmacotherapy will be more efficacious than combined supportive therapy education and pharmacotherapy in decreasing adolescents' depressive symptoms and suicidal behaviors (including suicidal ideation). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
26 Suicide
•
Project Title: COLLABORATIVE DEPRESSION STUDY Principal Investigator & Institution: Fawcett, Jan A. Professor and Chairman; RushPresbyterian-St Lukes Medical Ctr Chicago, IL 60612 Timing: Fiscal Year 2001; Project Start 01-AUG-1977; Project End 31-MAY-2003 Summary: (Applicant's Abstract): Results from the NIMH Collaborative Depression Study (CDS) have clearly show that affective illness is a lifetime disorder and the longterm observation will be necessary to adequately characterize it. Follow-up so far shows high rates of recovery, recurrence, changes in inter-episode psychosocial functioning, comorbid alcoholism, minor affective syndromes, mortality and suicide. Recoveries are likely even after lengthy periods of illness, the distribution of episode length is relatively constant and unimpaired psychosocial functioning appears to require a complete absence of symptoms. It is essential that this follow-up continue, especially as the probands enter their sixth and seventh decades of life. This application seeks to extend the prospective annual follow-up of the CDS proband sample to at least 22 years for all subjects. The general aim in doing this is to describe the long-term course of the affective disorders. The specific aims are to collect data that will describe more fully: 1) the cumulative probability of recovery and recurrence, and the changes in polarity, severity, and episode and cycle lengths; 2) the predictors of long-term course and diagnostic change; 3) the eventual level of psychosocial functioning, physical health likelihood of suicide and mental health services utilization; 4) the influence of naturalistically applied treatments as a mediating variable; 5) the course and outcomes of subsyndromal states of affective disorders; and 6) the long-term inter-relationships of the affective disorders and other chronic and recurrent disorders such as alcohol and drug us disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: COLLABORATIVE DEPRESSION STUDY Principal Investigator & Institution: Rice, John P. Professor of Mathematics in Psychiatry; Psychiatry; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2001; Project Start 01-JUL-1977; Project End 30-JUN-2003 Summary: Results from the NIMH Collaborative Depression Study (CDS) have clearly shown that affective illness is a lifetime disorder and that long-term observation will be necessary to adequately characterize it. Follow-up so far shows high rates of recovery, recurrence, changes in inter- episode psychosocial functioning, co-morbid alcoholism, minor affective syndromes, mortality and suicide. Recoveries are likely even after lengthy periods of illness, the distribution of episode length is relatively constant and unimpaired psychosocial functioning appears to require a complete absence of symptoms. It is essential that this follow-up continue, especially as the probands enter their sixth an seventh decades of life. This application seeks to extend the prospective annual follow-up of the CDS proband sample to at least 22 years for all subjects. The genera aim in doing this is to describe the long-term cause of the affective disorders. The specific aims are to collect data that will describe more fully: 1.) the cumulative probability of recovery and recurrence, and the changes in polarity, severity, and episode and cycle lengths; 2.) the predictors of long-term course and diagnostic change; 3.) the eventual level of psychosocial functioning, physical health, likelihood of suicide and mental health service utilization; 4.) the influence of naturalistically applied treatments as a mediating variable; 5.) the cause and outcomes of subsyndromal stages of affective disorders; and 6.) the long-term inter-relationships of the affective disorders and other chronic and recurrent disorders such as alcohol and drug use disorders.
Studies 27
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONDUCT DISORDER AND DEPRESSION IN CHILDHOOD Principal Investigator & Institution: Beauchaine, Theodore P. Assistant Professor; Psychology; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2002; Project Start 07-JUN-2002; Project End 31-MAY-2007 Summary: (provided by applicant): Conduct Disorder (CD) and depression are highly comorbid conditions in childhood and adolescence. This comorbidity is associated with increased risk for several adverse outcomes, including social rejection, substance use, anxiety disorders, and suicide. However, because much of the extant research in this area has been conducted at the symptom level, relatively little is known about the mechanisms of action that are responsible for the observed rates of comorbidity. Moreover, a number of plausible alternatives obtain. Identifying which of these mechanisms is at work is likely to require the application of several strategies that have generally not been employed in the comorbidity literature to date. These include (a) distinguishing between childhood-onset and adolescent-onset CD, (b) expanding the scope of comorbidity research to include biological and physiological measures, (c) generating and testing mechanistic theories of comorbidity, and (d) studying the development of comorbidity and its associated symptoms longitudinally. In the proposed research, each of these issues will be addressed in a study including childhood-onset conduct-disordered, depressed, comorbid (conduct-disordered + depressed), and control preadolescents, ages 8-12. Studies conducted within this age range are critical, as it represents a period of escalating delinquency, depression, and substance use, which often co-occur. Following from theories of emotion regulation (Porges, 1995) and motivation (Gray, 1 982a, 1 982b, 1 987a, 1 987b), patterns of psychophysiological responding will be assessed in participants during conditions of reward, punishment, and social threat. In addition, extensive family history interviews with be conducted with parents, and measures of child delinquency, symptoms of depression, and substance use will be obtained at each of three one-year intervals. Using these data, the following Specific Aims will be pursued: (1) elucidate patterns of autonomic nervous system activity within and across groups through assessment of appropriate psychophysiological markers of behavioral inhibition (electrodermal responding during punishment), behavioral activation (cardiac pre-ejection period during reward), and emotion regulation (respiratory sinus arrhythmia during social threat); (2) assess developmental trajectories in autonomic responding within and across disorders, and relate these trajectories to parental background characteristics and parenting practices; and (3) assess developmental trajectories in child substance use patterns, and examine the potential mediating roles of autonomic responding in relations between parental and child use. Findings obtained should further our understanding of the autonomic substrates of CD, depression, and their comorbidity, and may have differential treatment implications for depressed probands who do and do not present with comorbid CD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--BRAIN IMAGING Principal Investigator & Institution: Laruelle, Marc A. Associate Professor; New York State Psychiatric Institute 1051 Riverside Dr New York, NY 10032 Timing: Fiscal Year 2001
28 Suicide
Summary: Numerous lines of evidence reviewed in the introduction of this CCNMD suggest that alterations of serotonin (5-HT) neurotransmission in discrete brain areas confer vulnerability to suicidal behavior. Recent development of methods to assess 5HT neurotransmission in vivo with PET allows direct testing of this hypothesis in patients. The brain imaging core is an integrated team of scientists from various disciplines (chemistry, pharmacology, physics, mathematics), covering the range of expertise needed to develop and support PET neuroreceptor studies. The services provided to the Center by the brain imaging core fall into four general categories: 1) To provide logistical support and technical expertise to brain imaging projects of the Center. The core provides expertise at the level of study design, implementation, and analysis. In addition, these studies benefit from the general infrastructure maintained by the core, such as radiochemistry laboratories and image analysis workstations. 2) To provide chemistry and radiochemistry services to other cores, such as tritiated ligands or other compounds not available commercially. 3) To provide training in brain imaging to young investigators. These include PGF-IV to VI residents, who are completing a fellowship in the Brain Imaging Division, as well as other investigators in the Center, interested in applying brain imaging techniques to the study of mood disorders and suicide. 4) To develop new imaging modalities that are pertinent to suicide research. Over the next five years, our development effort will be targeted at the serotonin (5-HT) system with PET. The choice of these objectives is guided by a general model of neurochemical imbalance associated with suicide vulnerability provided in the background section. 1) To develop and validate a measure of 5HT/2A receptors binding potential in humans using the radiolabeled antagonist [11C],DL 100907; 2) To develop a new radiotracer to measure 5-HT/1B receptors with PET ([11C]GR127935); 3) To develop a new radiolabeled agonist to measure the agonist high affinity state of the 5HT/1A receptors ([11C]MHA) and to develop with this ligand a measure of 5-HT release based on endogenous competition techniques; 4) To develop a radiolabeled agonist to measure high affinity state of 5HT/2A receptors ([123I]/[11C]DOI). Together, these projects should provide new and sophisticated tools for the in vivo characterization of 5-HT neurotransmission in patients with history of suicidal attempts. The radiotracers developed during this funding cycle of the Center will be used in clinical studies in the next funding cycle. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--CHEMISTRY Principal Investigator & Institution: Han, Xianlin; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: Numerous animal studies have demonstrated that the diabetic states induces a fatty acid-based metabolic dysfunction which has complex effects on multiple endorgan systems. Both accelerated atherosclerosis and diabetic cardiomyopathy are the major etiologic agents in the excessive cardiovascular mortality and morbidity present in diabetic patients. A central theme in diabetic cardiovascular disease is the dysfunctional accumulation of lipids in multiple critical cell types. The proposed research in the component projects focuses on the role of alterations in peroxisomal regulatory proteins (e.g., peroxisomal phospholipases) and proliferative elements (e.g., PPARalpha and PPARgamma) which accelerate atherosclerosis and predispose critical cells in the cardiovascular system to maladaptive metabolic alterations. Core A of the program project embodies five major technical advances either made in our early research or developed in the current chemistry Core. Provision of lipid-analytical,
Studies 29
synthetic, and proteomic services to the component projects will facilitate the costeffective accrual of vital scientific information for the elucidation of the molecular mechanisms underlying altered lipid metabolism in the diabetic state. The Core will offer a wide variety of state-of-the-art analytic (mass spectrometry, evaporative light scattering detection (ELSD), fluorescence spectrometry, quantitative PCR) and synthetic (chiral BEL, fluorescence probe for real-time PLA2 assays) expertise. Specifically Core A will perform: 1) analysis of polar and neutral lipid individual molecular species including free fatty acids, triacylglycerides, cholesterol, acylcarnitines, and all types of phospholipids from biological sources using state-of-the-art ESI/MS and ELSD with sensitivity at the subpicomole to picomole range; 2) proteins sequencing and protein post- translational modification determinations utilizing LC/MC (proteomics); 3) the synthesis of the iPA2 suicide inhibitor (i.e., BEL) and its resoled enantiomers which selectively inhibit iPA2beta dn iPLA2gamma; 4) real-time PLA2 activity assays utilizing novel fluorescence substrates we have developed; and 5) quantitative PCR utilizing Taqman methodology. As it has done during the current grant interval, the Core will continue to provide methodologic advances to facilitate the study of lipid and protein alterations in the diabetic state (see Progress Report). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--CLINICAL Principal Investigator & Institution: Klein, Rachel G. Professor; New York State Psychiatric Institute 1051 Riverside Dr New York, NY 10032 Timing: Fiscal Year 2002 Summary: Since its inception in 1989, the Clinical Core has been a key component in the Clinical Research Center to study Depression, Anxiety, and Suicide-Related Disorders. The Clinical Core?s principal activity was to assist therapeutic trials. These activities will remain essentially unchanged in the proposed Intervention Center, since they are ideally suited to its focus. The proposed Core has been designed to provide an infrastructure to foster the development and execution of clinical trials. The program of therapeutic studies of child and adolescent psychiatric disorders at Columbia University/New York State Psychiatric Institute is a large one and includes psychopharmacological and psychotherapy studies in most of the common disorders of childhood, including anxiety, mood, eating, disruptive-behavior disorders, ADHD, and early-onset schizophrenia. The feasibility and quality of these studies can be greatly assisted by the services that the Clinical Core will provide, which will include: Systematic and centralized patient recruitment (from clinical outpatient services, from respondents to advertisements and other activities that publicize the Core, and from the Department?s school-based screening and outreach efforts; State-of-the-art diagnostic assessments; An efficient data-management system that matches screened individuals to available protocols and provides a database for present collaborations and future follow-up studies; and Clinical care after the experimental phase of treatment has been completed. The clinical Core will also foster the development of clinical researchers. It will offer child psychiatry research trainees from the Research Training Program (5T32 MH16434) an opportunity to participate in numerous and varied clinical trials. It will interface closely with clinical staff and trainees and expose them to therapeutic research. In the past the Core has attracted clinical trainees into research. The Core?s interface with clinical services also provides a way to conduct efficacy studies in the real-world clinical setting and reduces competition for patients between research and clinical services. To the above ends, the Clinical Core has been designed to: Systematically assess large numbers of children and adolescents using state-of-the-art clinical procedures. The Core
30 Suicide
will determine suitability for protocol research, introduce children and their parents to research opportunities, and establish a systematic database to serve as a basis for additional studies; Ascertain and coordinate investigators? interests, and thus maximize the variety of interventions that are investigated and minimize unhelpful competition between researchers studying similar patients; 3. Facilitate the smooth transition from efficacy to effectiveness research; and Enhance opportunities for the development of clinical researchers in child psychiatry. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--CLINICAL EVALUATION Principal Investigator & Institution: Sackeim, Harold A. Professor; New York State Psychiatric Institute 1051 Riverside Dr New York, NY 10032 Timing: Fiscal Year 2001 Summary: The Clinical Evaluation Core's goals are to: (1) recruit, characterize, and follow all human subjects participating in projects #2-7 of the CCNMD (2) develop and maintain state-of-the-art methods for clinical characterization of human framework for testing the stress-diathesis model of suicidal behavior. The CEC identified and recruits patients with MDE, BPD, and Schizophrenia across the life cycle (and post-mortem). Normal volunteers are recruited to provide normative values on the clinical and neurobiological measures used and to establish psychometric properties of measures in a non-pathological population. The CEC utilizes a core of clinical/neuropsychological instruments covering major risk factor domains for suicidal behavior, and ensures uniformity of assessment domains and measures across the projects of the CCNMD. These assessments include Axis I and II diagnostic interviews, measures of state and trait-related risk factors, neuropsychological assessment, measures of suicidal behavior, demographic history, life events, social functioning, family psychiatric history. Assessments are performed at intake, at time of biological procedures, at discharge, at 3 month, 1 and 2 year follow-up. The CEC investigates, develops and tests new assessment procedures to address current and future needs in the field of suicide research, and regularly reviews the reliability and validity of instruments. The CEC ensures the quality of clinical assessments through inter-rater reliability rounds using live or taped interviews. On all measures, our faculty provides consultation to investigators in research methodology and result interpretation. The CEC faculty provides consultation to investigators in research methodology and result interpretation. The CEC has successfully recruited and followed adequate members of life subjects in the proposed diagnostic and age categories. The training and reliability of all CCNMD raters is coordinated by the CEC. The CEC works with SCC staff in developing forms, data management procedures and in generating reliability statistics The CEC coordinates with the BIC regarding recruitment, interviewing, control matching and subject flow. The CEC obtains the blood and cerebrospinal fluid from subjects to be analyzed by the CLC. The CEC interfaces with the Administrative Core regarding recruitment of new staff and maintenance of a central database of all CEC manuscripts. The CEC coordinates all diagnostic consensus conferences. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--CLINICAL LABORATORY Principal Investigator & Institution: Cooper, Thomas B.; New York State Psychiatric Institute 1051 Riverside Dr New York, NY 10032 Timing: Fiscal Year 2001
Studies 31
Summary: Clinical Laboratory Core. The CLC comprises an analytical laboratory directed by Mr. T.B. Cooper and a molecular genetic studies laboratory directed by Dr. T. Conrad Gilliam, Head of the Columbia Genome Center. In the latter blood will be collected for genotyping from all Conte Center subjects and DNA will be extracted from postmortem brain tissues of suicides and controls. These samples will be tested for a series of candidate genes related to central serotonin metabolism and include the serotonin transporter, tryptophan hydroxylase and serotonin receptors 5HT/1A, 5HT/1D, 5HT/1E and 5HT2A. The Genome Center will be responsible for development and interpretation of the microarray assays to be run in postmortem brain samples from selected regions to detect differences in gene expression and identify new candidate genes. The promoter region of the 5-HTT from postmortem causes that are phenotypic extremes will be sequenced in a attempt to determine new functional polymorphisms. The analytical laboratory will be responsible for assay of neurotransmitters and metabolites (cortisol, prolactin, HIAA, HVA, MHPG, GABA and glutamate) and neuroendocrine measures (cortisol, prolactin, ACTH, and CRF) in CSF and brain tissue from patients, controls, non-human primates and rodents. Brain tissue samples are being screened for the presence of drugs which effect the serotonergic system. Similarly hair samples are screened for these same drugs to detect long term exposure (months or even years). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--PRINCIPAL RESEARCH CORE Principal Investigator & Institution: Jeste, Dilip V. Professor & Chair; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, CA 92093 Timing: Fiscal Year 2002; Project Start 20-SEP-2002; Project End 30-JUN-2007 Summary: The aim of the Principal Research Core (PRC) is to build the Center's capacity to facilitate the testing of interventions for middle-aged and elderly patients with schizophrenia and other psychotic disorders. The goal of such capacity building is to increase the number of evidence-based interventions applicable to community care. We will use different intervention approaches (preventive, treatment, and rehabilitative), with the focus being on the following themes: (I) Reducing psychopathology (including primary deficits such as positive symptoms, negative symptoms, and cognitive impairment, depressive symptoms with suicidability, and functional impairment), (II) Reducing physical comorbidities (both age-associated and itrogenic), (III) Optimizing health behaviors (especially, reducing substance use and increasing medication adherence), and (IV) Minimizing healthcare disparities (e.g., among Latino and other ethnic minority groups). Our prior work over the past decade included a number of pharmacologic intervention trials targeted to older patients with psychotic disorders. During the past 3 years, our group has developed manualized cognitive and behavioral interventions for this patient population. Our recent studies have highlighted undertreatment of physical comorbidity in older psychosis patients along with ethnic and other disparities in the utilization of mental healthcare services in the San Diego County public mental health system. Our proposed work in the PRC will incorporate pharmacologic, psychosocial, and services interventions. To illustrate this process, we have selected seven examples of pilot projects relevant to the Center themes, including community-dwelling middle-aged and elderly persons with schizophrenia, and involving: (1) Delivery of manualized cognitive behavioral social skills training with therapists from community settings, (2) Citalopram augmentation of anti-psychotic treatment to reduce suicidality, (3) Vocational rehabilitation, (4) Healthcare case management for older homeless patients with psychosis, (5) A multi-pronged smoking
32 Suicide
cessation intervention, (6) Medication adherence therapy for anti-psychotic and selected non-psychotropic medications, and (7) Cross-cultural needs assessment using qualitative and quantitative methods. A critical component of our work will be a close two-way partnership with community stakeholders including patients, caregivers, care providers, and payers throughout the development and execution of research projects. With the help of our collaborators in the community, we propose to implement and disseminate successful treatment strategies for use in community settings. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--PRINCIPAL RESEARCH CORE Principal Investigator & Institution: Coyne, James C. Professor; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2002; Project Start 16-SEP-2002; Project End 30-JUN-2007 Summary: (provided by applicant): The Principal Research Core is directed by Dr. James Coyne. This section of the application describes a) the background and rationale for our focus on latelife depression in medical care settings; b) "bulleted" descriptions of recent research findings; c) current and planned research grants enabled and facilitated through the Center; and d) specific pilot research projects. The pilots reflect a number of themes of the Center: the focus on both enabling research and investigator development; the use of qualitative as well as quantitative methods, and newer as well as standard designs; investigations of both psychotherapy and pharmacotherapy; the locus of studies in primary-, medical specialty-, and long-term care settings; and the design of studies to facilitate the evaluation of findings between- as well as within- comorbidities and contexts. There are four sets of pilot projects: a) Qualitative and quantitative followup of providers and patients who participated in the Prevention of Suicide in Primary Care Elderly: Collaborating Trial (PROSPECT) and PRISMe studies. They will allow us to incorporate what stakeholders have learned from research participation in the dissemination of findings and the design of subsequent interventions. b) Pilot studies on the course of minor depression in older and middle-aged women with breast cancer, and older patients, women and men, in primary-care. These studies will inform the design of a "biased-coin toss", adaptive randomization design to help to evaluate "early treatment" versus "watchful waiting strategies", and to determine the optimal period of "watchful waiting" before the initiation of treatment for each group. c) Studies to evaluate patients' preferences and to estimate effect sizes for continued antidepressant treatment versus drug discontinuation and monitoring for nursing home residents and primary-care patients in remission from a first episode of late-life depression. These pilots will facilitate the design of a partially randomized patient preference study designed to evaluate the benefits versus the risks of maintenance treatment for patients who recover from a first episode of geriatric depression. d) Studies evaluating the feasibility and the nature of the adaptations to standard methods that are necessary to allow the delivery of cognitive therapy for depression to patients with Parkinson's disease, developing a manual for this treatment, and early tests of its outcomes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--STATISTICS AND COMPUTING Principal Investigator & Institution: Waternaux, Christine M. Associate Professor; New York State Psychiatric Institute 1051 Riverside Dr New York, NY 10032 Timing: Fiscal Year 2001
Studies 33
Summary: The Statistics and Computing Core (SCC) provides the following services to CCNMD Center Projects and Cores: 1) Statistical consultation to Center investigators at all stages of their research; 2) Management of data and maintenance of a centralized data base with standardized data forms and rigorous quality control procedures; 3) Data analysis and preparation of manuscripts for publication; 4) Implementation and/or development of innovative applications of statistical techniques for suicide research; 5) Administration of the NYSPI/Columbia Conte Center Local Area Network to facilitate access to and sharing of Center data; Training in research design, statistical design, statistical methodology, and computer software to relevant CCNMD personnel. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COUNSELORS AND PARENTS PREVENT YOUTH SUICIDE RISK Principal Investigator & Institution: Randell, Brooke P. Psychosocial & Community Hlth; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2001; Project Start 01-MAY-1999; Project End 31-JAN-2004 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CTI IN THE TRANSITION FROM HOSPITAL TO COMMUNITY Principal Investigator & Institution: Herman, Daniel B. Assistant Professor; New York State Psychiatric Institute 1051 Riverside Dr New York, NY 10032 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (Applicant's abstract): We propose a controlled study of Critical Time Intervention (CTI) for men and women with severe mental illness (SMI) during the transition from psychiatric hospital to community care. The primary objective of CTI is to reduce adverse outcomes during this transition and thereby improve community integration for mentally ill persons. Homelessness is the primary adverse outcome we hope to diminish. Other adverse outcomes include: suicidal ideation and behavior; violence toward others; and psychiatric re-hospitalization. CTI is a time-limited intervention designed specifically to enhance the continuity and focus of care during such transitions. It does not replace community treatment and supports, but instead is meant to complement available services. CTI has previously been demonstrated to be effective with severely mentally ill men following discharge from psychiatric care in a shelter institution to community care. It consists of in vivo training in community living skills and team-managed transfer of caregiving to services and supports in the community. A key aspect of CTI is that the post-discharge phase of the intervention is delivered by staff who have established relationships with patients during their institutional stay. Effective outreach and support are greatly enhanced by staff knowledge of the population and the strength of the individual relationships that have been previously developed. A sample of 250 individuals (175 men and 75 women) will be enrolled into the study during their hospital stay. Subjects will receive a thorough baseline assessment, including research diagnoses of major mental disorders. After this assessment, subjects will be randomized into control (n=125) and experimental (n=125) treatment groups. Following hospital discharge, the control group will receive usual aftercare and community care services; aftercare services from this hospital are considered among the best in the region. Those in the experimental group will receive these services as well as nine months of CTI. Both groups will be followed for eighteen months. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
34 Suicide
•
Project Title: CYCLOOXYGENASE CATALYSIS AND SUICIDE INACTIVATION Principal Investigator & Institution: Smith, William L. Professor; Michigan State University 301 Administration Bldg East Lansing, MI 48824 Timing: Fiscal Year 2001 Summary: The goal of our research is to understand the mechanism of cyclooxygenase catalysis by PGH synthases (PGHSs). PGHS-1 and -2 catalyze the formation of prostaglandin endoperoxide H2 (PGH/2) from arachidonic acid--the committed step in prostaglandin biosynthesis. Both enzymes catalyze (a) a cyclooxygenase reaction in which arachidonate is converted to PGH/2 and (b) a peroxidase reaction in which PGH/2 is reduced to PGH/2. These two reactions occur at distinct but interconnected cyclooxygenase and peroxidase sites that are bisected by a heme group. The cyclooxygenase active site is a hydrophobic tunnel that protrudes from the membrane binding surface of PGHS into the major globular domain of the enzyme. Fatty acid substrates and probably 02 enter this site from the membrane at the base of the tunnel. The peroxidase site is located on the opposite surface of the protein and resembles that of myeloperoxidase. Our first specific aim to characterize the contributions of amino acids within the cyclooxygenase active site to the binding of arachidonic acid. We will determine the crystal structure of a cyclooxygenase-inactive Y371F human (h) PGHS-2 mutant with arachidonate bound in the active site. We will also prepare mutations of various active site amino acids and analyze the effects of these changes on substrate binding and catalysis. Our second specific aim is to determine if suicide inactivation of cyclooxygenase activity results from radical-initiated intramolecular protein cross linking involving a Tyr504 radical. We will characterize peptide products derived from native and suicide-inactivated ovine PGHS-1 to determine what residues are modified during inactivation. We will also determine the rates of formation of various spectral intermediates formed upon interaction of hydroperoxides with H386A ovine PGHS-1, a mutant PGHS that fails to undergo inactivation. Finally, we will determine the effect f replacing Tyr504. Our third specific aim is to determine if the H20 channel of PGHS that connects the cyclooxygenase active site with the exterior of the protein serves as a conduit for the proton that is abstracted from the active site Tyr385 during cyclooxygenase catalysis; we will characterize mutations likely to block the H20 channel (G227A, G536A) and mutations expected to negate proton transfer (R37G,L). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DELINEATING THE EXTERNALIZING CONSTRUCT & ITS FACETS Principal Investigator & Institution: Patrick, Christopher J. Psychology; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, MN 554552070 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant): Five years of funding are sought to pursue translational research on the externalizing spectrum of personality and psychopathology. The externalizing spectrum is conceived of as a coherent set of personality traits and psychopathological syndromes characterized by a lack of impulse control. At the highest level within this spectrum stands a variable that links specific externalizing disorders and traits, the externalizing dimension. Recent research demonstrates both the existence and high heritability of this dimension via significant observed (phenotypic) and etiological (genetic) connections between an unconstrained, impulse-driven personality style and psychopathological syndromes involving antisocial behavior and substance dependence. This application seeks to build on these preliminary data by pursuing three specific aims. First, quantitative models of behaviors
Studies 35
in the externalizing spectrum will be built by developing a hierarchical model of the externalizing spectrum that links the broad externalizing dimension to its manifestations as specific traits and syndromes. Second, models of externalizing behavior will be linked to models of neurocognitive processing, with a particular focus on event related potentials, to characterize the biobehavioral bases of externalizing behavior. Third, high levels of externalizing will be studied in criminal offender samples to characterize the implications of the externalizing spectrum model for understanding behaviors with high social costs, such as reactive violence and impulsive suicide attempts. This research is designed to realize the aims of the RFA to which it is a response by integrating ideas from diverse scientific areas (ranging from statistical modeling to cognitive neuroscience), in linking basic methodological advances in these areas to a broad range of costly, impulsive behaviors in both clinical and non-clinical samples. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEPRESSION IN LATE LIFE AND CAUSES OF DEATH Principal Investigator & Institution: Gallo, Joseph J. Associate Professor; Family Practice and Cmty Med; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2007 Summary: (provided by applicant): The overarching goal of this study is to assess mortality of depressive syndromes in older adults in relation to overall death rates as well as in relation to deaths from specific causes, especially cardiovascular disease, while accounting for baseline and time-varying cardiovascular risk factors and other potentially influential personal and clinical characteristics. We will compare death rates among a representative sample of older persons who participated in an intervention trial designed to increase the number of older adults who receive appropriate depression treatment, such as antidepressant medications and psychotherapy. The study sample is enriched with older primary care patients with major and minor depression (n = 719) participating in an intervention trial, making it possible to study the impact of treatment on mortality risk associated with depression. Specific aims of this study are: (1) to estimate the relative risk of all-cause mortality among older primary care patients with major depression and clinically significant minor depression compared to patients without significant depression after a 3-year follow-up interval, accounting for potentially influential personal and clinical characteristics; and, (2) to assess whether varying intensity of depression treatment is associated with different allcause mortality after a 3-year follow-up interval. To accomplish these aims, we will capitalize on screening, clinical assessment, treatment, and follow-up assessments which have occurred for up to 2 years in PROSPECT (the "Prevention of Suicide in Primary Care Elderly: Collaborative Trial"). PROSPECT is a collaborative multi-site intervention study funded by the NIMH in primary care practices have been randomized into one of two treatment conditions: (1) treatment as usual (n = 597 patients); and (2) a guideline management intervention (n = 620 patients). In all, 1,217 patients, including all patients who screened positive for depression and a random sample of patients who screened negative, have been enrolled in the 2-year longitudinal study and clinically evaluated for DSM-IV major depression, minor depression, and dysthymia. In PROSPECT, 719 patients met criteria for depression treatment. The adequacy of depression treatment is assessed for all 1,217 patients regardless of diagnosis. Our proposal seeks support for identifying the follow-up vital status of the participants (using the National Death Index) and, for the persons who have died, determining primary and underlying causes of death using data from NDI Plus and primary care medical records. What we learn from this follow-up will help design interventions that are specifically targeted to
36 Suicide
decrease mortality among older adults with depression that is frequently associated with concurrent medical conditions such as diabetes mellitus and hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DESIRE FOR DEATH AMONG TERMINALLY ILL PATIENTS WITH AIDS Principal Investigator & Institution: Breitbart, William; Professor and Chief; SloanKettering Institute for Cancer Res New York, NY 10021 Timing: Fiscal Year 2001; Project Start 01-JUL-1998; Project End 30-JUN-2003 Summary: (Applicant's Abstract): Despite the hope created by the recent introduction of protease inhibitors, patients with AIDS are still dying in large numbers,and palliative care/quality of life issues in patients with advanced AIDS remains an important area of clinical investigation. Perhaps the most compelling and clinically relevant issue in palliative care today concerns desire for death and physician assisted suicide (PAS). Despite the recent Supreme Court decisions, the issue of whether or not to legalize PAS will continue to be actively debated in many state legislatures. It is anticipated that several states will legalize PAS, and guidelines are being developed for its use that involve psychiatric evaluation as an important component. There have been several recent studies of patients with cancer or AIDS, including one on interest in PAS among ambulatory patients with AIDS published by the investigator's research group, demonstrating that depression plays an important and perhaps central role in some patients' desire for death or interest in PAS. With only one exception, these studies have failed to directly assess/measure desire for death among terminally ill patients,and no research to date has attempted to answer the question of whether treatment for depression has a significant impact on patients' desire for death. This project's overall aim is to describe desire for death among patients with end-stage AIDS, determine the correlates of desire for death, and assess the impact of treatment for major depression on patients' desire for death. Specifically, the investigators will assess the prevalence, severity, consistency over time (8 weeks), and medical/psychosocial correlated of desire for death among terminally ill AIDS patients, as well as the relationship between desire for death and a clinical diagnosis of Major Depressive Episode. Desire for death will be monitored over an 8-week period in a group of patients who receive a standardized pharmacological treatment for depression. This study aims to provide the first direct evaluation of the desire for death among terminally ill patients with AIDS, and will provide data on the critical issue of whether or not treatment for depression influences patients' desire for death. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DESTRUCTIVE EFFECTS OF SOCIAL REJECTION Principal Investigator & Institution: Baumeister, Roy F. Professor; Psychology; Florida State University 118 North Woodward Avenue Tallahassee, FL 323064166 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 31-MAY-2007 Summary: (provided by investigator): Social rejection and exclusion from social groups have been widely suggested as contributing to a broad range of societal and mental health problems, including aggression, drug abuse, suicide, and anxiety. The proposed research begins with a recognition of the pervasively social nature of adolescent and young adult human beings, a nature that includes a powerful motivation by excluding such people from social groups may therefore elicit an assortment of abnormal, antisocial, undesirable, and even pathological responses. The proposed research will
Studies 37
employ primarily laboratory manipulations of social rejection and exclusion to investigate the direct consequences of this common but often highly aversive experience. People will be exposed by random assignment to experiences of social acceptance and social rejection, such as hearing that no other member of an ad hoc group expressed a preference to work with them individually, or a diagnostic forecast that they will be alone later in life. The first part of the application proposes to study how social exclusion causes a shift toward antisocial behaviors (including aggression) and away from prosocial behaviors (such as affiliating and helping). The second part will investigate inner psychological processes that may contribute to these behavioral manifestations. The inner processes affected by exclusion may include self-regulation and volition, emotion, and passivity. Rejection may promote depression and impair people's control over attention. The third application will pull the first two parts together to show that the impairments in self-regulation mediate the antisocial responses. The fourth part of the application will examine possible gender differences in the effects of social exclusion in terms of the basis for rejection, internalizing versus externalizing responses, and the social sphere implicated in the exclusion. The fifth project will examine social exclusion outside the laboratory, in order to elucidate how exclusion affects people in everyday life. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DETECTING DEPRESSIVE SYMPTOMS IN OLDER ADULTS Principal Investigator & Institution: Duberstein, Paul R. Associate Professor; Psychiatry; University of Rochester Orpa - Rc Box 270140 Rochester, NY 14627 Timing: Fiscal Year 2002; Project Start 15-AUG-2002; Project End 31-JUL-2005 Summary: (provided by applicant): One consistent and disturbing finding in the suicide literature compels this investigation. Most older adults who take their own lives have an affective disorder, but the potential risk for suicide was unrecognized by family members and health professionals. The central thrust of our symptom detection model is that specific factors deter the detection, diagnosis, and treatment of depression in older adults. ROl funding is sought to test aspects of this model in a demographically and clinically heterogeneous sample of 1000 primary care patients 65 years of age and older. Beginning in August 2001, these patients were recruited into a naturalistic study, "Depression Outcome in Primary Care Elderly" (DPC) (NIMH ROl MH61429-O1A1, J. Lyness, M.D., P.I.). For this proposed ROl, we will collect data from informants who are members of the social networks of participants in the DPC study in order to examine informant detection of depressive disorders and symptoms of depression and anxiety. We will strive to recruit one informant for each subject in that study, and plan to collect data from more than 628 informants. We will ask the informants questions about themselves and the DPC participants' psychiatric symptoms. Specifically, we will examine informant detection of depression as a function of: the severity and history of patients' psychiatric disorders (Aim 1), patients' psychosocial (personality and social support) characteristics and physical health parameters (Aim 2), patients' demographic characteristics (Aim 3), and informants' psychiatric history and self-reported health (Aim 4). We will explore the role of informants' personality traits and attitudes toward mental illness, and differences between African-Americans and Whites will be explored. We hypothesize the detection will be poorer for: disorders that are less severe and first episode (Aim1); patients with certain personality traits (e.g., low extraversion; low openness to experience) or poor physical health (Aim 2); and men and unmarried participants (Aim 3). Detection will also be poorer when informants have no prior history of depression or are in poor physical health (Aim 4). For Aim 2, the mediating
38 Suicide
effect of social support will be examined. Confirmation of these hypotheses will indicate needed revisions in current approaches to late-life depression and suicide. Findings will help guide the development of screening instruments, educational and clinical interventions, and surveillance strategies to lessen the public health impact of unrecognized and untreated depression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEVELOPMENT AND APPLICATIONS OF NOVEL SERT PET LIGANDS Principal Investigator & Institution: Goodman, Mark M. Professor of Radiology; Radiology; Emory University 1784 North Decatur Road Atlanta, GA 30322 Timing: Fiscal Year 2002; Project Start 19-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): Considerable evidence accrued over the last two decades have convincingly implicated decreased serotonin transporter (SERT) binding in the pathophysiology of major depression and suicide. Although a tremendous amount of information regarding the SERT and its role in depression and suicide has been obtained, this supporting evidence has, however, been indirect in being derived almost exclusively from the study of postmortem tissue and animal and peripheral cell models of transporter cell function and pharmacology. The mechanisms responsible for decreased brain SERT binding in depression and suicide are still unknown. We propose to develop fluorine-18 and bromine-76 imaging agents as tools to the exploration of the mechanism of major depression by assessing the functional status of SERT using Positron Emission Tomography (PET). This application wide focus on the development of positron emitting analogs of 2beta-carbomethoxy-3 beta-(4'-(Z-2iodoethenyl)phenyl)nortropane (ZIENT) that show high selectivity and affinity for the SERT and low nonspecific binding. Our recent preliminary data with iodine-123 labeled ZIENT indicate that structural features unique to ZIENT permit in vivo measurement of SERT density in cortical brain regions suggesting ZIENT is a suitable lead compound for PET radiotracer development. Two goals of this proposal are: 1) conduct a structure activity relationship study (SAR) to identify a sutiable fluorine-18 and bromine-76 radiotracer for in vivo imaging of the SERT in atients with mood disorders; the SAR study will involve: (a) the development of synthetic methods for the preparation of new 18F- and 76Br-labeled 2beta-carboalkoxy-3beta-(4'-(Z-2-haloethenyl)phenyl)nortropanes, (b) the in vitro determination of relative affinity of 18F- and 76Br- candidates (c) ex vivo estimation of brain penetrance and regional distribution in rats. (d) microPET studies defining time- activity curves for specific and nonspecific binding in brain regions-ofinterest in rhesus monkeys. (e) ligand metabolite studies performed on arterial samples (f ) microPET studies of in vivo binding site selectivity assessed by "chase" competition in rhesus monkeys. (g) Graphical analysis of cerebral SERT site binding using microPET in non-human primates with the lead radiolabeled analog; 2) To conduct toxicity studies on an optimized ligand that will support the submission of an RDRC and an IND application. Our hypotheses include: 1) the introduction of fluorine onto an alkyl group in the 2P-carboakoxy- position of ZIENT and replacement of iodine with bromine on the 3beta-(4'-(Z-2-haloethenyl)phenyl) group will generate a PET ligand with imaging characteristics equivalent to ZIENT; 2) A 18F- and 76Br-analog of ZIENT provides substantial temporal and logistical benefits for SERT imaging as compared to a SERT [11C] radiotracer due to the longer half-life of fluorine-18 (t1/2=110 min) and bromine76 (t 1/2= 16 h) compared to carbon (tlI2=20min). After the best novel PET SERT ligand is identified, it will be applied in humans to define the relationship between brain SERT binding and depression and suicidal behavior. We will also begin to define SERT
Studies 39
alterations in dimensional traits that are related to suicide, such as aggression, impulsivity and anxiety. The relationship between SERT 5-HTTLPR promoter region and in vivo SERT expression will be explored. Once SERT binding is determined in depressed patients, we will be able to assess the relationship of SERT binding and treatment response to SSRIs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEVELOPMENT OF SUICIDE RESEARCH IN CHINA Principal Investigator & Institution: Zhang, Jie; Sociology; Buffalo State College 1300 Elmwood Ave Buffalo, NY 14222 Timing: Fiscal Year 2001; Project Start 25-SEP-2000; Project End 31-AUG-2003 Summary: This is a revised proposal requesting small grant support to conduct a pioneering project to study suicide in China. The high suicide rates in China, especially those for rural young women in China have recently been noticed by the international community with China's open door policy. So far, no scientific and systematic studies have been accomplished to investigate the leading cause of premature death in China, where the overall suicide rate is one of the highest in the world and approximately 56 percent of the world's female suicides - about 500 a day - occur in China. The long term goal of our research team is to develop and test suicide prevention measures that are efficient and effective for use by young women in rural China, as well as other populations in China. The current small grant is proposed to conduct a feasibility study of psychological autopsy (PA) to be later used in China for a larger scale survey on the effect of mental health on Chinese suicide. Instruments commonly used in the US need to be pilot studied for their reliability and validity with Chinese samples. In addition, we will make full use of the data, if feasibility and instrument tests are passed, to conduct some exploratory studies to examine some very basic questions in Chinese suicide. Dalian Medical University in China will collaborate to collect data. The aim for this project are as follows: (1). To examine the feasibility of the psychological autopsy (PA) method for the studies of completed suicides in China using rural suicides aged 1549 (n=65) and matched normal controls (n=65) (2). To test the reliability and validity of the instruments to be used in future studies with rural Chinese suicides aged 15-9 and matched normal controls (3). To pilot study the effects of psychiatric status, suicidal intent, life events, and social support on Chinese rural young female suicide with a case control design. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DNA RISK FACTORS IN YOUTH SUICIDE Principal Investigator & Institution: Mcmahon, William M. Associate Professor; University of Utah 200 S University St Salt Lake City, UT 84112 Timing: Fiscal Year 2001 Summary: This proposal was designed to identify hereditary risk factors (genetic polymorphisms) that contribute to risk of youth suicide. Two methods are under study, each examining candidate genes in Utah's suicide victims. The methods include haplotype relative risk and direct mutation analysis. Previous research has indicated that factors contributing to suicide are both environmental and inherited. The serotonergic system has been implicated in impulsivity and suicidality, and tryptophan hydroxylase (TPH) is the rate-limiting enzyme in the synthesis of serotonin. The Principal Investigator has detected polymorphisms in intron 7 of the TPH gene, and this was studied in a sample of 66 suicide victims from the Utah Youth Suicide Study.
40 Suicide
Studies of polymorphisms at several loci in and surrounding this gene did not appear to be associated with suicide in this population. Additional loci are now being sought. DNA for these studies is obtained from post-mortem blood or other tissues made available through the Medical Examiner's office (located at the University Medical Center). Blood from pedigree members of probands who were suicide victims is collected under another IRB-approved study, entitled "A Community Approach for Investigating Suicide Among Teenagers and Young Adults in Utah" (IRB #5698-95). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DRUG-RELATED SUICIDAL AND/OR HOMICIDAL BEHAVIOR Principal Investigator & Institution: Wines, James D. Instructor in Psychiatry; Mc Lean Hospital (Belmont, Ma) Belmont, MA 02478 Timing: Fiscal Year 2001; Project Start 20-FEB-2000; Project End 31-JAN-2005 Summary: This application is in response to PA-98-052 for the Mentored PatientOriented Research Career Award (K23). The broad intersection of drugs and violence both directed toward oneself (suicide) and toward others (assault) remains a serious public health problem. A substantial proportion of these events are drug-related. The main objective of this application is to allow the candidate to develop a research career in the area of drug-related harm, specifically drug-related suicidal and/or homicidal behavior (hereafter, DRSHB). The mentor, Dr. Jack Mendelson, will provide a unique source of supervision and guidance for the candidate. The goals of the career development plan are to (1) develop the expertise necessary for the design and execution of clinical studies pertaining to DRSHB, (2) acquire further training in public health for research in clinical populations, (3) obtain the necessary qualities and skill for independence as a researcher. The primary aim of the research plan is to amplify our understanding of the impact of recent drug use (within 24 hours), co-morbid diagnosis (depression and alcohol), and drug combinations (cocaine and alcohol) on the course of DRSHB. Three prospective studies on psychiatric inpatients are specifically designed to rigorously examine DRSHB. Study One, Hypothesis: Suicide attempters with recent drug use will have more severe attempts and higher levels of suicidal/homicidal ideation than attempters without recent drug use. Study Two, Hypothesis I: Depressed alcoholics, compared to patients with major depression only and patients with alcohol dependence only, will have more severe attempts and higher levels of suicidal/homicidal ideation. Hypothesis II: For depressed alcoholics, the amount of recent alcohol use will be positively associated with the degree of suicidality/homicidality. Study Three, Hypothesis I: Patients with alcoholic and cocaine use disorders, compared to patients with alcohol use disorders only and cocaine use disorders only, will have more severe attempts and higher levels of suicidal/homicidal ideation. Hypothesis II: For patients with alcohol and cocaine use disorders, recent use of alcohol and cocaine will have more severe suicidal/homicidal behavior than either drug alone. The present studies as designed will extend and enhance our current knowledge of the phenomenology of DRSHB and shed light on the complex interplay of the drug-individual-environment triad. Understanding these relationships is essential for the development of useful risk-assessment instruments, appropriate intervention strategies and improved suicide and violence prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 41
•
Project Title: DST AND SUICIDE PREDICTION Principal Investigator & Institution: Young, Elizabeth Ann. Professor; Psychiatry; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2002; Project Start 25-JUL-2002; Project End 30-JUN-2004 Summary: (provided by applicant): Suicide is a major public health problem in the US. To date, the main risk factors identified in multiple clinical samples include male sex, living alone and suicidal ideation. Recent data suggest that demonstrating nonsuppression to cortisol on the dexamethasone suppression test (DST) may be a more robust clinical predictor than these other variables. This is further supported by postmortem data indicating chronic activation of the HPA axis such as increased adrenal weight and increased POMC mRNA in the anterior pituitary. Furthermore, strong evidence supports the effects of cortisol in modulating brain serotonin systems. This project depends upon the existence of a large database of subjects with the diagnosis of major depression who received the DST between 1978 and 1987. All subjects also received SADS interviews and weekly Ham-D ratings during assessment and follow-up. After identifying index cases, we will examine mortality rates particularly suicide in DST positive and negative subjects as well as examining the relationship between a number of other potential risk factors for suicide and completed suicide. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EARLY COGNITIVE INTERVENTION FOR SUICIDE ATTEMPTERS Principal Investigator & Institution: Beck, Aaron T. Psychiatry; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2002; Project Start 15-DEC-1999; Project End 30-NOV-2003 Summary: Suicide attempts constitute a major risk factor for completed suicide. The current study aims to determine the efficacy and effectiveness of a short-tem cognitive therapy intervention for suicide attempters, implemented as soon as possible after a suicide attempt. The target group of suicide attempters, largely compromised of people from economically disadvantaged and minority groups, has a high rate of substance abuse. Our approach addresses the social as well as the psychological problems that contributes to suicide attempts in this disadvantaged group. The proposed intervention includes: (1) Cognitive and behavioral strategies that focus on the modifiable psychosocial risk factors including depression, hopelessness and suicide ideation, (2) problem-solving strategies, (3) utilization of social support, (4) addressing thoughts and beliefs that lead to substance abuse, and (5) increasing compliance with adjunctive medical, substance abuse, psychiatric and social interventions. In the research design, 120 patients evaluated at the emergency, medical, surgical, or psychiatric departments of a large urban hospital following a suicide attempt will be randomly assigned to cognitive therapy plus treatment-as-usual (CT+TAU) condition or to a treatment-asusual condition. To test the generalizability of this intervention, all suicide attempters will be eligible for study participation. Patients in the CT+TAU condition will receive therapy immediately after the pre-treatment evaluation. The therapy will continue on a weekly basis post-hospitalization for ten sessions followed by booster sessions at the time of the post-treatment evaluations. All patients will receive in- hospital evaluations and then re-evaluations at 1, 3, 6, 12, 18 and 24 months after the suicide attempt. The primary outcome variable will be the incidence of subsequent suicide attempts. In addition, we will assess changes in hopelessness, depression, suicide ideation, appropriate health care utilization, cost-effectiveness and overall psychological and
42 Suicide
social adaptation. Analyses of repeated measures data will be performed for each measure to determine and characterize differences in the pattern of change over time between the two treatment conditions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EATING BEHAVIOR AFTER GASTRIC BYPASS Principal Investigator & Institution: Hsu, L. K. George. Professor; New England Medical Center Hospitals 750 Washington St Boston, MA 021111533 Timing: Fiscal Year 2001; Project Start 15-JUL-1997; Project End 30-JUN-2002 Summary: (Adapted from Applicant's Abstract): This is a 30-month longitudinal study of 74 severely obese (BMI greater than 40 kg/m2) patients who have undergone gastric bypass (GBP) for weight reduction. It will focus on longitudinal changes in eating behavior, energy metabolism, health status, psychiatric status and psychosocial functioning in 37 binge-eating and 37 non-binge-eating, severely obese subjects followed for 30 months after GBP. It will clarify the outcome of GBP and its prognostic indicators, particularly the role of binge eating and energy expenditure in mediating its outcome. Severe obesity increases both morbidity and mortality and is often resistant to conventional weight loss treatments. Bariatric surgery, particularly GBP, is effective for severe obesity. However, there is great variation in weight loss after GBP and weight regain is common after 18 to 30 months [following] surgery. Furthermore, GBP may not improve binge eating behavior which is very common in severe obesity and may be related to weight regain after GBP. Therefore, the role of binge eating in mediating the outcome of GBP should be studied. Mechanisms that govern energy regulation may influence both eating behavior (including binge eating) as well as energy expenditure. The role of energy expenditure in mediating the outcome of GBP has never been studied. Because of the major weight loss which occurs after GBP, and because weight regain occurs in many patients 18 to 30 months after surgery, the opportunity exists in GBP subjects for a definitive study of energy expenditure in severe obesity. Outcome in psychiatric status and psychosocial functioning after GBP remains unclear. Despite improvement in health status and successful weight loss, suicide is a major cause of death after bariatric surgery. Furthermore, initial improvement in psychosocial functioning may not be sustained despite successful weight loss. Therefore, research in outcome of psychiatric status and psychosocial functioning after GBP is needed. This study is significant because a better understanding of the outcome and the prognostic indicators of GBP may allow better patient selection and the implementation of adjunctive treatments such as cognitive therapy or anti-obesity medications for individuals demonstrating poor outcome predictors or showing persistent psychosocial impairment. Furthermore, it may clarify the role of binge eating and energy expenditure in the pathogenesis of severe obesity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EBV VECTORS FOR TARGETED GENE THERAPY OF BLYMPHOMAS Principal Investigator & Institution: Pagano, Joseph S. Professor; Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2001; Project Start 10-SEP-2000; Project End 31-AUG-2004 Summary: (Applicant's Abstract): The goal of this application is to effectively and selectively eliminate B-cell derived lymphoma and leukemia cells in cancer patients using a naturally targeted viral vector system. To achieve this goal, the applicant
Studies 43
proposes to develop a novel combinatorial gene therapy approach as applied to Burkett B lymphoma based on i) a minimal "gene-less" B lymphotropic Epstein-Barr virus (miniEBV) vector, and ii) a genetically enhanced "hyper-suicide" HSV1 thymidine kinase (super-TK). Specifically, the following studies will be undertaken: Aim 1) To test the efficacy of B lymphotropic miniEBV vectors to deliver and express a suicide gene into human B-cell lymphomas following oncotropic and oncolytic strategies. This approach is based on the transfer of the viral thymidine kinase (TK) gene into B-cell derived lymphomas rendering them sensitive to the prodrug ganciclovir (GCV). For this endeavor miniEBV/sTK will be used to infect B-lymphoma cells in vitro and the transiently infected cells implanted in an animal model to analyze prodrug mediated eradication of the lymphoma using ex vivo protocol. Aim 2) Development of an in vitro cultured packaging cell system to produce helper-free infectious miniEBV. This will involve cloning the genome of EBV in a BAC based vector to delete the packaging sequence by homologous recombination. In addition, EBV negative cell lines will be evaluated for their permissivity to miniEBV replication and packaging into infectious virions. Aim 3) Use the results obtained in Aims 1-2 to test the miniEBV system for its efficiency and safety in a SCID-Human lymphoma/leukemia animal model using an in vivo protocol. Pre-established human B-lymphoma in vivo by intravenous (i.v.) injection with this system will be also evaluated in order to eliminate the disseminated Blymphoma from various organs of the animal. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EMERGENCY LINKAGE TO OUTPATIENT PSYCHIATRIC CARE Principal Investigator & Institution: Currier, Glenn W. Psychiatry; University of Rochester Orpa - Rc Box 270140 Rochester, NY 14627 Timing: Fiscal Year 2003; Project Start 03-DEC-2002; Project End 30-NOV-2007 Summary: (provided by applicant): My ultimate goal is to become a leading expert in the design, implementation, and evaluation of novel therapeutic and preventative interventions for patients receiving care in the psychiatric emergency service (PES), which for many is the primary entrance point to the mental health care system. Viewing the PES as an alternative portal of entry provides a compelling opportunity to rethink how we provide mental health services to underserved, highly distressed patient populations at elevated risk of morbidity and mortality, and to extend our understanding of how best to deploy the costly resources of the PES. During the K23 award period, I will build my patient-oriented, research, evaluation and system-oriented intervention skills with a specific goal in mind. By the end of this award period, I hope to be well prepared in all academic, administrative, and methodological skill areas needed to carry out the highest quality randomized controlled trials in the most challenging patient populations imaginable. The project that I am proposing for this application will have two related parts. First, using population-level profiles of those patients at highest risk for treatment noncompliance, I will implement and test a model intervention aimed at non-hospitalized suicidal patients, discharged from the PES, who are at highest risk of not sustaining prescribed outpatient care. For the most part, these patients now are 'lost to care' until they reappear at the PES door for another transient contact. The proposed randomized prospective trial will compare two alternative approaches to linking discharged PES patients to outpatient mental health services: treatment as usual (provision of an outpatient intake appointment within five days of PES discharge) versus a home or community mobile crisis team (MCT) visit within 48 hours. The content of all initial clinical contacts will be standardized. In the second part of the proposed project, I plan to examine the implications of interventions both from
44 Suicide
the patients' perspective (using symptom and functional measures), and from a health services perspective (through mental health service usage data). By the end of this Career Development Award period, I will be highly prepared to implement and rigorously examine large-scale PES-based clinical interventions to reduce morbidity and mortality for disenfranchised patient populations. This preparation will facilitate future R01 level studies, applying skills gained during the K23 award period to conduct trials focused on children and youth, elders, ethnic and cultural minorities, substance abusers, personality disordered patients, and possibly other groups receiving care in the emergency treatment setting. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EMOTIONAL AROUSAL AS A PREDICTOR OF SUICIDAL BEHAVIORS Principal Investigator & Institution: Welch, Stacy S. Psychology; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2002; Project Start 16-JUN-2002; Project End 15-JUN-2004 Summary: (provided by applicant): Patterns of physiological arousal as well as selfreported emotional arousal associated with parasuicidal behavior in borderline personality disorder are examined. Women with BPD will participate in personally relevant imagery procedures while both physiological measures of arousal (heart rate, skin conductance, respiration, and blood pressure) as well as self-report measures are conducted. Arousal patterns associated with imagery involving suicide attempts and non-suicidal self-injury will be compared to each other and to arousal patterns elicited during control scenes using a four-stage methodology (cue situation, approach, incident, consequence). The research is based on the theory that parasuicidal behavior is learned via escape conditioning with relief from negative emotional states serving as the negative reinforcer. It is hypothesized that both non-suicidal self-injurious behaviors as well as non-lethal suicide attempts are maintained (i.e., negatively reinforced) by immediate reductions in aversive tension and emotional arousal, which will appear in both physiological and psychological measures. It is further hypothesized that changes in these patterns will predict subsequent changes in the frequency of parasuicide and suicide ideation four months after testing. Analysis of variance techniques and regression analyses are employed. Research of this nature is extremely important to help develop and improve treatments for chronic parasuicide in BPD. It remains a serious public health problem with few efficacious treatments, and is very costly in terms of health services utilization. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ENGINEERING ENZYMES FOR ANTI-TUMOR SUICIDE GENE THERAPY Principal Investigator & Institution: Stoddard, Barry L. Full Member; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, WA 98109 Timing: Fiscal Year 2003; Project Start 01-MAY-2003; Project End 30-APR-2007 Summary: (provided by applicant): Prodrug gene therapy is a therapeutic strategy in which tumor cells are transfected with a 'suicide' gene that encodes a metabolic enzyme which is capable of converting a nontoxic prodrug into a potent cytotoxin. Such a method allows selective eradication of tumor cells while sparing normal tissue from significant cell killing. The effectiveness of this strategy is dependent on a bystander effect in which untransfected tumor cells are killed through active or passive transport
Studies 45
of the cytotoxic enzyme product. Several enzyme/prodrug combinations are under active investigation, demonstrating effectiveness in both tissue culture and animal models. However, the combination of low transfection efficiencies and poor turnover of prodrug substrates limit the efficiency of cell killing in the tumor. In order to improve such therapies, enzyme variants must be selected and engineered for enhanced turnover of the prodrug substrate. In this proposal, a collaboration of two laboratories propose to optimize the nucleoside salvage enzymes cytosine deaminase and deoxycytidine kinase for prodrug suicide gene therapy, using a combination of structural biology and directed evolution screens, and to test the efficacy of enzyme variants in cell line and animal models. Cytosine deaminase (CD) catalyzes the deamination of cytosine to uracil and ammonia. Cytosine deaminase is found in bacteria and fungi but is not present in mammalian cells. Cells expressing CD are sensitive to the nucleoside analog, 5fluorocytosine. Due to the enzymatic conversion of 5FC to 5-fluorouracil (5FU). This compound and its deoxyribonucleoside, fluorodeoxyuridine (FUdR), are potent inhibitors of DNA synthesis and RNA function and are widely used in cancer treatment. In contrast, deoxycytidine kinase (dCK) generates cytidine-monophosphate from cytidine nucleoside, and also activates the antineoplastic agents gemcitabine and cytarabine. The specific aims for this project are: (1) Determine the structure of bacterial CD, yeast CD and human dCK. (2) Perform structure-based mutagenesis and genetic screens to isolate enzyme variants with enhanced binding and turnover of prodrug substrates. This aim will exploit crystallographic information both to direct the mutagenesis of specific regions of the enzyme, and to directly visualize the structural basis of enhanced prodrug. activation by selected enzyme variants (3) Test enzyme variants for tumor cell killing in established tumor model systems, using cell lines and animal models. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EPIDEMIOLOGIC SEQUELAE OF SUICIDE IN SCHOOLS Principal Investigator & Institution: Gould, Madelyn S. Associate Professor; New York State Psychiatric Institute 1051 Riverside Dr New York, NY 10032 Timing: Fiscal Year 2001; Project Start 01-AUG-1995; Project End 31-JUL-2002 Summary: The increase in adolescent suicides has led to an increase in the development of suicide prevention programs throughout the United States. The most common programs are school-based and are directed to students. There is evidence that many of these programs are initiated after a suicide has occurred in a school or community (postvention). However, a review of the literature indicates that current knowledge about the sequelae of a suicide within a school community is restricted to anecdotal accounts, that there is no empirical basis for traditional postvention programs, and that their efficacy or impact is untested. We propose a program of epidemiologic research in 24 community schools, reaching an estimated 24,000 students, to address these deficiencies. The goal of the project is to identify the prevalence of postulated sequelae (such as, induction of suicidal behavior or ideation; new onset depression; posttraumatic stress responses; and pathological bereavement responses) in a series of schools where a suicide has occurred and use this information to identify the logical components of a postvention program. The exposed group will consist of all children in 12 high schools, within specified geographical limits in three downstate counties in New York State, in which a fellow student has committed suicide within the past month. A two-stage screening procedure will be employed to estimate the range of disorders in those schools. The two-stage screening procedure will also be conducted in a matched comparison group of schools in which no death occurred, in order to determine the
46 Suicide
extent to which excess morbidity is associated with the occurrence of a suicide. To determine whether distress among the surviving student body is transient or of a more persistent nature, a six month and twelve month follow-up will be conducted. The examination of the duration of clinical distress following a student's death and the identification of pathological sequelae that evolve over time are of particular import. The implications for the need or type of intervention are different if the death of a student generates transient symptoms in the surviving student body in contrast to more enduring disorders. The information yielded by this study will provide the empirical basis upon which to develop a school-based suicide postvention program, rather than merely relying on well-intentioned but not necessarily well-informed efforts. Our ultimate goal is to utilize the information generated from the present study to develop a school based suicide postvention program and to prepare a controlled clinical trial to examine the efficacy of the postvention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ETHNIC DIFFERENCES IN ADOLESCENTS MENTAL DISTRESS Principal Investigator & Institution: Choi, Heeseung; Nursing Systems and Technology; University of Texas Hlth Sci Ctr Houston Box 20036 Houston, TX 77225 Timing: Fiscal Year 2001; Project Start 16-NOV-2001 Summary: Examining the role of ethnicity in mental distress (depression, somatic symptoms, and suicidal behaviors) is important to overcome disparities in mental distress and to develop culturally competent prevention programs for vulnerable youth in this culturally diverse society. The specific aims of the study are to: 1) examine differences among four ethnic groups of middle school students (African, Anglo, Hispanic, and Asian Americans) in: (a) three indicators of mental distress (b) social stress (general social stress and sociocultural stress) and resources (family relationships, coping, and self-esteem) 2)(a) investigate the relations of ethnicity, resources, and the interaction of ethnicity and resources with mental distress to identify the significant resources for each ethnic group; and 2)(b)investigate the relations of ethnicity, social stress, and the interaction of ethnicity and social stress with mental distress, controlling for resources, to identify the extent to which ethnicity moderates the relation between social stress and mental distress. The sample for this cross-sectional epidemiologic study will consist of a minimum of 320 male and female middle school students. Social stress, depression, and suicidal behaviors will be measured using the Social Attitudinal, Familial, and Environmental Stress Scale for Children (SAFE-C), DSM scale for depression (DSD), and Youth Risk Behavior survey (YRBS) questionnaire, respectively. Resources will be measured using the Family Environment Scale (FES) and ageappropriate adaptations of two existing coping scales and Rosenberg?s Self-Esteem Scale. ANOVA, logistic regression, and the general linear model will be used to analyze the data. Conducting this study is significant and very timely considering the increasing number of minorities and their needs for culturally competentnursing care in the United States. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DEPRESSION
ETHNICITY,
GENDER,
AND
MEASURING
ADOLESCENT
Principal Investigator & Institution: Randall, Brandy A. Child Devel & Family Science; North Dakota State University Fargo, ND 581055756 Timing: Fiscal Year 2003; Project Start 01-MAY-2003; Project End 30-APR-2004
Studies 47
Summary: (provided by applicant): In recent years, there has been increasing recognition that it is inappropriate to make cross-racial/ethnic group comparisons without empirically establishing the equivalence of the measure being used. It has been suggested that some racial/ethnic groups and subgroups have higher rates of depression. However, whether these differences are, in part, an artifact of the measures used is unclear. In the proposed 1-year project, data from the National Longitudinal Study of Adolescent Health (Add Health) will be used to examine the crossracial/ethnic measurement equivalence (ME) of the Center for Epidemiologic Studies Depression Scale (CES-D) among adolescents. The following aspects of ME will be examined: (1) equivalence of the factor structure and factor Ioadings for boys and girls within each of four ethnic/racial groups (Anglo Americans, African Americans, Hispanic Americans, and Asian Americans) and within the following Hispanic American subgroups (Mexican Americans, Cuban Americans, and Puerto Rican Americans) and Asian American subgroups (Chinese Americans and Filipino Americans); (2) equivalence of the factor structure and factor Ioadings between whites and each racial ethnic group and subgroup listed in Aim 1 separately for boys and for girls (3) impact of level of acculturation on the ME of the CES-D for boys and girls in each ethnic/racial group and subgroup; (4) compare the mean levels of depression for groups that show ME of the CES-D (5) examine the relation between depression and suicide risk within and across groups. Confirmatory factor analytic and structural equation models will be utilized to examine the dimensions of ME. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FACTORS IN AN ADOLESCENT SUICIDE CLUSTER Principal Investigator & Institution: Norberg, Karen E.; Boston Medical Center Gambro Bldg, 2Nd Fl, 660 Harrison Ave, Ste a Boston, MA 02118 Timing: Fiscal Year 2001; Project Start 05-FEB-2000; Project End 31-JAN-2005 Summary: The purpose of this project is to develop the candidate as an independent researcher with skills in clinical psychiatry, epidemiology, and economics, investigating the role of social and economic factors in an epidemic of adolescent suicide. The Research Plan will have three components: (1) a case/control retrospective investigation of an outbreak of adolescent suicide in South Boston in 1997, with a focus on the role of social networks linking victims of suicide and a large number of adolescents in the community who made non-lethal attempts during the outbreak; (2) a record linkage study, making use of a unique database collected by the candidate and by the Boston Emergency Services Team, comparing the roles of neighborhood risk and protective factors as predictors of adolescent self-injury in South Boston and in neighborhoods elsewhere in Boston; and (3) an econometric analysis, using cross-sectional and longitudinal data, placing the South Boston epidemic in a national context. The Training Plan is designed to develop the candidate's practical skills in research methodology and biostatistics, and to deepen her theoretical background in the psychological study of trauma and affective disorders, economic theory, and epidemiology. Her training will involve three components: (1) individual guidance and instruction from a multidisciplinary group of mentors and consultants, representing the disciplines of psychology, epidemiology, and economics; (2) formal coursework in biostatistics, economics, other social sciences, and epidemiology, and (3) the completion of the three research projects, as outlined. The principal mentors for the candidate's career development will be Dr. Terence Keane (psychology) and Prof. Jonathan Gruber (economics); other consultants will include Drs. Eva Deykin and Madelyn Gould
48 Suicide
(psychiatric epidemiology), and Drs. David Cutler and Richard Frank (health economics). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FAMILIAL PATHWAYS TO EARLY-ONSET SUICIDE ATTEMPTS Principal Investigator & Institution: Brent, David A. Professor; Psychiatry; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2001; Project Start 15-JUL-1997; Project End 30-JUN-2002 Summary: This is a resubmission of MH#56612. This two-site R-10 proposal, based at Western Psychiatric Institute and Clinic (WPIC, the site of this proposal) and at New York State Psychiatric Institute (NYPSI) requests five years of support for a high risk design to study the familial transmission of early.onset suicidal behavior. The probands are adult depressed suicide attempters and depressed non-attempters well characterized in previous interrelated studies in Pittsburgh and New York. In Pittsburgh, approximately 161 offspring of 36 attempters and 25 non-attempters, and in New York, 338 offspring of 90 attempters and 68 non-attempters will be studied. Because clinical and demographic characteristics of the probands in Pittsburgh and New York are similar, it is likely that the data can be pooled across sites. Probands, biological offspring over the age of 10, and the other biological parent will be characterized as to Axis I and II disorder, suicide attempt history, aggression, impulsivity, and family environment. Probands will be genotyped with polymorphic markers for tryptophan hydroxylase and other candidate genes related to central serotonergic metabolism. After the initial assessment, offspring will be followed up at one and two years after intake to observe the development of aggression, impulsivity, psychopathology, and suicidal behavior. We predict that the confluence of aggression and impulsivity, "impulsive aggression," the tendency to impulsively respond to provocation or frustration with anger or overt aggression, is central to the familial transmission of suicidal behavior. The project will test the following hypotheses: (1) offspring of attempters will have higher rates of suicide attempts than the offspring of non-attempters; (2) aggression, impulsivity, and the dimension of impulsive aggression will be greater in offspring of attempters, and will predict development of suicide attempts, especially in those who also develop mood disorders; (3) the familial transmission of suicide attempts will not be explained by the familial transmission of mood disorder alone; (4) there will be evidence of familial transmission of suicide attempt even after controlling for the expected greater exposure to family adversity in the offspring of attempters; and (5) polymorphisms of the tryptophan hydroxylase gene and other genes related to central serotonergic function will be associated with impulsive aggression and suicide attempts among probands. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FAMILIAL TRANSMISSION OF YOUTH SUICIDAL BEHAVIOR Principal Investigator & Institution: Glowinski, Anne L. Psychiatry; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2002; Project Start 18-MAY-2002; Project End 30-APR-2007 Summary: (provided by applicant): Dr. Anne L. Glowinski is an instructor in child and adolescent psychiatry and a postdoctoral fellow in psychiatric genetic epidemiology at the Washington University School of Medicine. This is a revised application for a Mentored Clinical Scientist Development Award (K08) to support 5 years of investigation of the familial transmission of youth suicidal behavior. The Candidate will
Studies 49
be mentored by Dr. Andrew Heath, an internationally renowned behavior geneticist, and Dr. Richard Todd, a child psychiatrist with advanced expertise in molecular genetics and neurobiology. The research funded by this award will be in keeping with the 1999 Surgeon General's call to heed youth suicide. The Candidate's preliminary analyses of twin and family data sets suggest the existence of genetic and environmental susceptibilities to suicidal behavior. Major Depressive Disorder (MDD) has been found in many studies, to be the disorder most firmly associated with suicidal behavior, yet the precise etiological relationship of suicidal behavior and depression is unclear. Also, familial factors, such as parental alcoholism appear to substantially increase the risk of youth suicidal behavior. Using a program of comprehensive secondary data analysis of existing twin-family data sets and new data, collected in a community sample of adolescent female and male twins, the Candidate will examine: 1) Epidemiological, clinical and other characteristics associated with youth suicidal behavior; 2) Familial aggregation of suicidal behaviors; 3) Genetic and environmental influences on youth suicidal behavior; 4) The relationship between genetic influences on suicidal behavior and genetic factors involved in the familial transmission of depression and other psychiatric disorders in adolescents; 5) The contribution of parental alcoholism to suicidal behavior is adolescents (including genotype by environment interaction effects) and the mediators involved in this contribution. In carrying out this plan of research, and through formal coursework, tutorials and selected readings, the Candidate will acquire expertise in conducting twin-family studies, analyzing complex twin-family data and will additionally gain knowledge in other areas upon which she anticipates her career as a clinician scientist will draw in the future including: Developmental neurobiology, molecular genetics, genetic association and linkage analysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FAMILY INFLUENCES ON BORDERLINE OUTCOME Principal Investigator & Institution: Hoffman, Perry D. Psychiatry; Weill Medical College of Cornell Univ New York, NY 10021 Timing: Fiscal Year 2002; Project Start 15-JUN-1999; Project End 28-FEB-2005 Summary: This applicant requests a Mentored Clinical Scientist Development Award to identify the influence of family factors on the course of borderline personality disorder (BPD) and its treatment in the community. A five year program of research and education will furnish the principal investigator with the multifaceted skills and expertise needed to completed state-of-the-art research with this segment of the persistently mentally ill and their relatives. BPD patients are not only challenging and expensive to treat but are also the largest growing subset of psychiatric patients with persistent illnesses. Although the role that the family environment plays in the genesis of the disorder plays in the course and effective treatment of the disorder. The absence of this critical information severely limits the range of potential treatment strategies that are crucial to the recovery process. The research component has two studies. The first study will collect data to test the hypothesis that certain family patterns and attributes (e.g., the absence of parental pathology, high emotional involvement, low perception of burden, high patient validation, effective familial problem-solving, low negative affective style, knowledge about the disorder) will predict one-year patient outcome as measured by: 1) frequency and severity of suicidal behaviors; 2) number of rehospitalizations; 3) behaviors that limit the quality of life, including: a) depression, b) alienation in family relationships, c) generalized hopelessness, d) level of loneliness; and 4) reasons for living. The second study is to conduct a pilot study on a family intervention as an additional treatment to standard Dialectical Behavior Therapy. The
50 Suicide
"add-on" intervention will be pilot tested in a controlled study targeting the variables that are shown to be documented as influential, prevalent, and modifiable in the longterm course of the disorder. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FAMILY PSYCHOEDUCATION: EFFICACY IN CHILD MOOD DISORDERS Principal Investigator & Institution: Fristad, Mary A. Professor; Psychiatry; Ohio State University 1800 Cannon Dr, Rm 1210 Columbus, OH 43210 Timing: Fiscal Year 2001; Project Start 01-MAY-2001; Project End 30-APR-2006 Summary: Mood disorders and suicide in youth represent major health concerns. Clinicians working with these youth need effective intervention strategies. However, there are no well established psychosocial interventions for prepubertal children with depression or manic-depression. Existing literature suggests that reducing expressed emotion (EE) via family psychoeducation improves outcome for adults with mood disorders, but similar studies in children are lacking. We developed an eight session, manual-driven, multi-family psychoeducation group therapy program (MFPG) designed to serve as an adjunct to the ongoing medication management and individual/family psychotherapy a child receives. Preliminary studies suggest MFPG is associated with multiple improvements for families, including: increased knowledge about mood disorders and improved coping skills in parents; improved family climate; increased perceptions of social support for parents and children; and increased effective treatment utilization. However, these studies have had significant methodologic limitations. In the proposed study, we hope to rigorously test the efficacy of MFPG with 165 mood disordered children aged 8 to 11. Participants will be recruited from multiple settings to obtain variability in socioeconomic status (SES), ethnicity, prior treatment history, and typical access to mental health services. Children and their primary and secondary parents/caregivers will complete pre-treatment assessment batteries at Time 1, then will be randomized into immediate MFPG plus treatment-as-usual (TAU) or a wait-list condition (WLC) plus TAU. All will be reassessed at Time 2 (approximately 3 months after study entry), Time 3 (7 months), and Time 4 (12 months). After the Time 4 assessment, WLC+TAU families will receive MFPG. A final assessment (Time 5, 15 months) will occur post-treatment. Hypotheses are: 1) MFPG+TAU families will function better than WLC+TAU families at Times 2, 3 and 4; 2) all families will improve functioning from immediately pre-treatment to immediately post-treatment; 3) several baseline variables (healthier child and parent functioning, higher caregiver concordance regarding treatment, and greater access to services) will be associated with better outcome for all participants; and 4) differences in gender and ethnicity will be unrelated to outcome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FETAL ALCOHOL EXPOSURE AND NEURODEVELOPMENT Principal Investigator & Institution: Miranda, Rajesh C. Associate Professor; Human Anatomy and Medical Neurobiology; Texas A&M University Health Science Ctr College Station, TX 77843 Timing: Fiscal Year 2002; Project Start 01-MAR-2002; Project End 28-FEB-2007 Summary: (provided by applicant): Heavy alcohol consumption during pregnancy is the leading preventable cause of craniofacial and central nervous system birth defects. These defects include hypodevelopment of the mid-face, microcephaly, and loss of brain
Studies 51
tissue mass. Fetal alcohol exposure is especially linked to a significant risk for mental retardation, attention deficits, hyperactivity and other mental health disorders. Alcohol induces a loss of neural tissue by inhibiting neurogenesis while promoting neuronal death. However, the underlying mechanisms are not well understood. We know little about the neurotrophic mechanisms that are targeted by alcohol. We also know little about the gene transcription gestalt that is associated with the deleterious actions of alcohol on the brain. Therefore, our central hypothesis is that is that alcohol suppresses survival and neurogenesis signals, and related patterns of gene expression in the developing cerebral cortex. We will test our hypothesis in cerebral cortical models of neural development. We propose three specific aims: (#1): To identify the extent to which alcohol alters the balance between developmental cell-suicide and survival mechanisms. Our working hypotheses are that alcohol will increase activation of Fas/Apo [apoptosis]-1 suicide receptor and repress compensatory Akt-related survival signals. Furthermore, inhibition of Fas/Apo-1 will prevent alcohol-induced apoptosis. We will test these hypotheses in embryonic mouse cerebral cortical cultures exposed to alcohol. (#2): To identify neural p53-associated genetic differentiation patterns that are regulated by alcohol. p53 is a key intracellular initiator of differentiation. Based on our studies, our working hypothesis is that alcohol alters p53 activation to prevent differentiation-related patterns of gene expression in the cortex. We will use western immunoblot analyses to examine p53 activation, and cDNA microarray analyses to specifically identify p53-associated genes that are regulated by alcohol. (#3) To identify neurogenesis-related genes that are regulated by alcohol in the cerebral cortex. We have identified neurogenesis-related genes in an embryonic cerebral cortical model, using differential hybridization strategies. Based on our data, our working hypothesis is that alcohol will suppress expression of proliferation-associated genes in embryonic cortex. We will use cDNA microarrays to identify relationships between alcohol exposure and induction of genes related to neurogenesis. At the conclusion of the proposed research, we expect to have identified some of the trophic support mechanisms underlying alcohol neurotoxicity. We also expect to identify unique neurogenesis and differentiation gene patterns that are regulated by alcohol during development. These outcomes will be significant because they are expected to provide the foundations for an analysis of neurobiological processes targeted by a leading environmental teratogen. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FLUOXETINE & COGNITIVE BEHAVIOR THERAPY IN SOCIAL PHOBIA Principal Investigator & Institution: Foa, Edna B. Professor; Psychiatry; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2001; Project Start 15-FEB-1999; Project End 31-JAN-2002 Summary: This competing continuation application is one-half of a jointly proposed multicenter study by Drs. Foa, Franklin, and Kozak, of the Allegheny University of Health Sciences and Drs. Davidson and Keefe of Duke University Medical Center. Who are submitting two separate but similar proposals. We request that the two proposals be reviewed together. The proposed research is a continuation of an ongoing study funded by NIMH for the period of 9/30/94 though 8/31/98. Patient recruitment in the ongoing study has been slower than anticipated, and we are seeking funds to extend the study for an additional 3 years to accrue sufficient sample size to test the original hypotheses. The major goals of the study are: (a) to evaluate the effectiveness of FLU, a comprehensive cognitive behavioral program (CCBT) that includes CT,EX and SST, and a combination of FLU and CCBT in generalized anxiety disorder (GSP); (b) to compare
52 Suicide
relapse rates associated with different groups after discontinuation of treatment; ~ to examine the transportability of the two treatment approaches; and (d) to examine possible predictors of treatment response. GSP is chronic and debilitating anxiety disorder, affecting over 2% of the population and resulting in significant morbidity and suicide attempts. Recent studies have indicated a number of promising treatments, including fluxetine (FLU), cognitive therapy (CT), exposure therapy (EX) and social skills training (SST). No studies have compared FLU ( or any other serotonergic drug) with cognitive behavior therapy in GSP or examined the effectiveness of a combined treatment group. Moreover, no study has yet evaluated the extent to which different treatments for GSP (e.g., medications, CBT) can be transported/replicated across sites. One hundred and sixty subjects (80 per site) in addition to the 200 to be accrued in the ongoing study, meeting DSM-IV criteria for GSP will be randomly assigned to one of five conditions: FLU, CCBT, FLU+CCBT, CCBT + pill placebo, and placebo alone. Treatment is administered for 14 weeks, followed by a 24 week treatment free followup. Outcome is assessed by independent evaluator ratings, self-report scales, and behavioral measures of social skills. Assessments are conducted before, during and after treatment as well as during an extended follow-up phase. Important to this proposal is the collaboration between pharmacologically and cognitive- behaviorally oriented research programs. Long range goals are to establish guidelines for the pharmacological and cognitive behavioral treatment of GSP, to understand the separate and combined effects of pharmacotherapy and cognitive behavioral therapy in this condition, and to integrate pharmacological and psychosocial approaches to the anxiety disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FLUOXETINE AND BEHAVIOR THERAPY IN SOCIAL PHOBIA Principal Investigator & Institution: Davidson, Jonathan R. Professor; Psychiatry; Duke University Durham, NC 27706 Timing: Fiscal Year 2001; Project Start 30-SEP-1994; Project End 30-NOV-2002 Summary: This application is one-half of a jointly proposed multicenter study by Drs. Davidson and at DUMC and AUH respectively, who are submitting two separate but similar competing continuation proposals. Generalized social phobia (GSP) a chronic and debilitating anxiety disorder affecting over 10 percent of the population and resulting in significant morbidity and suicide attempts. Recent studies have indicated that fluoxetine (FLU), a selective serotonin reuptake inhibitor (SSRI), comprehensive cognitive behavioral therapy (CCBT) may be effective in treating GSP. No studies have compared FLU vs. CCBT vs PBO in GSP, nor have they examined the effectiveness of combined FLU-CCBT. No study has yet evaluated the extent to which different treatments for GSP (e.g. medications, CCBT) can be transported/replicated across centers, nor have the comparative effects of an SSRI, a widely used class of drugs in GSP, been assessed relative to psychosocial treatments. Major goals of this ongoing study are to (1) evaluate the effectiveness of FLU, CCBT, the combination of FLU plus CCBT, vs CCBT with placebo vs placebo; (2) to compare relapse rates associated with different treatment groups following discontinuation at week 14; (3) to examine the transportability of the two treatment approaches; (4) to examine possible predictors of treatment response. This study was begun in 1994, and involves both a pharmacologically oriented site and a psychosocial treatment oriented site, thus providing state-of-the-art treatment in each mode. The collaborative study has been very successful to date, but we have proceeded at a slower speed than we had expected, and propose to extend the study for three more years in order to accumulate a sufficient sample of completed subjects to allow adequate power to test our original hypotheses.
Studies 53
We will enroll 160 subjects at each site, to attain 120 completers (n=25 per group; n=20 for placebo). This will provide adequate statistical power to test treatment and site effects. This study serves as a model for psychotherapy-pharmacotherapy comparisons because experts in each modality are providing both forms of treatment. As a result, this protects against expert bias for either treatment and the results of this study are expected to establish guidelines for pharmacotherapy and behavioral therapy of GSP, to understand the separate and combined effects of each type of therapy in this disorder, and to integrate pharmacological and psychosocial treatments in generalized social phobia. Effective treatments can be a long way towards reducing the societal burden associated with the disorder. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FOLLOW-UP OF VIETNAM VETERANS AT RISK FOR SUICIDE Principal Investigator & Institution: Price, Rumi K. Research Associate Professor of Epidemio; Psychiatry; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2001; Project Start 28-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant): This amended application (RO I MH/DA6096 1-01 A2) requests support for four and a half years (July 200 Ito December2005) to conduct a follow-up of Vietnam veterans whose risk levels for current suicidal behaviors have been projected from the results from the Washington University Vietnam Era Study Phase III (VES-HI), carried out in 1996-97. The VES cohort originates from a study initiated by the White House in 1971 to address substance abuse and adjustment problems to civilian life among returning servicemen deployed to Vietnam. Two waves of in-person interviews were conducted by Washington University in 1972 and 1974 with two national probability samples of male Vietnam War veterans and a comparison sample of nonveterans (total target N=l,227). The 25-year follow-up (VES-Ill) implemented life crisis intervention protocols after a suicide occurred during fieldwork. Analyses of VES-Ill and two large general-population studies, the National Mortality Followback Survey, 1993, and the National Longitudinal Alcohol Epidemiologic Survey, 1992, together confirmed a significant excess risk of both suicide and suicide attempts among Vietnam veterans, within men of the age group of 40-60, controlling for demographic risk and protective factors. Alcoholism, drug use, depression, and trauma/PTSD appear to largely explain Vietnam veterans' excess risk. This application (VES-IV) will attend closely to protective factors mitigating suicidal risk to improve the precision of suicidal behavior prediction. Based on self-reports and a suicide behavior predictive scale, higher-risk (n=168) and lower-risk (n=250) target samples have been selected from VES-III to balance the considerations for scientific yields and challenges expected in the field. The scientific aims are to examine: 1) the mechanisms of coping and other protective factors using mixed qualitative and quantitative measures, including analyses of a) qualitative measures of appraisal, coping, religiosity, optimism, substance use, social networks, and barriers to care based on suicide episodes or negative events, b) quantitative measures of qualitative codes used in a), c) quantitative measures of episode/event-based and general coping, and d) quantitative measures of time-dependent protective factors; and 2) the interactions of risk and protective factors in predicting suicidal behaviors, using the measures including a) quantitative episode/event -based or time-dependent risk and protective factors obtained from VESIV, and b) previous risk and protective factors obtained from VES-III and earlier waves. A human subject protection aim is added to: 3) provide follow-up treatment triage and access to an on-call suicide intervention for those with current suicidal risk. The study
54 Suicide
will provide a better understanding of the inner working of protective factors, and their interaction with risk factors, which were identified as a gap in knowledge in the literature. We hope the study's results will help guide intervention for those with known risks for suicidal behavior. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FORMATION AND NATURE OF SERPIN COMPLEXES WITH SERINE AND CYSTEINE PROTEINASES Principal Investigator & Institution: Olson, Steven T. Professor; University of Illinois at Chicago 1737 West Polk Street Chicago, IL 60612 Timing: Fiscal Year 2001 Summary: Protein proteinase inhibitors of the serpin superfamily play an important role in regulating intracellular and extracellular proteolytic enzymes in blood coagulation, fibrinolysis, inflammation, apoptosis and other key physiological processes. Serpins are distinguished by their ability to inhibit both serine and cysteine proteinases and by their novel mechanisms of trapping proteinases in kinetically stable covalent complexes through major conformational changes. While the multi-step serpin inhibitory mechanism has provided serpins with function through natural mutations associated with disease. The long range goals of this project are to dissect the stepwise sequence of molecular events involved in the conformational trapping mechanism by which serpins inhibit proteinases and to characterize the molecular events involved in the conformational trapping mechanisms by which serpins inhibit proteinases and to characterize the molecular basis of kinetic stabilization of the complexes for both serine and cysteine proteinase targets. The knowledge gained from such studies is expected to deepen our understanding of how serpins regulate proteolysis and to illuminate the multiple ways in which serpin mutations disrupt this regulation. Three hypotheses for how serpins function as unique protein proteinase inhibitors will be tested in these studies: i) serpins function as suicide substrate inhibitors, being initially recognized as normal substrates by their target proteinase, by then being induced to undergo a major conformational change which traps the proteinase at the acyl-intermediate stage of proteolysis; ii) the trapping of proteinases in stable serpin-proteinase complexes results from conformational changes induced in the proteinase by the serpin which disrupt the proteinase catalytic machinery and thereby prevent deacylation of the complex; iii) cysteine proteinases are inhibited by serpins by the same suicide substrate mechanism of kinetic trapping but with different outcomes dictated by the greater reactivity of the thioester linkage between serpin and proteinase. The three specific aims which will test the hypotheses are: 1) to elucidate the novel multi-step mechanism by which serpins inhibit serine proteinases; 2) to determine the nature of the trapping mechanism and elucidate the role of proteinase conformation changes in inducing the trap; and 3) to determine the mechanism by which serpins inhibit cysteine proteinases and assess any differences from serine proteinase inhibition mechanism. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FUNCTION-BASED SELECTION OF TARGET GENES IN TUMOR CELLS Principal Investigator & Institution: Roninson, Igor B. Professor/Head; Ordway Research Institute, Inc. 150 New Scotland Ave Albany, NY 12208 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2006
Studies 55
Summary: (provided by applicant): This proposal uses a new methodology to identify human genes that are required for tumor cell growth. Such genes, which provide potential targets for cancer treatment, will be identified through expression selection of genetic suppressor elements (GSEs). GSEs are biologically active sense- or antisenseoriented cDNA fragments that inhibit the function of the gene from which they are derived. Genes that are essential for cell proliferation are expected to give rise to GSEs that inhibit cell growth. Such GSEs can be isolated by bromodeoxyuridine (BrdU) suicide selection from a normalized (reduced-redundance) library of human cDNA fragments in an inducible retroviral vector. In preliminary studies, selection for growthinhibitory GSEs has been carried out in breast carcinoma cells, yielding growthinhibitory GSEs from about 60 genes. Many of the genes identified by GSE selection are known oncogenes or positive regulators of cell growth, while other genes have no known function or had not been previously implicated in cell proliferation. This analysis will now be extended to several other types of tumor and normal cells. A normalized cDNA fragment library in an inducible retroviral vector will be generated from a mixture of RNA preparations from multiple human tumor cell lines. This library will be transduced into recipient cell lines derived from several major types of human cancer and into telomerase-immortalized lines of normal human cells. Prior to transduction, the recipient cell lines will be derivatized to provide for high efficiency of retroviral infection and for the ability to regulate gene expression from retroviral vectors. The transduced cells will be subjected to BrdU suicide selection for growth-inhibitory GSEs, and GSE-enriched population of cDNA fragments will be recovered from the selected cells. Genes enriched by GSE selection will be identified by sequencing, and representative GSEs from each gene will be tested by several functional assays. The role of GSE-cognate genes in cell proliferation will be confirmed via siRNA inhibition. Genes identified through GSE selection will be prioritized as potential targets by comparing the ability of their cognate GSEs to inhibit cell growth in different types of tumor and normal cells and by analyzing the ability of the GSEs to induce tumor cell death through mitotic catastrophe. This analysis will provide a database of potential new targets for the development of anticancer drugs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENE EXPRESSION PROFILE OF ANTIDEPRESSANTS Principal Investigator & Institution: Duman, Ronald S. Professor; Psychiatry; Yale University 47 College Street, Suite 203 New Haven, CT 065208047 Timing: Fiscal Year 2002; Project Start 07-AUG-2002; Project End 31-JUL-2004 Summary: (provided by applicant): Depression is characterize behaviorally by depressed mood, inability to experience pleasure, withdrawal of interest, and feelings of worthlessness which can often result in a debilitating quality of life, as well as suicide in many cases. Despite the significant advances that have been made in neurobiology and neuropharmacology of antidepressants, the molecular mechanisms underlying the actions antidepressant treatment have not been identified. Although the acute action of most antidepressants occurs via inhibition of the reuptake or breakdown 5-HT and NE, increased synaptic levels of these monoamines alone cannot account for the therapeutic action of antidepressants. Recent studies have shown that chronic antidepressant treatment (ADT) alters gene expression, especially components of cAMP signal transduction cascade. The delay in the therapeutic effects of ADT coincides with changes in gene expression in intracellular pathways, and it is thought that these changes mediate the therapeutic effects of antidepressants. It is known that stress and antidepressants have opposing actions on neuronal growth and vulnerability, in part
56 Suicide
due to the opposing effects on expression of neurotrophic factors. We hypothesize that stress and antidepressant administration have reciprocal changes in gene expression profiles. The aim of this R21 Exploratory Grant is to characterize the gene expression profiles to different classes of ADT, including 5-HT and norepinephrine selective reuptake inhibitors and ECS, and compare these profiles with changes observed with stress. It is however necessary to distinguish between acute and chronic alterations in response to ADT as only chronic ADT has been shown to possess therapeutic effects. This can be accomplished by comparing expression profiles by microarray analysis at various time points after and ADT. Gene expression changes will be characterized in the hippocampus and dentate gyrus of rat brain. This will increase our understanding of the mechanisms underlying the actions of antidepressant treatment and could lead to novel therapeutic targets. The results from these studies should lead to an ROl proposal aimed at extending these findings. Briefly, further studies would involve modulating the expression of genes identified by viral-mediated expression of genes in discrete brain regions and generation of transgenic mice, for study in behavioral models of stress and depression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENE THERAPY TARGETING HYPOXIC GLIOMA CELLS Principal Investigator & Institution: Deen, Dennis F. Berthold and Belle N. Guggenhime Profess; Neurological Surgery; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001; Project Start 01-FEB-2001; Project End 31-JAN-2006 Summary: Radiation is a primary treatment modality for patients with malignant gliomas, and in most patients radiation therapy is clearly beneficial. However, the overall outcome of therapy for these patients is dismal, and most patients with glioblastoma multiforme (GBM) die within a year of diagnosis. The presence of hypoxic cells in brain tumors is a major obstacle for radiation therapy, because these cells are notoriously resistant to radiation-induced damage. Therefore, we propose to devise a gene therapy approach for killing hypoxic brain tumor cells during the course of radiation therapy. The DNA construct to be delivered to the tumor cells contains hypoxia-responsive elements (HREs) in the enhancer region of the promoter and a suicide gene. Under hypoxic conditions, the transcriptional complex hypoxia inducible factor-1 (HIF- 1) builds up in cells and binds to HREs. This, in turn, activates the adjacent promoter and causes expression of the downstream suicide gene that kills the cell. This project has 2 goals. The first is to investigate how several cellular or intratumoral characteristics impact on this gene therapy strategy. The second is to investigate whether the gene therapy enhances the radiation response of the tumor cells. We propose 4 specific aims to accomplish these goals. 1) investigate the relationship between HIF-1 and oxygenation status in brain tumor and normal brain; 2) evaluate suicide genes under low pH and in noncycling brain tumor cells; 3) reveal and investigate any bystander effect (BE) produced by specific suicide genes under hypoxic conditions; 4) determine whether expression of suicide genes in hypoxic and oxic cells enhances their response to radiation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENE MYASTHENIA
TRANSFER
FOR
SPECIFIC
IMMUNOTHERAPY
OF
Principal Investigator & Institution: Drachman, Daniel B. Professor; Neurology; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218
Studies 57
Timing: Fiscal Year 2001; Project Start 09-FEB-2001; Project End 31-JAN-2005 Summary: (adapted from applicant's abstract): This is a proposal to develop and apply a unique and powerful new gene transfer strategy for specific immunotherapy of myasthenia gravis (MG). Ideally, therapy of MG should specifically inhibit the autoimmune response to the autoantigen, acetylcholine receptor (AChR), without otherwise interfering with the immune system. Because the antibody response to AChR is T cell dependant, elimination of the AChR-specific T cells interrupts the autoimmune disorder at a pivotal point, resulting in clinical benefit. This requires elimination of virtually all AChR-specific T cells. However, the marked heterogeneity of T cell responses to AChR in humans and in experimental animals presents a challenge in designing specific treatment capable of eliminating the entire repertoire of AChRspecific T cells. The investigator's targeting strategy is based on the fact that a myasthenic individual's own antigen presenting cells (APCs) can present AChR epitopes to that indivudual's entire repertoire of AChR specific T cells. They have adapted a method that induces the APCs to process and present AChR by inserting a cDNA construct that encodes the key immunogenic domain of the AChR flanked by signals that induce the APCs process and present it. These APCs target AChR-specific T cells highly effectively. In order to eliminate the targeted T cells, they utilize Fas ligands as a "warhead." When FasL interacts with Fas, which is abundantly expressed on activated T cells, it induces apoptosis and death of the T cells. Insertion of the gene for FasL in APCs induces them to express FasL, which effectively kills Fas-expressing target cells. It is essential to protect these APCs, which would die by FasL- induced "suicide," because they also express Fas. To protect these APCs, they insert a 3rd gene for a truncated form of FADD, which acts as a dominant negative inhibitor of Fas-mediated cell death, into the APCs. To insert all 3 genes simultaneously into APCs ex vivo, they have developed a vaccinia virus vector (vvv), which carries all 3 genes. This vaccinia vector can transfer multiple genes simultaneously, inducing high level production of the gene encoded proteins. When it is attenuated (by treatment with psoralen and UV light) the vvv does not replicate but does direct expression of the gene products. Finally, the expression of FasL directed by their vvv system should confer protection against an immune attack by the host's immune system on the virus vector itself. They now propose to optimize the system and develop it in two animal models: (1) experimental MG, including a new transgenic myasthenic mouse model; and (2) a transgenic mouse model of hemaglutinin (HA) sensitivity. The experiments described in the present proposal will develop this novel strategy in experimental animals, both for prevention and for treatment of EAMG. This method is designed to be suitable for treatment of human autoimmune diseases. When optimized in experimental animals, it will be adaptable for treatment of patients with MG and other autoimmune diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC EFFECTS ON SEROTONERGIC ACTIVITY AND AGGRESSION Principal Investigator & Institution: Hen, Rene; Associate Professor; New York State Psychiatric Institute 1051 Riverside Dr New York, NY 10032 Timing: Fiscal Year 2001 Summary: The diathesis for suicidal behavior plays a major role in determining risk and includes aggressive and impulsive traits. Low serotonergic activity correlates with greater aggressive impulsivity. Genetic factors play a role in determining aggressiveimpulsive traits and serotonergic activity. While suicidal behavior is unique to humans, certain associated behaviors such as aggression, impulsivity, novelty seeking and risk
58 Suicide
taking behaviors in animals may be of direct relevance to suicide-related behaviors in humans. Studies are proposed to examine the hypothesis that alterations in neurodevelopment may result in enduring impairment in the serotonergic system and an increase in impulsivity, novelty seeking and aggression in animals. To further understand these genetic-biological-behavioral relationships, three studies using different, but complementary, strategies are proposed. Study 1 (AGGRESSION IN SEROTONIN RECEPTOR KNOCKOUT MICE, R. Hen) will identify differences in aggressive behavior, serotonin receptor (serotonin transporter, 5-HT/1A, 5-HT/2A) concentrations, and differential gene expression in the brain of 5-HT/1B knockout mice (more aggressive) and compare them with less aggressive 5-HT1A knockout mice and wild type control animals. The genes that produce candidate proteins will be rescued in specific brain regions, and the resulting effects on aggressive behaviors will be determined. Behavioral genetics will be examined in two populations. One population, the vervet monkey component of Study 2 (SEROTONIN SYSTEM NEURODEVELOPMENT, M. Underwood), proposes studies of neurodevelopment to understand the conditions under which genetic factors influence behavioral outcomes. In this work, and in parallel experiments in knockout mice, candidate genes and the morphometry of serotonergic neurons in the dorsal raphe nucleus are examined. Study 3 (GENETICS OF TEMPERAMENT AND CENTRAL MONOAMINERGIC ACTIVITY IN PEDIGREED BABOONS, J. Kaplan) examines the second population, baboons, in a linkage study of candidate genes, aggression, novelty seeking and neurobiology (CSF indices). It offers the possibility of identifying the genetic loci of other genes possibly contributing to the aggression or the level of central monoaminergic activity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC ALCOHOLISM
EPIDEMIOLOGY
OF
SOCIAL
PHOBIA
AND
Principal Investigator & Institution: Nelson, Elliot C. Assistant Professor; Psychiatry; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2001; Project Start 01-AUG-1999; Project End 31-JUL-2004 Summary: This proposal is for a NIAAA Mentored Clinical Scientist Development Award (KO8) to foster the development of Dr. Elliot Nelson's career by supporting his work with Dr. Andrew Heath and Dr. Richard Todd. The award will enable the candidate to explore the relationship of alcohol dependence and social phobia, controlling for comorbid major depressive disorder (MDD). The candidate's career development will include a program of formal coursework and independent tutorials focusing on biostatistics, genetic epidemiology, research methodology (including the mediation of alcohol dependence and dangerous behavior risks), and behavioral and quantitative genetics. The skills acquired will be applied to both the analysis of existing data and to an independent research project designed to provide a better understanding of the mediation of shared risk. The preliminary data from adolescent female twins suggests that comorbid alcohol dependence is likely to be seen at increased rates in individuals with social phobia and that these subjects are also at increased risk for dangerous behaviors such as having unprotected sex, suicidal ideation, suicide plans, and suicide attempts. The goals of the proposal are to collect two waves of data on l00 control pairs and l00 pairs where at least one twin has a history of social phobia. We will use these data, plus existing data-sets, to address the following Specific Aims: l) To characterize prospectively the profile of comorbid illness observed in individuals with social phobia; 2) To determine prospectively the risk for alcohol dependence and harmful alcohol use given a primary diagnosis of social phobia; 3) To use multivariate
Studies 59
twin analysis to characterize the relative contributions of disorder-specific and shared genetic and environmental risk factors for social phobia, alcohol dependence, and MDD; 4) To examine whether a variety of dangerous behaviors are seen more frequently in individuals with social phobia, and determine their association with the development of alcohol problems; 5) To examine the routes by which the shared risks appear to be mediated (including both risks of comorbid illness and dangerous behaviors). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC MANIPULATION OF T CELLS--PRECLINICAL MODELS Principal Investigator & Institution: Dipersio, John F. Cheif, Division of Oncology; Medicine; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (Applicant's Description Verbatim): Allogeneic bone marrow transplantation is a curative therapy for hematologic malignancies, marrow failure states, and selected inherited metabolic diseases. Unfortunately, BMT is associated with significant morbidity and mortality related to graft vs. host disease (GvHD). Attempts to mitigate GvHD using T-cell depletion resulted in increased rates of graft failure, post-transplant lymphoproliferative diseases, leukemia relapse and opportunistic infections. We propose to genetically modify T-cells using novel cell surface chimeric suicide genes. We will test the expression and purification of novel fusion suicide genes in vitro and in vivo using instructive transgenic and "knock-in" murine pre-clinical models. The optimal method and potential role of genetically manipulated T-cells to mitigate GvHD while maintaining engraftment and graft vs. leukemia can only be defined by developing new reagents and novel pre-clinical murine transplant models. We propose to generate important new reagents to study T-cell transduction by suicide genes and to use a number of well-defined pre-clinical models to develop a rational approach and a clear foundation for future clinical trials. In Aim I, we will design methods to optimize transduction, selection, and expansion of transduced T-cells, using OKT3 and 11-3 and CD3/CD28 magnetic beads. In addition, we will generate novel second-generation suicide genes designed to optimize detection and killing in response to prodrug. We will also test the survival and function of transduced murine and human T cells using in vivo using allogeneic transplant models and several murine SCID models. Aims II and III, we will use the chimeric suicide genes developed in Aim I to generate informative transgenic and knock-in pre-clinical murine models in which these suicide genes will be expressed in all (Aim II) or in subsets (Aim III) of peripheral T-cells. Allogeneic bone marrow transplantation will be performed using the transgenic and knock-in mice developed in Aims II and III to further develop the optimal method of suicide in vivo, its effect on GvHD and engraftment, and its possible role in clinical trials. In Aim 1V, we will utilize three novel murine leukemia models in which the effects of genetically modified T-cells and their in vivo suicide on GvHD, engraftment and graft vs. leukemia can be compared to animals receiving unmanipulated T-cells and T-cell depleted BM. These studies will provide new insights into the pathophysiology of GvHD and its effective treatment. Issues regarding the use of genetically manipulated T-cells to control GvHD can best be investigated through the use of informative animal models and the comprehensive studies described in this proposal. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENETICS OF EARLY ONSET DEPRESSION Principal Investigator & Institution: Depaulo, J R. Associate Professor; Psychiatry and Behavioral Scis; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218
60 Suicide
Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2003 Summary: (Adapted from investigator's abstract) Major depressive disorder (MDD) has at least a 5-10% lifetime population prevalence and causes severe morbidity and mortality including suicide. Heritability in twins is 0.4-0.70. Mapping of susceptibility genes may be feasible with the recurrent, early-onset subtype (MDD-RE) which demonstrates a three- to eight-fold increase in risk to first-degree relatives of probands, vs. twofold for all MDD. The complex pattern of transmission suggests multigenic transmission and/or locus heterogeneity, so that large samples may be required. We propose a four-year, six-site project to collect an estimated 770 pedigrees which contain 1,000 independent affected sibling pairs (ASPs), extended by first-degree relationships to include additional affected relatives, plus unaffected relatives (parents and sibs) for genetic phase information. All sites will have identical inclusion criteria, clinical assessment DIGS and FIGS interviews and the NEO personality inventory), interviewer training and reliability monitoring, consensus diagnostic procedures, data management system, and administrative oversight including a quality assurance program. Permanent cell line specimens will be created and DNA extracted at the NIMH-sponsored cell repository. A 10 cM genome scan will be completed on all affected subjects at the Center for Inherited Disease Research (CIDR), which has approved this project for CIDR access. A three-stage design is proposed: regions with maximum lod scores (MLS) exceeding a liberal simulation-based threshold will be identified in a genome scan of the affected individuals from the first half of the sample, and candidate regions selected which continue to meet this threshold after unaffected individuals are typed in these regions and added to the analysis. Evidence for linkage in these regions will then be tested in the entire sample with parametric and non-parametric analyses using stringent simulation-based thresholds for 5% genome-wide significance. In the four-year project period, genetic analyses can be completed on 80% of the sample (over 600 pedigrees, 800 ASPs), with the remaining families to be available by the end of the project period for immediate completion of the genome scan on these pedigrees at CIDR. A timetable is proposed for rapid sharing of all biological materials, blinded clinical data, genotypes and linkage analyses with the scientific community through the NIMH-sponsored Center for Genetic Studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENOMIC CHARACTERIZATION IN DEPRESSION AND SUICIDE. Principal Investigator & Institution: Sibille, Etienne L. Psychiatry; Columbia University Health Sciences New York, NY 10032 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2008 Summary: (provided by applicant): Major depression is emerging as a disease of the central nervous system with a characteristic pathophysiology. For inpatients with major depression, the lifetime mortality due to suicide reaches 15%. Despite a global burden of neuropsychiatric disorders on individual mental health and society's productivity, little is known on mechanisms or molecules that are responsible for these diseases. Accordingly, the identification of the neurobiological underpinnings for mood disorders represents an important challenge in neuropsychiatric research. Complex polygenic mechanisms are likely, with environmental factors contributing to the development of depression and suicidal behavior. However, research efforts have been largely limited to components of brain biology that are affected by antidepressants and mood stabilizers. Microarray technology and genomic characterization represent new investigational developments that allow for unbiased identification of new molecular components and mechanisms of mood disorders. During the award period, the
Studies 61
applicant aims to train in the application of microarrays to postmortem human brain studies, to initiate a genomic and molecular characterization of prefrontal cortex dysfunction in depressed patients who died by suicide, and to seek new mechanisms, genes and molecules that contribute to the development of the disease. Preliminary results indicate a rich potential for genomic approaches to psychiatric disorders and hints at a possible molecular classification of depression into unrecognized subtypes. The specific aims of the study are /) to characterize gene expression profiles in the prefrontal cortex of human subjects, ii) to assess the effect of major depression and suicide on gene expression, iii) to investigate genes and molecular pathways that were affected by the disease, and iv) to develop new understanding of biological mechanisms involved in depression and suicide, with possibilities for designing new genetic mouse models, and uncovering new molecular targets for treatment and prevention of mood disorders. The proposed training plan will enable the applicant to benefit from recent advances in genome sequencing and genomic technologies, and to develop expertise to bridge these approaches to the study of neuropsychiatric disorders. In particular, the applicant will receive valuable training in genomics, statistics and bioinformatics, and in clinical and basic science aspects of brain function. The training program proposes formal courses, supervised training and frequent interactions with several research groups involved in pioneering aspects of genomic research in mood disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GOD/HIGHER POWER CONTROL BELIEFS AND PROBLEM DRINKING Principal Investigator & Institution: Goggin, Kathy J. Psychology; University of Missouri Kansas City Kansas City, MO 64110 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 30-JUN-2003 Summary: Drinking among adolescents is prevalent. By the age of 14, over half all secondary school students drink at least occasionally. Further, adolescents are one of the major at-risk populations for alcohol abuse, with an estimated 30% of adolescent boys and 15% of adolescent girls meeting the criteria for heavy drinking (consuming greater than or equal to 5 drinks at a time) by the age of 18. The initiation of drinking is associated with a variety of negative outcomes for teens including higher risk of alcohol dependence, serious health problems including suicide and alcohol-related traffic accidents. While rates of heavy drinking among other adolescents have declined, rates among African-American youth have stayed consistently high (15% for boys and 5% for girls) over a 10-year period. Frequent heavy drinking places African-American youth at high risk for the development of problems related to their alcohol use. In fact, AfricanAmerican adolescents who drink experience disproportionately more negative consequences as a result of alcohol use even though their levels of use are comparable or even lower than youth of other ethnic groups. Due to the severity of the problems associated with adolescent alcohol misuse, researchers have begun to explore protective factors that may inoculate at-risk adolescents from developing problem drinking patterns. Several of those inquiries have examined the potential protective role that religiosity and spirituality might play. Higher ratings of global religiosity and spirituality do indeed appear to be protective factors against problem drinking in adolescents. However, in adults recent evidence suggests that the extent of an individual's belief that God directly controls his or her alcohol use may have particular importance as a protective factor against problem drinking. This new evidence suggests a need for research on the protective role of alcohol- related God/Higher Power control beliefs in adolescents, however no published studies exist. The dearth of studies in this
62 Suicide
area is due at least in part to the paucity of available measures of domain-specific God/Higher Power control beliefs for use with African-American youth, 2) to explore the protective role of alcohol-related God/Higher Power control beliefs in the development of problem drinking among African-American youth. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEALTH SERVICES FOR PARASUICIDAL BEHAVIOR Principal Investigator & Institution: Comtois, Katherine A. Psychiatry and Behavioral Scis; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2001; Project Start 13-JUN-2001; Project End 31-MAY-2006 Summary: The Mentored Research Scientist Development Award (K01) will provide the education and skills that I need to make the transition from clinically based randomized controlled trials and survey designs to population-based health services research. I am particularly concerned about assuring that high quality treatments with empirical support are in use in the public mental health system. This will require not only available evidence based treatments but the skills to adapt these treatments when necessary for effectiveness, dissemination, and implementation trials. Some disorders, such as depression in primary care, have benefitted from adaptation of evidence based efficacy treatments to meet the clinical needs of primary care patients and to fit into the primary care system. I am interested in expanding such research interventions to the treatment of parasuicidal behavior in the public sector. My long term goal is to develop a population-based allocation of mental health services for parasuicidal behavior within the public sector that is (a) guided by evidence based treatments, (b) implementable, given variable local system needs and structures, and (c) is cost-effective relative to usual care. To pursue this goal, I will need to expand my training in three areas: (1) clinical epidemiology and quality of care evaluation of usual care, (2) issues that facilitate or impede implementation of evidence based treatments in public mental health settings, and (3) health services research and design of population-based effectiveness studies. These goals reflect NIMH's recommendations of bridging science and service. The proposed study is a naturalistic epidemiologic follow-up of a sample of patients admitted to the psychiatric emergency department (ER) of a county hospital on a random-selection of assessment periods. Subjects will be assessed in the ER for parasuicidal behavior, psychiatric diagnosis, and service utilization for the previous 6 months. Subjects will then be re-interviewed 3 and 6 months following their ER admission regarding parasuicidal behavior and service utilization since admission. The goal is to identify the patterns and predictors of the course of parasuicide as it relates to utilization of treatment. The specific aims for the research study are as follows: 1) Determine subgroups of parasuicidal patients as defined by service utilization patterns and describe them based on clinical and diagnostic characteristics. 2) Evaluate quality of care for parasuicidal patients based on process indicators of mental health treatment quality. 3) Identify service utilization patterns related to system factors above and beyond patient factors (e.g., crisis services replacing outpatient as primary treatment for parasuicidal individuals). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HIV AND SUBSTANCE USE IN THE PACIFIC Principal Investigator & Institution: Havens, Jennifer F. Epidemiology; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2002; Project Start 15-NOV-2002; Project End 14-NOV-2006
Studies 63
Summary: (provided by applicant): Garment and other contract workers account for more than half of the population of the Commonwealth of the Northern Marianas Islands (CNMI). The majority are immigrant laborers who are young women from Asia and other Pacific Islands, and who are exposed to harsh working and living conditions. Allegedly, some women have been forced into the sex trade, whereas others may choose to participate in the sex industry (e.g., because it is lucrative). It is hypothesized that these stressors result in substance use and risky sexual practices, which can lead to the aquisition of HIV and other sexually transmitted diseases (STDs). To date, data on substance use, STDs and HIV risk behaviors among CNMI contract workers are sparse, however, the CNMI experienced a methamphetamine epidemic in recent years and its use is believed to be prevalent. This prospective study will measure baseline substance use and sexual history via an interviewer-administered questionnaire as part of government-sponsored HIV/STD screening, which is required by the workers' employment contract upon entry into the CNMI. Prevalence and correlates of substance use, HIV and STDs will be determined. Subsequent visits at six months and one year would measure changes in substance use and sexual practices, as well as stress, depression, and suicidal behavior, in addition to HIV/STD testing. Identifying incident HIV/STD cases and the correlates of infection among the female migrant workers could aid in the design of HIV/STD education programs for contract workers, prevent spread of HIV/STDs to/from women working in the sex trade, and identifying appropriate treatment options for those infected young women. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HUMAN POSTMORTEM STUDIES OF THE STRESS AXIS Principal Investigator & Institution: Watson, Stanley J. Co-Director/Research Scientist; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2001 Summary: Studying the neuroanatomical substrates of stress, suicide and depression in human brain is the central theme of this project. While these are also major foci of this entire Program Project application, this project specifically emphasizes postmortem human brain in an effort to understand the fundamental anatomy of stress-related circuits in man, and the possible changes in gene expression within these circuits which may accompany suicide and depression; in addition, however, this project includes some pre-clinical studies in the rodent specifically focused on the interface between stress circuits and the sites of action of antidepressant drugs, as these studies will help us interpret the human findings. Therefore, this project comprises 3 Specific Aims. The first Specific Aim involves the study of serotonergic (5HT) and nor-adrenergic (NA) systems as they respond to stress and antidepressants in rodent models. These paradigms will allow us to establish a clearer view of the functional links between the stress axis and monoamine systems, thereby clarifying the impact of monoaminealtering compounds on depression and on the endocrine disturbances associated with it. The second Specific Aim directly analyzes postmortem human brain from suicide victims, suicide victims also having a documented history of affective disease, and controls. The same circuits and systems laid out in the rodent will now be analyzed inhuman brain (prefrontal cortex, limbic circuits associated with the stress axis, 5HT and NA nuclei and their receptors). The third Specific Aim is designed to allow the threedimensional (3D) analysis of individual human brain nuclei at cellular resolution using mRNA levels. This method will substantially increase the power and value of human postmortem studies by combining the regulatory information found in mRNA levels
64 Suicide
with anatomical precision and with high resolution statistical tools. In sum, at the end of the requested 5 years of this proposal we expect that we will have made very substantial gains in appreciating the circuitry of the stress axis in rodent and man, and begun to establish the relationship between the stress axis and affective disease at the level of biochemically specific brain nuclei and structures. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HUMAN TYROSINE HYDROXYLASE AND SCHIZOPHRENIA Principal Investigator & Institution: Haycock, John W. Professor; Biochem and Molecular Biology; Louisiana State Univ Hsc New Orleans New Orleans, LA 70112 Timing: Fiscal Year 2001; Project Start 01-MAR-1992; Project End 31-DEC-2003 Summary: This is a revised application for competitive renewal of K02 support for Dr. John W. Haycock. This award will enable Dr. Haycock to continue his scientific development and to pursue his recently funded research program (MH55208) on brain monoaminergic systems in mental illnesses, which was initiated and developed over the course of the current award. The ability to study clinical issues related to catecholamine function concurrently with his previously established fundamental neuroscience research program (NS25134) has realized one of the candidate's major long-term goals. As a result, the candidate's short-term goals are focused upon development of his laboratory by recruiting younger scientists to participate in effecting the scientific goals of both the clinical and fundamental research projects. In addition to developing his role as a laboratory director, the candidate will continue his scientific development by pursuing a novel, multidisciplinary approach which he has recently developed, using antibodies to labile epitopes for studying the regulation of signaling molecules in vivo. The proposed research plan focuses upon tyrosine hydroxylase (TyrOH) and tryptophan hydroxylase (TrpOH), which catalyze the initial and rate- limiting steps in catecholamine (dopamine and norepinephrine) and serotonin biosynthesis, respectively. Alterations in each of these systems have been implicated in mental disorders and, in particular, schizophrenia. TyrOH is highly regulated--by protein phosphorylation in the short-term and by transcriptional control in the long-term; and, alternative splicing (which occurs exclusively in monkeys and humans) produces multiple TyrOH isoforms and perhaps, an additional level of regulation. By contrast, comparatively little is known about TrpOH, despite its evolutionary and functional proximity to TyrOH. Postmortem human brain tissue will be analyzed using quantitative blot immunolabeling techniques and a bank of antibodies developed for this purpose by the applicant. TyrOH and TrpOH protein levels, as well as the relative abundances of TyrOH isoforms, will be measured in neurochemically appropriate brain regions dissected from cryostatic sections. DOPA decarboxylase (immediately downstream of both TyrOH and TrpOH) and dopamine beta-hydroxylase (which converts dopamine to norepinephrine) protein levels will also be quantitated, and similar assays have been developed for another class of presynaptic monoaminergic markers--the vesicular and plasmalemmal monoamine transporters. The primary study groups will consist of (a.) suicide/sudden death victims having confirmed diagnoses of schizophrenia and (b.) age-matched, sudden-death control subjects having no Axis 1 mental disorder. Parallel, collaborative studies of major depressives will provide comparison groups and allow identification of potential disease-specific differences. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 65
•
Project Title: ICOHRTA: CHINA-ROCHESTER SUICIDE RESEARCH CENTER Principal Investigator & Institution: Caine, Eric D. Professor; Psychiatry; University of Rochester Orpa - Rc Box 270140 Rochester, NY 14627 Timing: Fiscal Year 2001; Project Start 26-SEP-2001; Project End 30-APR-2006 Summary: (provided by applicant): This ICOHRTA application from the University of Rochester?s Center for the Study and Prevention of Suicide (UR/CSPS) proposes to develop, along with colleagues from Hong Kong and China, the China-Rochester Suicide Research Center (CRSRC). The "MFC" for the ICOHRTA will be based at the Chinese University of Hong Kong, and the CRSRC also will include The University of Hong Kong and the Dalian Medical University. Suicide and attempted suicide are major public health problems, now recognized in China and Hong Kong, by the US Congress and the Surgeon General, and by the WHO. Yet it only has been during the past few years that they have begun to draw the attention of policy makers and researchers. China and Hong Kong have few investigators equipped to carry out rigorously designed epidemiological or clinical risk research devoted to understanding the factors associated with suicide and suicidal behaviors. As well, there is no widespread infrastructure developed on which one could build an array of carefully evaluated prevention efforts. It is in this context that we make this proposal. The UR/CSPS has grown from 15 years of concerted effort to study suicide and attempted suicide into an integrated, multidisciplinary group of investigators, who conduct an array of NIH funded grants and two T32 training programs that will serve as the base on which we will build the ICOHRTA training and research efforts. The ICOHRTA will allow what has become a vibrant but informal research and training alliance among researchers in Rochester, Hong Kong, and Dalian to emerge as a formal, institutionalized research and training "engine." We propose to carry out the following aims as we undertake this transformation. We will build a collaborative "clinical research center without walls." The "China-Rochester Suicide Research Center" (CRSRC) will maintain a formal organizational structure, a well-planned training program and curriculum, and key core faculty. It will gradually build its collaborative consortium over the course of five years, emphasizing the effective incorporation of new faculty and trainees into established education and research operations. The CRSRC will recruit and train talented individuals to participate in interdisciplinary research teams. We will develop and conduct effective and productive risk research pertaining to suicide and attempted suicide in Hong Kong and China, and in its later years broaden its scope to include prevention-focused initiatives. Finally, the CRSRC will systematically evaluate the effectiveness of our recruiting, training, and research efforts throughout the course of the grant period. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMAGING REPORTER GENE EXPRESSION USING PET Principal Investigator & Institution: Gambhir, Sanjiv S. Professor; Molecular & Med Pharmacology; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, CA 90024 Timing: Fiscal Year 2001; Project Start 01-JUL-1999; Project End 30-APR-2003 Summary: Reporter genes have been used by molecular biologists for over a decade to track gene expression in cell culture and in animals. Endogenous gene expression is monitored through the creation of a chimeric fusion gene, in which the promoter of an endogenous gene is coupled to the reporter gene. If the endogenous gene promoter is off, neither the endogenous gene nor the reporter gene are transcribed (because they
66 Suicide
share the same promoter). Similarly, if the promoter for the endogenous gene is activated, then the reporter gene is transcribed. Through the use of reporter genes such as beta-galactasidase, chloramphenicol acetyl transferase, alkaline phosphatase, and luciferase the study of endogenous genes in vivo has been possible. However, these traditional reporter gene methods are limited by their inability to track the location, magnitude, and persistence of gene expression over time. We are developing quantitative assays to image reporter gene expression using positron emission tomography (PET) in living animals and humans. We propose to study two distinct reporter gene/reporter probe systems. These include (i) the Herpes Simple Type 1 Thymidine Kinase (HSV1-tk) reporter gene/8-[18-F]- fluoroganciclovir (FGCV) reporter probe; (ii) the Tyrosinase (TYR) reporter gene/6-[18-F]Fluoro-L-DOPA (FDOPA) reporter probe. For both these systems we will (a) relate the PET signal to levels of gene expression using both an adenoviral delivery model and a tumor model; (b) develop tracer kinetic models for uptake and trapping of the reporter probe; (c) develop inducible constructs to show induction of gene expression in vivo; (d) construct a dual reporter gene system in which both reporter genes are expressed with the use of an internal ribosomal entry site (IRES). For the HSV1-tk reporter gene we will study mutant genes and alternate reporter probes to enhance the sensitivity of the imaging assay to detect lower levels of gene expression. We will also study transgenic animals which express HSV1-tk. Pre-clinical studies with suicide gene therapy will also be performed. The assays developed through this work should lead to direct methods for the noninvasive study of gene expression in living animals, and allow for the monitoring of gene expression in human gene therapy trials (e.g., trials using suicide gene therapy to destroy brain tumors). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMIDAZOLINE RECEPTORS IN DEPRESSION--BASIC STUDIES Principal Investigator & Institution: Piletz, John E. Psychiatry and Human Behavior; University of Mississippi Medical Center 2500 N State St Jackson, MS 39216 Timing: Fiscal Year 2001; Project Start 01-SEP-1993; Project End 30-JUN-2004 Summary: (Adapted from applicant's abstract): This grant application presents the cloning of a candidate for the human imidiazolene receptor (IR) cDNA and gene. The brainstem IR has been thought to function in the central neuronal modulation of blood pressure by clonidine, but the probable role of IR in other brain region is currently under investigation. The investigator's laboratory has demonstrated consistent and robust elevations in platelet IR radioligand binding in five earlier studies of depressed patients, followed by a normalization of radioligand binding after chronic treatments with earlier desipramine or fluoxetine. The investigator and other investigators also observed alterations in IR in depressed suicide victims brain tissue. Hence it is of interest to identify the signaling mechanisms of IR and the manner in which IR are normally regulated, or possibly dysregulated in depression. The following studies are proposed in order to characterize a cloned IR-like cDNA: a)The first aim is to establish whether the investigator's IR- like cDNA encodes the pharmacological properties expected of the IR, subtype of imidzoline receptors. Preliminary transfection data have indicated that the expressed protein possesses high affinity for IR1>IR2 ligands. b) To test the investigator's hypothesis that IR are coupled to a phosphatidylcholine-selective phospholipase C (PC-PLC) signal transduction pathway, it will be determined whether transfected IR-like cDN will express ligand-specific coupling to the PC-PLC, and other second messenger pathways. c) To determine the regionalization of brain IR (and to test whether an endogenous IR candidate neurotransmitter, agmatine, shares a similar
Studies 67
distribution in rats and humans), the regional distribution of IR-like mRNA will also be determined by situ hybridization. d) A final aim of this grant will be to identify possible regulatory DNA sequences in the upstream gene promoter region of the human and rat IR gene. These studies will clarify the molecular nature of the IR anit's signal transduction pathways. This basic grant is thematically linked to a clinical grant (Halaris, PI) which has also been submitted for consideration. The clinical grant will explore whether brain IR1 protein, IR1 mRNA and agmatine are elevated in brains of depressed suicide victims, whether imidazoline receptors underlie a blunted growth hormone response to clonidine as observed in depressed patients, and whether platelet IR1 levels and/or plasma agmatine concentrations are sensitive to the severity of depression. The findings from the clinical grant will best be understood within the context of these studies in the basic grant, and vice versa. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMIDAZOLINE RECEPTORS IN DEPRESSION--CLINICAL STUDIES Principal Investigator & Institution: Halaris, Angelos E. Psychiatry and Human Behavior; University of Mississippi Medical Center 2500 N State St Jackson, MS 39216 Timing: Fiscal Year 2001; Project Start 01-MAR-1998; Project End 28-FEB-2003 Summary: (Adapted from applicant's abstract): For the last twelve years the investigator's laboratory has attempted to identify a specific and readily obtainable biological marker for depression. Platelet a2-adrenergic receptors (a2AR) were of theoretical interest because brain a2AR modulate monoamine output. In the wake of over 60 studies or the platelet a2AR in depression, the investigator noted a high degree of consistency only with an elevation in radioligand binding amongst those studies which utilized imidazolines (principally 3H-clonidine) in their "a2 assays". After thoroughly characterizing the imidazoline-receptive sites on human platelets, the investigator concluded that platelets possess a nonadrenergic imidazoline receptor (IR1) binding site, in addition to an a2AR. In four studies of depression, and one of dysphoric PMS, the investigator has consistently observed an elevation of IR1 on platelet plasma membranes of depressed patients compared to matched controls, suggesting that the earlier literature might be explained by IR1 sites. The investigator also found that treatment of patients with either desipramine (DMI) or fluoxetine for 6 weeks leads to normalization (i.e., down regulation) of platelet IR1, suggesting that the platelet IR1 site might be a state marker for depression. These alterations were not correlated with changes in catecholamines. After transferring the grant from Case Western Reserve University the investigator replicated his findings in depressed patients with a demographically different population. Furthermore, he has developed a selective antibody assay for the IR1 protein, which is 100-fold more sensitive than the older IR1 radioligand binding assay. Using IR1-selective antiserum, depressed patients continue to display a marked elevation in the platelet IR1 density. The density of this single band (33 kDa), as detected on Western blots, is linearly correlated with the IR1 Bmax values of platelet samples. Recently the investigator has also observed an increase in 33 kDa/IR1 in hippocampi of depressed victims of suicide. Thus, in our search for an a2AR marker, he uncovered a novel nonadrenergic receptive protein which in five pre-treatment and 3 post-treatment studies of depression (and as assayed by two independent techniques) appears to be a marker for depression. The investigator's specific aims will determine: a) the extent to which IR1 elevation is observed throughout brain regions of depressed suicide victims, b) whether depressed patients also exhibit a functional IR1 alteration in hypothalamic growth hormone (GH) and prolactin responses to moxonidine infusions (as assessed under an a2AR mask), c) whether the potential platelet IR1 marker is
68 Suicide
sensitive to the severity of depressive illness, and d) whether the IR1 neurotransmitter candidate, agmatine, is also altered in depression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMPROVED SUICIDE GENE THERAPY FOR HEPATIC CANCERS Principal Investigator & Institution: Ensminger, William D. Professor; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2002; Project Start 18-JAN-2002; Project End 31-DEC-2005 Summary: (provided by applicant): The goal of this proposal is to examine the potential for a new generation of regional treatments for intrahepatic cancers using improved methods of delivery and forms of cytosine deaminase/5-flucytosine (CD/FC) in enzyme/prodrug gene therapy. Current gene therapy approaches have at least two critical limitations. The first concerns the ability to generate sufficient cytotoxicity and radiosensitization because of an inadequate ability to kill adjacent cultured tumor cells that are not transduced ("bystander effect"). FU generated from FC has been demonstrated to have a significant bystander effect. Unfortunately, FC is an inefficient substrate for bacterial CD compared to cytosine, the natural substrate. To begin to overcome this limitation we will develop the use of yeast (y) CD for which FC is a far more efficient substrate compared to the previously utilized bacterial (b) CD (Aim 1) and, thus will work at FC levels lower than the bCD in gut bacteria (for lowered systemic toxicity). A second limitation of the current versions of CD/FC system is selectivity. Preliminary data using a clinically relevant animal model for intrahepatic cancer (BD9 rats bearing intrahepatic K12 adenocarcinoma tumors) suggest that even (regional) hepatic arterial infusions of bCD adenovirus produce significant FU levels in the normal liver, high systemic concentrations of PU, and potential normal tissue toxicity. To overcome this limitation, we will construct an adenoviral vector using a tumor selective promoter for yeast CD (Aim 2). Preliminary data suggest that the use of CEA as a promoter significantly enhances the specificity of expression. In addition, we will enhance regional delivery of virus using vascular manipulations (Aim 3), including osmotic (mannitol), mechanical (microspheres) and hormonal (epinephrine) methods, and pretreatment with focal ionizing radiation. Preliminary data show that pretreatment with mannitol or with ionizing radiation can increase tumor CD expression. These improvements will be developed and then tested in therapy trials comparing the most aggressive standard therapy, i.e., hepatic arterial FUdR, with the best "enhanced" CD/FC gene therapy (Aim 4) using MRI to monitor antitumor effects in vivo. Nude rats will be used in therapy trials and in all longer term studies where immunogenicity could affect results. Although the goal of this project is to understand how to design better regional chemoradiation treatments, our long term objective is to generate information and principles relevant and applicable to effective, systemic, tumorselective gene therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMPROVING SUICIDE GENES FOR CANCER GENE THERAPY Principal Investigator & Institution: Black, Margaret E. Assistant Professor; Pharmaceutical Sciences; Washington State University 423 Neill Hall Pullman, WA 99164 Timing: Fiscal Year 2001; Project Start 11-MAY-2000; Project End 30-APR-2005
Studies 69
Summary: Gene therapy offers the prospect of selectively introducing genes into cancer cells, leaving them susceptible to specific antitumor drugs. Current protocols to elicit tumor reduction utilize Herpes Simplex Virus type 1(HSV) thymidine kinase (TK) with the prodrug ganciclovir (GCV) or the E. coli cytosine deaminase with the prodrug 5fluorocytosine (5FC). While the wild-type TK is functional as a suicide gene, a number of caveats restrict its full effectiveness. These include a poor Km or binding affinity for GCV (approximately 47muM) and the toxicity associated with high doses of GCV. Another prodrug, acyclovir (ACV), predominantly used as an anti-herpetic drug, does not demonstrate the immunosuppressive attributes of GCV, even at very high doses. However, the very high Km that HSV TK displays towards ACV (approximately 320 muM), precludes its use as a prodrug in ablative gene therapy. Similarly, there are caveats with cytosine deaminase and 5FC that preclude its potential as a safe and effective suicide gene. We seek to identify the optimal suicide gene and prodrug combination for the safest and most effective cancer gene therapy. Towards this end we seek 1) to understand the structure-function relationship of nucleoside metabolizing enzymes important to suicide gene therapy and 2) to manipulate HSV-1 thymidine kinase and cytosine deaminase genes for superior performance in ablative gene therapy settings. The goal of this work is to 1) create novel genes by mutagenesis, 2) evaluate mutant genes for improved tumor sensitivity to various prodrugs, 3) construct minipathways and 4) create fusion proteins with other genes to enhance prodrug activation and tumor ablation. Not only will the results from the project impact the choice of gene(s) used for cancer treatment, but it also has wide-reaching applications including graft versus host disease, restenosis, AIDS, tumor imaging, cell lineage ablation studies, in negative selection systems and selection against non-homologous recombination for the generation of transgenic mice. Furthermore, understanding the molecular basis of nucleoside metabolizing enzyme function and interaction with current drugs will have far-reaching ramifications in the design, development and use of novel antiviral, antifungal and antibacterial drugs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMPUTATION FOR MODERATE SIZED MENTAL HEALTH STUDIES Principal Investigator & Institution: Belin, Thomas R. Associate Professor; Psychiatry & Biobehav Sciences; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, CA 90024 Timing: Fiscal Year 2001; Project Start 18-SEP-2001; Project End 30-JUN-2005 Summary: In mental health research, it is common for there to be numerous variables measured, many of which may have some missing values. When sample sizes are modest, existing strategies that address missing data using multivariate statistical models can easily have too many parameters for the available data to estimate. This R01 proposal-revises an earlier application, seeking support to evaluate a newly-developed factor-based multivariate statistical method for imputation of missing values, to extend the method to accommodate longitudinal factor-analysis models, to integrate software programs into a user-friendly Windows-based interface, and to snake the programs available to researchers over the world-wide web. Two applied problems motivate the present work, one from a suicide prevention study by Rotheram-Borus, Piacentini, Van Rossem, et al. (1996), where because of scattered missing values only 107 of 140 subjects for whom data were collected were available for model fitting, and another from an investigation of medication use and unmet need among children who live in foster care in Los Angeles County, where scattered missing values resulted in only 216 out of 302 subjects being available for model fitting (Zima, Bussing, Crecelius, Kaufman, Belin
70 Suicide
1999). The proposed statistical methods offer the prospect of including all subjects in these analyses, of incorporating information from partially observed cases, and of accurately reflecting uncertainty. Ideas from factor analysis are central to the strategy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTIMACY IN DEPRESSED ELDERLY WITH AXIS II COMORBIDITY Principal Investigator & Institution: Compton, Jill S. Psychiatry; Duke University Durham, NC 27706 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-AUG-2003 Summary: Major depression is a serious and prevalent psychiatric disorder among the elderly. Psychotropic and psychosocial interventions have been used with some success, still significant numbers of patients fail to respond adequately to treatment. Approximately one third of depressed elderly patients show only partial response to treatment, and partial responses are associated with higher rates of relapse. Many others are unable to tolerate pharmacotherapy because of existing medical conditions, interactions with other prescription medications, and unwanted side effects. Thus, it is important to understand the factors associated with treatment resistant depression in the elderly. Many patients with chronic depression have co-existing personality disorders (PD's) that complicate treatment. Comorbid PD's among the elderly have been associated with poorer response to treatment, greater risk of suicide, and impaired social support. Social support factors have been associated with the onset and maintenance of depressive symptoms and level of emotional support, in particular, appears to have a critical role in the course of depressive disorders. However, research investigating intimate relationships in the elderly have been scarce, overly global, and often contradictory. The primary aim of the proposed study is to better understand tile role of emotional support and relationship quality in the treatment of older adults with major depression and coexisting Axis II psychopathology. This study is an add-on to a larger project investigating the relative outcomes of antidepressant medication and a combination of cognitive-behavioral therapy plus antidepressant medication for this complex population. Thirty-six subjects (n = 36) will complete pre- and post-treatment assessments, including questionnaires, interviews, and interaction tasks. Videotaped interactions will be coded using the IDGOS, an observational coding system that measures intimacy. Bivariate correlations and MANCOVA procedures will be used to examine correlations between relationship factors and depressive symptoms at Time 1 and Time 2. Data from this study will clarify the role between emotional support and complex depression in the elderly and will yield estimates of effect size for a subsequent K Award submission. Thus, the proposed study is the first step in a research trajectory aimed at developing and testing a couple/family intervention for improving outcomes among treatment resistant elderly. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INVESTIGATIONS OF DNA DAMAGE AND REPAIR Principal Investigator & Institution: Greenberg, Marc M. Professor; Chemistry; Colorado State University Fort Collins, CO 80523 Timing: Fiscal Year 2002; Project Start 01-JAN-2002; Project End 30-JUN-2002 Summary: (provided by applicant): The overall goal of the proposed research is to probe the DNA mutagenicity and repair of three lesions that are produced in nucleic acids via a variety of oxidative stress mechanisms. These lesions all lack the presence of a nucleobase, and result from formal oxidation of the carbohydrate moiety. The presence
Studies 71
of these oxidized abasic lesions in DNA in vivo is associated with cancer and aging. Despite their importance, the effects of these abasic lesions on the function of DNA at the molecular level are not well understood. Using the fundamental knowledge gained from these and previous related studies, we are designing enzyme inhibitors of DNA repair processes. First generation molecules that inhibit the lyase step of base excision repair (BER) enzymes are presented in this proposal. Our general experimental approach involves the unambiguous synthesis (and characterization) of oligonucleotides containing individual oxidized abasic lesions site specifically incorporated. The effects of the lesions on duplex stability and enzyme activity are examined using these chemically synthesized substrates. Specific aims include: 1. Investigation of the in vitro and in vivo mutagenicity of the lesions. 2. Investigation of the repair of these lesions by BER enzymes in vitro and in vivo. 3. Examination of the lethality of these lesions in E. coli and in yeast. 4. Design of suicide inhibitors of BER. Increased understanding of the effects of oxidized abasic lesions on nucleic acid structure and function will be useful for understanding the association between nucleic acid damage and aging, as well as the etiology of diseases such as cancer. Application of these studies, such as the design of enzyme inhibitors may provide new therapeutic agents. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: JABSOM ENDOWED CHAIR FOR NATIVE HAWAIIAN HEALTH Principal Investigator & Institution: Cadman, Edwin C. None; University of Hawaii at Manoa 2500 Campus Rd Honolulu, HI 96822 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 29-SEP-2005 Summary: (provided by applicant): The National Center on Minority Health and Health Disparities (NCMHD) Endowment Program for Increasing Research and Training Capacity provides the Native Hawaiian Center of Excellence (NHCOE) at the University of Hawaii (UH) John A. Burns School of Medicine (JABS(o)M) an opportunity to establish a research program through the recruitment of a Director of Research under the $21 funding mechanism and to pursue a renewable source of funding for infrastructure, programs, education and research. Both of these opportunities will encourage efforts to reduce and eliminate health disparities in Native Hawaiians and other underserved populations. Although residents of Hawaii enjoy one of the longest overall life span and the best health status in the nation, the comparative life expectancy of Native Hawaiians (NH) is the lowest of all major ethnic groups and is about 5 years less than the state average. The NH suffer the highest age-sex standardized mortality rates of any major ethnic group in Hawaii and have more years of productive life lost due to heart disease, accidents, cancer, suicide, AIDS, stroke, diabetes, chronic lung disease and chronic liver disease. The following specific aims are proposed to address these major health disparities: 1) to establish an endowment fund for a Chair at JABSOM who will serve as the Director of Research at the NHCOE. The fund will be managed by the UH Foundation and administered by the NHCOE at JABSOM; 2) To increase the corpus of the NCMHD endowment through reinvestment of earnings, solicitations and bequests from charitable trusts, private industry, private citizens and applications for other funding opportunities from the NIH and other agencies; 3) To recruit a Director of Research to develop a strong research program focused on health disparities of NH and other underserved populations; and 4) To establish a renewable source of funding for researchers engaged in disparities in NH health research, support for students, enhance educational and training programs and build infrastructure to support the objectives of the NHCOE and the health disparities research program. The goal of this grant is to develop an effective organization for promoting the physical and mental health of all
72 Suicide
Native Hawaiians and underserved populations in Hawaii. The research program addresses the objective of this RFA to "close the gap between disparities in the burden of illness and death experienced by. Asian Pacific Islanders and other underserved populations as compared to the Nation as a whole." Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LEUKOTRIENES AND SLOW REACTING SUBSTANCE OF ANAPHYLAXIS Principal Investigator & Institution: Murphy, Robert C. Professor; National Jewish Medical & Res Ctr and Research Center Denver, CO 80206 Timing: Fiscal Year 2001; Project Start 15-SEP-1989; Project End 28-FEB-2002 Summary: (Adapted from the applicant's abstract). Leukotrienes are lipid mediators derived form arachidonic acid by enzymatic oxidation catalyzed by 5-lipoxygenase (5LO). Interest in these molecules stems from their potent activities in causing neutrophil chemotaxis (LTB4) and bronchial smooth muscle constriction (LTC4). Fundamental questions remain concerning their biosynthesis and metabolism and these are the focus of the proposed work. This project consists of four major goals. The first goal will be to utilize mass spectrometry (MS) for the structural characterization of the major human urinary metabolites of LTB4. A MS quantitative assay will be developed to asses in vivo biosynthesis and normal entry rate of LTB4 into the circulation. The second goal is to asses LTC4 and LTB4 biosynthesis in asthmatic patients that are intolerant to aspirin by quantitative analysis of urinary metabolites for each eicosanoid. LTB4 biosynthesis involves 5-LO and LTA4 hydrolase that are inactivated through a mechanism based suicide reaction that results in covalent binding of an electrophilic eicosanoid intermediate to the enzyme. LTA4 also binds covalently to human serum albumin, a carrier protein for this triene epoxide. The application's third goal is to utilize electrospray tandem MS and MALDI-TOF MS in order to determine the site of covalent attachment and structure of the protein bound lipid. It is expected that such information will provide insights into the mechanism of suicide inactivation and the importance of specific amino acids to the catalysis event The fourth goal will be to investigate the autocrine and paracrine effects of LTB4 on leukotriene biosynthesis and metabolism. The mechanisms by which extracellular LTB4 can modulate neutrophil LTB4 biosynthesis will be investigated. LTB4 has been suggested to increase LTB4 metabolism through the interaction with the nuclear peroxisomal proliferation activating receptor (PPARalpha) and by this mechanism, limit the proinflammatory properties of LTB4. This putative effect of LTB4 will be investigated in hepatocytes and other cells by analysis of both kinetics and extent of leukotriene metabolism. An understanding of the metabolic events occurring in vivo is essential to an understanding of the role these molecules play in inflammation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: LIMBIC DOPAMINERGIC SYSTEM IN MAJOR DEPRESSION Principal Investigator & Institution: Ordway, Gregory A. Associate Professor; Psychiatry and Human Behavior; University of Mississippi Medical Center 2500 N State St Jackson, MS 39216 Timing: Fiscal Year 2002; Project Start 14-DEC-2001; Project End 30-NOV-2005 Summary: A vast amount of research reveals that central dopamine (DA) containing systems are neuronal substrates of a broad spectrum of behaviors related to rewardseeking, motivation, and environmental responsivity. Disruption of these behaviors
Studies 73
leads to anhedonia, social isolation, and psychomotor retardation that form core symptoms of depression. While there is little debate for a critical role of limbic structures, e.g. amygdala, in the regulation of mood and affect, the role of limbic DA in the pathobiology of depressive illness is not known. Functional imaging studies report involvement of limbic structures in depression, but few have focused on dopaminergic indices. Furthermore, there is a paucity of neurochemical studies of depression that have utilized postmortem brain tissue. Studies using postmortem brain tissue offer much higher anatomical resolution than it is offered by functional imaging. In preliminary studies, we have found lower dopamine transporter (DAT) and up-regulation of D2 receptors in the basal and central nuclei of the amygdala, but not in the other nuclei of this complex region, in major depression as compared to psychiatrically normal controls. These and other findings compel us to examine the possibility that there is diminished DA neurotransmission in subjects diagnosed with major depression (who died of suicide or natural causes). The central hypothesis of this proposal is that subjects with major depression have diminished mesolimbic DA activity that can be revealed by neurochemical abnormalities in discrete regions of the mesolimbic dopaminergic system. These neurochemical measures will be performed in discrete regions of the amygdala, (Aim 1), in the nucleus accumbens (Aim 2), and in the ventral tegmental area (VTA, Aim 3), core limbic regions of the brain. We also hypothesize that a distinct constellation of neurochemical abnormalities within limbic structures is specific for major depression (Aim 4), and will differentiate the pathobiology of major depression from that of suicide or schizophrenia. Groups of subjects to be studied will be: a) subjects with major depression who committed suicide, b) subjects with major depression not dying by suicide, c) sudden death non-psychiatric controls, and d) schizophrenics not dying by suicide. The proposed research will be the first focused investigation of potential abnormalities of limbic DA in major depression utilizing psychiatrically characterized subjects. The research will establish the specificity of neurochemical findings with respect to major depression and with respect to regional brain anatomy. Uncovering the potential role of DA in the pathobiology of depression may lead to advancements in the pharmacological, and possibly genetic, intervention of major depression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LONGITUDINAL ADOLESCENTS
STUDY
OF
SUICIDE
ATTEMPTS
IN
Principal Investigator & Institution: Goldston, David B. Associate Professor; Psychiatry and Behavioral Med; Wake Forest University Health Sciences Winston-Salem, NC 27157 Timing: Fiscal Year 2001; Project Start 01-MAY-1993; Project End 31-JUL-2003 Summary: (Adapted from Applicant's Abstract): Over the last four years, 180 youths discharged from an impatient psychiatric facility have been successfully recruited and followed longitudinally as part of a FIRST Award. The project was designed to examine the course, predictors, and covariates over time of suicidal behavior among a high risk population of adolescents. Eighty four percent of the eligible sample of consecutively referred adolescents were recruited, and the cumulative rate of attrition in the study has been limited to less than 10%. This continuation application describes a proposal to follow these high risk youths for an additional five years until the youngest subjects reach late adolescence and the oldest subjects reach young adulthood. Late adolescence is a period of multiple developmental transition, and a period of time during which young people presumably are at continued risk for suicidal behavior. Within this developmental context are a number of psychiatric, cognitive, sociodemographic, and
74 Suicide
environmental factors that may interact in increasing the risk that youths will make additional suicide attempts. The first specific aim of this continuation is to examine the rates of suicide attempts among these high-risk adolescents from mid-adolescence to young adulthood. The second specific aim is to examine the effects of the course of affective disorder, and of comorbid affective and substance disorders on the likelihood of suicidal behavior. The final aim of this continuation is to test the utility of a hopelessness diathesis stress model (derived from Beck's cognitive model of depression) in predicting suicide attempts among